US20150265833A1 - Transvascular diaphragm pacing systems and methods of use - Google Patents

Transvascular diaphragm pacing systems and methods of use Download PDF

Info

Publication number
US20150265833A1
US20150265833A1 US14/410,022 US201314410022A US2015265833A1 US 20150265833 A1 US20150265833 A1 US 20150265833A1 US 201314410022 A US201314410022 A US 201314410022A US 2015265833 A1 US2015265833 A1 US 2015265833A1
Authority
US
United States
Prior art keywords
breath
stimulation
diaphragm
patient
ventilator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/410,022
Inventor
Ramasamy Meyyappan
Joaquin Andres Hoffer
Marcelo Baru
Bernard Coquinco
Rodrigo Andres Sandoval
Jessica Kit-Sum Tang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lungpacer Medical Inc
Original Assignee
Simon Fraser University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Simon Fraser University filed Critical Simon Fraser University
Priority to US14/410,022 priority Critical patent/US20150265833A1/en
Assigned to SIMON FRASER UNIVERSITY reassignment SIMON FRASER UNIVERSITY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: TANG, Jessica Kit-Sum, COQUINCO, Bernard, BARU, MARCELO, HOFFER, JOAQUIN ANDRES, MEYYAPPAN, Ramasamy, SANDOVAL, Rodrigo Andres
Assigned to SIMON FRASER UNIVERSITY reassignment SIMON FRASER UNIVERSITY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SANDOVAL, Rodrigo Andres, COQUINCO, Bernard, HOFFER, JOAQUIN ANDRES, MEYYAPPAN, Ramasamy, TANG, Jessica Kit-Sum, BARU, MARCELO
Publication of US20150265833A1 publication Critical patent/US20150265833A1/en
Assigned to LUNGPACER MEDICAL, INC. reassignment LUNGPACER MEDICAL, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SIMON FRASER UNIVERSITY
Priority to US16/114,064 priority patent/US10561844B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/3605Implantable neurostimulators for stimulating central or peripheral nerve system
    • A61N1/3606Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
    • A61N1/3611Respiration control
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/08Detecting, measuring or recording devices for evaluating the respiratory organs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/0057Pumps therefor
    • A61M16/0066Blowers or centrifugal pumps
    • A61M16/0069Blowers or centrifugal pumps the speed thereof being controlled by respiratory parameters, e.g. by inhalation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/021Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes operated by electrical means
    • A61M16/022Control means therefor
    • A61M16/024Control means therefor including calculation means, e.g. using a processor
    • A61M16/026Control means therefor including calculation means, e.g. using a processor specially adapted for predicting, e.g. for determining an information representative of a flow limitation during a ventilation cycle by using a root square technique or a regression analysis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/02Details
    • A61N1/04Electrodes
    • A61N1/05Electrodes for implantation or insertion into the body, e.g. heart electrode
    • A61N1/0551Spinal or peripheral nerve electrodes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/02Details
    • A61N1/04Electrodes
    • A61N1/05Electrodes for implantation or insertion into the body, e.g. heart electrode
    • A61N1/056Transvascular endocardial electrode systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/3601Applying electric currents by contact electrodes alternating or intermittent currents for stimulation of respiratory organs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/3605Implantable neurostimulators for stimulating central or peripheral nerve system
    • A61N1/36128Control systems
    • A61N1/36135Control systems using physiological parameters
    • A61N1/36139Control systems using physiological parameters with automatic adjustment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/0003Accessories therefor, e.g. sensors, vibrators, negative pressure
    • A61M2016/0015Accessories therefor, e.g. sensors, vibrators, negative pressure inhalation detectors
    • A61M2016/0018Accessories therefor, e.g. sensors, vibrators, negative pressure inhalation detectors electrical
    • A61M2016/0024Accessories therefor, e.g. sensors, vibrators, negative pressure inhalation detectors electrical with an on-off output signal, e.g. from a switch
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/05General characteristics of the apparatus combined with other kinds of therapy
    • A61M2205/054General characteristics of the apparatus combined with other kinds of therapy with electrotherapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2230/00Measuring parameters of the user
    • A61M2230/60Muscle strain, i.e. measured on the user

Definitions

  • PPMV positive pressure mechanical ventilation
  • VDD Ventilator-Induced Diaphragmatic Dysfunction
  • PPMV Central Hypoventilation Syndrome
  • SCI Spinal Cord Injury
  • CCHS Congenital Central Hypoventilation Syndrome
  • phrenic nerve stimulation and diaphragmatic pacing use electrical stimulation to induce contraction of the diaphragm using an electrode and an external pacing control box or an implanted pacemaker device.
  • the two phrenic nerves which control activation of the diaphragm, run through the thorax, along the left and right sides of the heart, and then to the diaphragm.
  • Phrenic nerve stimulation is performed by electrically stimulating the phrenic nerve to control the patient's diaphragm, which may induce a respiratory cycle.
  • Conventional techniques include surgically implanting a nerve cuff around the phrenic nerve (at the neck or chest level), and then delivering an electrical stimulus from an externally located controller through the cuff to the phrenic nerve. This procedure is quite invasive, requiring incisions when deploying the nerve cuffs, and quite expensive, so it is only selectively used in patients with a life-long requirement for assisted ventilation.
  • the direct placement of the nerve cuffs around the phrenic nerves may damage the phrenic nerves.
  • diaphragmatic pacing Another method for electrically stimulating the diaphragm is known as diaphragmatic pacing.
  • diaphragmatic pacing is performed by laparoscopically implanting four electrodes directly on the diaphragm (two on each side), with electrical leads connected to a controller residing external to the body.
  • Conventional diaphragmatic pacing procedures are also quite time consuming and relatively invasive, requiring incisions during implantation, presenting risk during the implantation procedure and risk of chronic infection at the lead entrance sites to the body. Accordingly, these diaphragmatic pacing systems have not heretofore been prescribed for temporary use in critically ill ICU patients.
  • the diaphragmatic pacing system of the '215 Patent is employed to administer therapy to convert Type IIa (fast-type) muscle fibers to Type I (slow-type) muscle fibers in patients who have been ventilated for prolonged periods, whose muscle fibers have all atrophied and converted to Fast-type (VIDD).
  • VDD Fast-type
  • the therapy described in the '215 Patent will not be desirable in the treatment of critical care patients that still have both Type IIa (fast-type) muscle fibers and Type I (slow-type) and will need to have both types to successfully wean off of PPMV.
  • Examples of systems and methods disclosed herein address this need and others by providing a minimally invasive nerve stimulation system that paces the phrenic nerves transvascularly via disposable endovascular electrodes that can be percutaneously placed under local anesthesia.
  • pacing systems and methods can be employed to provide short periods of electrical stimulation for preventing diaphragm disuse atrophy in patients at risk of becoming ventilator-dependent and/or to rehabilitate diaphragm disuse atrophy in ventilator-dependent patients.
  • the system is designed to work either in conjunction with a mechanical ventilator, causing diaphragmatic contractions in synchrony with each ventilator administered breath, intermittently synchronized to some ventilator breaths, or as a stand-alone system.
  • the systems and methods may be employed just minutes or hours after first intubation of the subject.
  • Such diaphragm pacing therapy is expected to prevent, reduce or reverse diaphragm disuse atrophy that typically occurs in patients who are on PPMV or are expected to require PPMV and sedation for prolonged periods and by extension, the adverse effects associated with PPMV will be avoided or reduced.
  • patients may be successfully weaned from PPMV earlier than currently known methods, providing drastic health benefits to patients not to mention substantial reductions in total in-patient costs.
  • a method for administering a treatment plan designed for preventing or reversing diaphragm disuse atrophy in a patient receiving respiratory assistance from a ventilator.
  • the ventilator is employed to provide a breath cycle to the patient, the patient having a prescribed assist level.
  • the method comprises monitoring the breath cycle of the ventilator, administering a pre-programmed stimulation signal to the patient to recruit the phrenic nerve of the patient, and regulating the diaphragm output of the patient for each breath cycle.
  • the stimulation signal is administered via one or more endovascular electrodes.
  • the administration of the stimulation signal can occur within a time period, such as 1 hour, 3 hours, 6 hours, 12 hours, 1 day, 3 days, and 1 week, of the patient's first reception of respiratory assistance from the ventilator.
  • the method also includes obtaining data indicative of at least one of: one or more ventilator breath parameters; one or more pacing parameters; and a prescribed assist level for the patient.
  • the one or more ventilator breath parameters includes timing data indicative of the duration of a ventilated breath.
  • the method also includes maintaining synchrony between the delivery of the stimulation signal and the ventilator breath cycle.
  • maintaining synchrony includes determining the current breath cycle via data from one or more sensors, and comparing the current breath cycle with the timing data from at least one previous breath cycle.
  • recruitment of the diaphragm provides at least a portion of the prescribed assist level.
  • the method further comprises determining a diaphragm contribution level attributable to the administration of the stimulation signal, wherein the prescribed assist level is the sum of the diaphragm contribution level and a ventilator contribution level.
  • the simulation signal includes stimulation signal characteristics that cause the stimulation signal, when delivered to the patient, to satisfy the diaphragm contribution level.
  • the diaphragm contribution level is measured in tidal volume or pressure, individually, in combination, and including components thereof.
  • the prescribed diaphragm contribution level is dependent on the condition of the patient and the contractile capacity and/or functional status of the diaphragm.
  • determining the contractile capacity includes measuring strength and endurance from the response of the diaphragm to test stimulation patterns.
  • the condition of the patient and contractile capacity of the diaphragm and/or functional status of the phrenic nerves are assessed prior to the administration of the treatment plan and/or during administration of the treatment plan.
  • determining the strength and endurance of the patient's diaphragm includes measuring maximum diaphragm output and fatigue characteristics of the diaphragm.
  • monitoring the breath cycle includes sensing breath cycle data via a breath sensor discrete from and interfaced with a breathing circuit of the ventilator and the patient airway, and determining the inspiration phase and the expiration phase of the breath cycle and the duration of each phase from the sensed breath cycle data.
  • monitoring the breath cycle further includes determining at least one of the amplitude and rate of change of ventilator output signals for each breath.
  • administering a stimulation signal includes generating a stimulation signal in accordance with one or more pacing parameters; and delivering the stimulation signal in relation to a ventilator breath cycle.
  • regulating the diaphragm output of the patient for each breath cycle includes monitoring the diaphragm output in response to the last administered stimulation signal; and comparing the diaphragm output of the last administered stimulation signal to a preset target range.
  • the method can skip pacing for one breath cycle (MV-Only), but stimulate the at the next breath cycle (i.e., mechanical ventilation and diaphragm pacing. The method can then compare both of these values and regulate the next paced breath.
  • monitoring the diaphragm output in response to the last administered stimulation signal includes sensing diaphragm output data via one or more sensors, wherein the diaphragm output data is indicative of one or more of: air flow, tidal volume, pressure, and/or parameters derived from combinations of flow, tidal volume and/or pressure; and processing the sensed diaphragm data to determine the diaphragm output.
  • regulating the diaphragm output of the patient for each breath cycle further includes modifying the stimulation signal to be administered with the next ventilator breath if the diaphragm output of the last administered stimulation signal is outside of the preselected target range.
  • the preselected target range includes a diaphragm contribution level.
  • the method further comprises determining a cause if the diaphragm output of the last administered stimulation signal is outside of the preselected target range.
  • the condition of the patient's diaphragm and respiratory system during administration of the treatment plan is assessed.
  • the method further comprises reprogramming the stimulation signal based on the condition of the assessed diaphragm.
  • assessing the diaphragm includes monitoring data indicative of flow and pressure of the ventilator breath cycle to determine timing of the end expiration delay; progressively stimulating the diaphragm with stimulating signals based on the monitored data of the ventilator breath cycle; and determining one or more functional characteristics of the diaphragm and respiratory system, wherein the one or more functional characteristics includes one or more of Maximum Static Inspiratory Pressure, Inspiratory Capacity, Work of Breathing, Pressure-Time Product, Pressure-Time Index, Electromyogram (EMG), Maximum Relaxation Rate, and Expiration Time Constant.
  • EMG Electromyogram
  • the diaphragm stimulation is targeted to take place during each ventilator breath in order to reduce positive pressure and reduce the risk of Ventilator Induced Lung Injury (VILI).
  • VIP Ventilator Induced Lung Injury
  • monitoring the breath cycle of the ventilator includes sensing signals indicative of ventilator inspiration and expiration; and calculating one or more of: inspiration phase; expiration phase; inspiration pause; expiration pause.
  • administering the stimulation signal includes delivery of the stimulation signal contemporaneously with inspiration phase.
  • a transvascular diaphragm pacing system for preventing or reversing diaphragm disuse atrophy in a patient receiving respiratory assistance from a ventilator.
  • the system comprises at least one endovascular electrode configured to transmit a stimulation signal delivered thereto.
  • the stimulation signal in some embodiments is configured to recruit a phrenic nerve of the patient, the stimulation signal in some embodiments have one or more stimulation parameters.
  • the system also includes one or more sensors configured to sense breath cycle signals from an associated ventilator and diaphragm response from recruitment of the phrenic nerve, and a pulse generator coupled in electrical communication with the at least one endovascular electrode, and at least one input device configured to input data indicative of one or more aspects of a therapy plan.
  • the system further includes a controller coupled in electrical communication with the one or more sensors, the at least one input device, and the pulse generator.
  • the controller is some embodiments is programmed to: receive input data indicative of one or more aspects of the therapy plan, wherein the input data includes sensed signals indicative of ventilator operation and one or more pacing parameters; monitor the breath cycle signals and determine the inspiration phase and expiration phase of the breath cycle; generate the stimulation signal according to the one or more pacing parameters and delivering the generated stimulation signal to the at least one transvascular electrode at a preselected time of the ventilator breath cycle; and regulate the diaphragm output of the patient for each breath cycle.
  • the controller is further programmed to regulate the diaphragm output of the patient to satisfy a prescribed assist level of the patient.
  • the controller is further programmed to maintain synchrony of the delivery of the stimulation signal with the ventilator breath cycle.
  • the controller is further programmed to: monitor the diaphragm output in response to the last administered stimulation signal; and compare the diaphragm output of the last administered stimulation signal to a preselected target range.
  • the controller is programmed to monitor the diaphragm output by sensing diaphragm output data via one of said one or more sensors and processing the sensed diaphragm data to determine the diaphragm output, wherein the diaphragm output includes flow, tidal volume and/or pressure and/or parameters derived from combinations of flow, tidal volume and/or pressure.
  • the controller is further programmed to modify the stimulation signal to be administered with the next ventilator breath if the diaphragm output of the last administered stimulation signal is outside a preselected range.
  • the signal could be modified and administered at the next breath with programmed pacing (i.e., a combined breath) as some ventilator breaths may be skipped between stimulations.
  • the controller is further programmed to determine a cause if the diaphragm output of the last administered stimulation signal is outside of the preselected target range.
  • the controller determines that the cause is due to a variation in the respiratory mechanics of the patient, then the controller is further programmed to assess the condition of the patient's diaphragm and respiratory system during administration of the treatment plan.
  • the controller is further programmed to reprogram the stimulation signal based on the condition of the assessed diaphragm.
  • the controller is further programmed to assess the diaphragm by monitoring data indicative of flow and pressure of the ventilator breath cycle to determine timing of the end expiration delay, progressively stimulating the diaphragm with stimulating signals based on the monitored data of the ventilator breath cycle, and determining one or more functional characteristics of the diaphragm and respiratory system.
  • the one or more functional characteristics includes one or more of Maximum Static Inspiratory Pressure, Inspiratory Capacity, Work of Breathing, Pressure-Time Product, Pressure-Time Index, EMG, Maximum Relaxation Rate, and Expiration Time Constant.
  • the controller is further programmed to determine the readiness to wean from the ventilator based on the assessment of the diaphragm.
  • the stimulation signal includes a doublet or triplet pulse at the beginning of the stimulation train or in the middle of the simulation train.
  • a method for preventing respiratory disuse atrophy in a patient who is attached to a mechanical ventilator and receiving artificial breath cycle respiratory assistance and sedation.
  • the method comprises placing a first electrode in the patient's vasculature in proximity to the left phrenic nerve, placing at second electrode in the patient's vasculature in proximity to the right phrenic nerve, and within hours of attaching the patient to the ventilator, delivering a pre-programmed stimulation signal to the first and second electrodes in order to stimulate the diaphragm in synchrony with the ventilator breath cycle.
  • within hours includes one of the following: within twelve hours; within six hours, within five hours; within four hours, within three hours; and within one hour.
  • a method for administering a treatment plan for preventing or speeding up reversal of diaphragm disuse atrophy in a patient receiving respiratory assistance from a ventilator.
  • the ventilator provides a breath cycle to the patient and the patient has a prescribed assist level.
  • the method comprises storing a measurement value indicative of a preselected range of diaphragm output, wherein the diaphragm output is at least a portion of the prescribed assist level, monitoring the breath cycle of the ventilator, administering a stimulation signal to the patient in synchrony with the breath cycle of the ventilator to recruit the diaphragm of the patient, the recruitment of the diaphragm causing a level of diaphragm output, and regulating the diaphragm output of the patient attributable to phrenic recruitment for each stimulated breath cycle in order to fall within the preselected range of diaphragm output.
  • regulating the diaphragm output of the patient for each breath cycle includes monitoring the diaphragm output in response to the last administered stimulation signal, and comparing the diaphragm output of the last administered stimulation signal to the preselected range of diagram output.
  • monitoring the diaphragm output in response to the last administered stimulation signal includes sensing diaphragm output data via one or more sensors, and processing the sensed diaphragm output data to determine the diaphragm output.
  • the diaphragm output includes one or more of: air flow, tidal volume, pressure, and/or parameters derived from combinations of flow, tidal volume and/or pressure.
  • regulating the diaphragm output of the patient for each breath cycle further includes comparing the determined diaphragm output to the preselected range of diagram output, and modifying the stimulation signal to be administered with the next ventilator breath if the diaphragm output from the last administered stimulation signal fell outside of the preselected range of diagram output.
  • modifying the stimulation signal includes increasing the intensity of the stimulation signal.
  • increasing the intensity includes one or more of: increasing the frequency of stimulation signal pulses; increasing the amplitude of stimulation signal pulses; and/or increasing the duration of stimulation signal pulses.
  • diaphragm output includes tidal volume, pressure, or combinations thereof.
  • a method for preventing diaphragm disuse atrophy in a critically ill patient.
  • the method comprises attaching a patient to a ventilator, monitoring the breath cycle of the ventilator; administering, within one of twelve hours or six hours of attaching the patient to the ventilator, a pre-programmed stimulation signal to the patient to recruit the diaphragm of the patient for outputting a level of diaphragm output, and regulating the level of diaphragm output of the patient for each breath cycle based on the administration of the stimulation signal to match or exceed a preselected threshold.
  • a method for constructing a therapy plan for a patient.
  • the therapy plan attempts to prevent disuse atrophy or rehabilitate the patient's diaphragm.
  • the method comprises assessing the diaphragm for maximum diaphragm output and fatigue characteristics, and determining one or more stimulation signals that cause diaphragm output to be a preselected percentage of the maximum diaphragm output.
  • the method further comprises creating a stimulation administration plan including a series of discrete stimulation signals, wherein the series of stimulation signals can vary by rate, duration, pulse width, frequency, and amplitude.
  • a method for assessing a diaphragm.
  • the method comprises monitoring data indicative of flow and pressure of a ventilator breath cycle, stimulating the diaphragm with stimulating signals based on the monitored data of the ventilator breath cycle, and determining one or more functional characteristics of the diaphragm from the response generated from the stimulation of the diaphragm with the stimulation signals.
  • the one or more functional characteristics including one or more of Maximum Static Inspiratory Pressure, Inspiratory Capacity, Work of Breathing, Pressure-Time Product, Pressure-Time Index, EMG, Maximum Relaxation Rate, and Expiration Time Constant.
  • a transvascular diaphragm pacing system for constructing a therapy plan for a patient.
  • the therapy plan in some embodiments prevents diaphragm disuse atrophy or rehabilitates the patient's diaphragm.
  • the system includes at least one endovascular electrode configured to transmit a stimulation signal delivered thereto.
  • the stimulation signal in some embodiments is configured to recruit a phrenic nerve of the patient and the stimulation signal has one or more stimulation parameters.
  • the system also includes one or more sensors configured to sense breath cycle signals from an associated ventilator and diaphragm response from recruitment of the phrenic nerve, a pulse generator coupled in electrical communication with the at least one endovascular electrode, and at least one input device configured to input data indicative of one or more aspects of a therapy plan.
  • the system further includes a controller coupled in electrical communication with the one or more sensors, the at least one input device, and the pulse generator.
  • the controller is some embodiments is programmed to assess the diaphragm for maximum diaphragm output and fatigue characteristics, and determine one or more stimulation signals that cause diaphragm output to be a preselected percentage of the maximum diaphragm output.
  • a transvascular diaphragm pacing system for assessing a diaphragm.
  • the system includes at least one endovascular electrode configured to transmit a stimulation signal delivered thereto.
  • the stimulation signal in some embodiments is configured to recruit a phrenic nerve of the patient and the stimulation signal has one or more stimulation parameters.
  • the system also includes one or more sensors configured to sense breath cycle signals from the ventilator and the diaphragm response from recruitment of the phrenic nerve, a pulse generator coupled in electrical communication with the at least one endovascular electrode, and at least one input device configured to input data indicative of one or more aspects of a therapy plan.
  • the system further includes a controller coupled in electrical communication with the one or more sensors, the at least one input device, and the pulse generator.
  • the controller is some embodiments is programmed to: monitor data indicative of flow and pressure of a ventilator breath cycle; stimulate the diaphragm with stimulating signals based on the monitored data of the ventilator breath cycle; and determine one or more functional characteristics of the diaphragm from the response generated from the stimulation of the diaphragm with the stimulation signals.
  • the one or more functional characteristics include one or more of Maximum Static Inspiratory Pressure, Inspiratory Capacity, Work of Breathing, Pressure-Time Product, Pressure-Time Index, EMG, Maximum Relaxation Rate, and Expiration Time Constant.
  • FIG. 1 is a schematic diagram of one example of a transvascular diaphragm pacing system formed in accordance with aspects of the present disclosure
  • FIG. 2 is a schematic diagram of the location of the left and right phrenic nerves in a patient in relation to the heart and diaphragm of the patient;
  • FIG. 3A is one example of one pair of catheter-mounted phrenic nerve stimulating electrodes positioned within the left subclavian vein of the patient;
  • FIG. 3B is one example of one pair of catheter-mounted phrenic nerve stimulating electrodes positioned within the superior vena cava of the patient;
  • FIG. 4 is a block diagram of the components of one embodiment of the system of FIG. 1 ;
  • FIG. 5 illustrates the shift in force generated when stimulating with a train that begins with a doublet/triplet
  • FIG. 6 illustrates one example of the programmable parameters of each stimulation pulse as well as the ratiometric relationship between the charge injection pulse and charge balance pulse when exemplifying net-charge;
  • FIG. 7 illustrates one example of three stimulation trains, in each of which the pulse width and frequency are modulated to increase from the start to end of the stimulation train to cause graded contraction of the diaphragm;
  • FIG. 8 illustrates one example of three stimulation trains, in each of which the pulse width and frequency are modulated to first increase and then decrease from the start to end of the stimulation train to cause graded contraction of the diaphragm;
  • FIG. 9 illustrates examples of representative ramp envelopes where the ramp slopes represent the modulations in pulse width and/or pulse frequency within a train
  • FIG. 10 illustrates examples of representative pulse width ramp envelopes and stimulus frequency envelopes, which can be combined together to form a single pacing ramp
  • FIG. 11 illustrates examples of timing for the start time and end time of stimulation trains generated and delivered to the phrenic nerves, relative to a ventilator breath;
  • FIG. 12 illustrates other examples of timing for the stimulation trains generated and delivered to the phrenic nerves
  • FIG. 13 illustrates yet other examples of timing as well as amplitude modulations for the stimulation trains generated and delivered to the phrenic nerves
  • FIG. 14 illustrates one example of a process configured to carry out one or more functions of the system 20 , including but not limited to the Ventilator Initiated Pacing Mode;
  • FIG. 15 illustrates one feedback scheme that may be practiced by the process of FIG. 14 and the system of FIG. 1 ;
  • FIG. 16 illustrates one example of a change in respiratory mechanics during pacing in synchrony with a volume controlled mechanical ventilator
  • FIG. 17A-B illustrate examples of maintaining the diaphragm output at a prescribed level despite a time dependent fatiguing and drop-out of stimulated Type IIb fibers
  • FIG. 17C illustrates a process for using doublets to enhance force in fatiguing muscle
  • FIG. 18 illustrates one example of progressive recruitment of nerve axons across the cross-section of the phrenic nerve and their associated motor units by increasing the pacing intensity
  • FIG. 19 is a graphical representation for scaling the contribution of the system of FIG. 1 to prescribed assist level and determining one or more initial pacing parameters using, for example, a binary algorithm;
  • FIG. 20A is a schematic representation of one example of scaling the contribution of the system of FIG. 1 to diaphragm response;
  • FIG. 20B is a schematic representation of another example of scaling the contribution of the system of FIG. 1 to diaphragm response;
  • FIG. 21 is a graphical representation of one example of calculating the Work of Breathing (WOB), the calculation in turn used to regulate diaphragm contribution;
  • WOB Work of Breathing
  • FIG. 22 is one example of a routine for assessing the diaphragm without disconnecting the patient from the ventilator
  • FIGS. 23 and 24 illustrate examples of the timing of administered stimulus in relation to the phases of the breath cycle
  • FIG. 25 is a graphical representation of airway pressure data obtained from a volume controlled ventilator with and without stimulation
  • FIG. 26 is a graphical representation of one example of calculating the Pressure-Time Product, the calculation in turn used to regulate diaphragm contribution.
  • FIG. 27 is one example of an assessment routine carried out by the system of FIG. 1 ;
  • FIG. 28 is a graphical representation of end expiratory pauses, sometimes referred to as quiet periods
  • FIG. 29 is one example of a routine for determining the duration of the end-expiratory pause
  • FIG. 30 is a schematic diagram showing one example of a Pacer-Initiated Ventilation Mode that can be carried out by one or more embodiments of the system shown in FIG. 1 ;
  • FIG. 31 illustrates the relationship between the pacing system and the ventilator in Pacer-Initiated Ventilation Mode
  • FIG. 32 is a schematic diagram showing one example of a pacing system operating in an Autonomous Mode.
  • FIG. 33A-C graphically represent the benefits of examples of the system of FIG. 1 in preventing diaphragm disuse atrophy or rehabilitating the diaphragm for successful weaning from respiratory assistance.
  • TDPS transvascular diaphragm pacing systems
  • Some examples of the TDPS provide rapid insertion and deployment of endovascular pacing electrodes in critically ill patients who require intubation and invasive PPMV in order to support the physiological requirements of the human ventilatory system.
  • Examples described herein make best use of the contractile properties of the diaphragm muscle and prevent muscle disuse and muscle atrophy. This can be carried out by engaging the phrenic nerves using patterned functional electrical stimulation applied to endovascular electrodes that are temporarily and reversibly inserted in central veins of the patient, such as the left subclavian vein and the superior vena cava.
  • the TDPS is designed to seamlessly interface with any commercially available positive-pressure ventilatory assistance/support equipment such as is commonly in use in hospital intensive care units (ICU) for treating critically ill patients with breathing insufficiencies, pain, trauma, sepsis or neurological diseases or deficits.
  • ICU hospital intensive care units
  • Rapid insertion and deployment of the disclosed systems can be effected via employment of minimally invasive central line catheter-based electrodes, such as those described in U.S. application Ser. No. 12/524,571, filed Jul. 25, 2009, which can be quickly installed in the patient under local anesthesia and rapidly activated, such that a pacing therapy can be initiated within one or a few hours of admission/intubation.
  • pacing via electrical stimulation can proceed in synchrony with ventilator breaths provided by virtually any brand or model of commercially available positive-pressure ventilator operating in typical modes such as Control Mode, Support Mode or Assist Mode.
  • the pacing catheter electrodes can be easily removed.
  • system pacing follows the operation of a ventilator while in other embodiments, the ventilator initiates and/or assists a breath cycle based on physiological responses generated by the pacing system.
  • FIG. 33A-C illustrate examples of employing the TDPS to prevent diaphragm disuse atrophy or rehabilitate the diaphragm for successful weaning from respiratory assistance. As a result, early and successful weaning from the ventilator can be realized.
  • each phrenic nerve may be recruited using a single channel of stimulation or two or more channels of stimulation per nerve.
  • An example showing one embodiment employing two channels of stimulation per phrenic nerve is shown in FIG. 3 .
  • the stimulation pulses can be delivered 180 degrees out of phase.
  • the system 20 includes a stimulator 24 coupled in electrical communication (e.g., wired or wireless) with one or more transvascular electrodes 28 suitable for placement in-vivo near the left and/or right phrenic nerves.
  • the stimulator 24 is configured to transmit a stimulatory signal in the form of stimulation pulses to one or more of the electrodes 28 .
  • the electrodes 28 emit the stimulatory signal in the vicinity of a left and/or right phrenic nerve. Stimulation of the left and/or right phrenic nerve, in turn, aims to cause recruitment of the subject's diaphragm.
  • the parameters (amplitude, duration, frequency, etc.) of stimulation pulses affect the amount of diaphragm recruitment, and the resulting output (such as tidal volume, pressure) therefrom.
  • sensors 48 configured to sense various physiological parameters of the patient, some indicating diaphragm output, can provide feedback to the stimulator 24 for regulation of the administered therapy.
  • the system 20 can be the sole respiratory aid for the patient.
  • the system 20 operates in conjunction with a positive pressure mechanical ventilator 32 (“ventilator 32 ”) in order to satisfy the respiratory needs of the patient.
  • a positive pressure mechanical ventilator 32 (“ventilator 32 ”) in order to satisfy the respiratory needs of the patient.
  • signals sensed from a breath sensor 50 that monitors the breath cycle of the ventilator 32 can be employed to synchronize the delivery of the stimulation signals with the ventilator breath cycle.
  • the respiratory needs of the patient are sometimes referred to as the patient's prescribed assist level.
  • the prescribed assist level is generally quantified as the amount of tidal volume or pressure (or a combination of the two) provided to the patient during one breath cycle that satisfies the minimum physiological functions of the patient.
  • the prescribed assist level in terms of tidal volume is approximately 7-10 mL per Kg of patient weight.
  • the prescribed assist level is satisfied solely via artificial means (e.g., via system 20 , via ventilator 32 , or a combination of the two). This may occur in patients that are heavily sedated and/or unconscious.
  • the prescribed assist level may include some patient initiated respiratory effort.
  • the clinician can program the system 20 in order to satisfy the prescribed assist level (i.e., in tidal volume, pressure, or both) via recruitment of the diaphragm.
  • the clinician can program the system 20 to contribute only a percentage of the prescribed assist level (in volume, pressure, or both), referred to herein as the diaphragm contribution or diaphragm contribution level, via electrical recruitment of the phrenic nerve or nerves.
  • the percentage can vary, and is patient-dependent based on a variety of factors, such as the condition of the patient, the ailment afflicting the patient, time elapsed preceding any stimulation therapy, etc.
  • the remaining percentage of the prescribed assist level can then be satisfied by the ventilator 32 , which can be appropriately programmed by the clinician at the onset of or during administration of the therapy plan.
  • the system 20 carries out one or more assessments of the patient in order to determine, for example, the current condition of the patient's diaphragm, the stimulation signal characteristics that relate to the recruitment of the diaphragm, such as threshold pulse width, pulse amplitude, pulse frequency, sub-maximal pulse width, and supra-maximal pulse width, etc.
  • Threshold Pulse Width refers to a minimum pulse width at and above which there is a diaphragmatic response.
  • Threshold Frequency refers to a minimum frequency at and above which partly or completely fused Tetanic contractions are produced, so as to generate useful diaphragmatic force and/or work.
  • the left and right phrenic nerves run along the lateral and medial side of the heart to a diaphragm D.
  • the left subclavian vein traverses in proximity to the left phrenic nerve and transmits blood from the upper extremities to the heart H.
  • the superior vena cava traverses near the right phrenic nerve and carries deoxygenated blood from the upper half of the body to the heart's right atrium.
  • FIG. 3 illustrates one embodiment showing two channels of transvascular stimulation delivered to the left phrenic nerve by endovascular electrodes placed in the left subclavian vein and two channels of transvascular stimulation delivered to the right phrenic nerve by endovascular electrodes placed along the lateral wall of the superior vena cava.
  • Each phrenic nerve can be partially or fully recruited from more than one endovascular electrode combination. Partial nerve recruitment from more than one electrode combination is useful to reduce muscle fatigue over time.
  • the system 20 includes a first electrode 28 A having anodal and cathodal electrode contacts 30 A, 32 A placed within the left subclavian vein and positioned in the vicinity of the left phrenic nerve.
  • a second electrode 28 B having anodal and cathodal electrode contacts 30 B, 32 B may be also placed within the left subclavian vein and positioned in the vicinity of the left phrenic nerve.
  • the system 20 further includes a third electrode 28 C having anodal and cathodal electrode contacts 30 C, 32 C placed within the superior vena cava and positioned in the vicinity of the right phrenic nerve.
  • a fourth electrode 28 D having anodal and cathodal electrode contacts 30 D, 32 D may be also placed within the superior vena cava and positioned in the vicinity of the right phrenic nerve.
  • Electrodes While two electrodes are shown and described for stimulating each of the left and right phrenic nerves, it will be appreciated that other numbers of electrodes may be practiced with embodiments of the present disclosure. For example, four electrodes can be used for stimulating each phrenic nerve.
  • U.S. application Ser. No. 12/524,571 filed Jul. 25, 2009, the disclosure of which is hereby expressly incorporated in its entirety.
  • electrodes with anodal and cathodal electrode contacts are utilized to emit the stimulation pulses into the phrenic nerves, other configurations are possible. For example, several cathodal electrode contacts may be used in conjunction with a single anodal electrode contact, and vice versa.
  • Each electrode 28 is connected in electrical communication with the stimulator 24 .
  • each electrode 28 is electrically connected to the stimulator 24 via lead(s) 40 .
  • the system 20 further includes one or more sensors 48 configured to monitor the response to phrenic nerve stimulation and/or other physiological characteristics of the patient. As will be described in more detail below, the one or more sensors 48 can be part of a feedback control scheme for regulating the stimulation administered to the patient.
  • the plurality of sensors 48 can transmit data to the stimulator 24 indicative of one or more of the following: electromyographic activity (intramuscular, surface, and/or intraesophageally monitored), central venous pressure (any specific component of this signal), heart rate, chest wall acceleration, blood oxygen saturation, carbon dioxide concentration, catheter position/depth within vein, mechanical movement (i.e., from accelerometers, length gauges, and/or strain gauges) resistance (.e., from impedance pneumographs, and/or piezoresistive sensors) and/or other physiological or mechanical parameters. It will be appreciated that the information can be appropriately processed (e.g., filtered, conditioned, amplified, etc.) prior to use by the stimulator 24 .
  • volume includes, but is not limited to, Inspired Tidal Volume, Expired Tidal Volume or Minute Volume.
  • pressure as used herein includes, but is not limited to, Airway Pressure, Alveolar Pressure, Ventilator Pressure, Esophageal Pressure, Gastric Pressure, Transdiaphragmatic Pressure, Intra-Thoracic Pressure Positive End-Expiratory Pressure or Pleural Pressure. Any pressure may be Peak Pressure, Mean Pressure or Baseline Pressure.
  • flow as used herein includes, but is not limited to, Inspiratory Flow or Expiratory Flow.
  • the electrodes 28 can also monitor physiological variables of the subject by virtue of their placement in the central veins.
  • monitored physiological variables can include, but are not limited to: central venous pressure, electrocardiogram, and mixed venous oxygen saturation.
  • one or more sensors discrete from the electrodes, such as one or more of the sensors 48 may be used to monitor such physiological variables.
  • the system 20 can additionally or alternatively include a breath sensor 50 for sensing parameters of the ventilator 32 .
  • the breath sensor 50 can be configured to interface with any standard breathing circuit used in critical care ventilators and therefore the pacing system is independent of the brand of ventilator used.
  • the breath sensor 50 by virtue of its location in the breathing circuit, can monitor and/or measure several ventilation parameters and communicate such parameters to the stimulator 24 .
  • the breath sensor 50 can be part of or used solely as a feedback control scheme for regulating the stimulation administered to the patient.
  • the sensed ventilation parameters may include, but not limited to, airflow (inspired and/or expired), volume, pressure (airway, esophageal, gastric, and/or some combination/derivative of the former).
  • other sensors may aid in the procurement of one or more ventilation parameters.
  • the example parameters are being measured both to and from the ventilator 32 .
  • the breath sensor 50 is external to the ventilator 32 so that the system is independent of ventilator model.
  • the system 20 could also be integrated to use a ventilator's internal sensors or signals externally supplied by the ventilator can provide the information to the system 20 for proper operation so that an external breath sensor can be omitted.
  • the stimulator 24 functions, in part, as a signal generator for providing therapy to the diaphragm in response to information received from the one or more of the sensors 48 and 50 and/or information programmed into the system 20 by the clinician.
  • the stimulator 24 delivers pulses to the endovascular electrodes 28 in accordance with one or more protocols described herein.
  • the pulses in some embodiments are generated by the stimulator 24 with characteristics that deliver a suitable charge to the phrenic nerves in order to provide enough diaphragm recruitment to satisfy the selected diaphragm contribution (e.g., in volume, pressure, both, or derived parameters from volume and pressure) of the prescribed assist level described above.
  • the stimulator 24 is configured to deliver fully programmable stimulation, including, but not limited to, the following: any number of pulses, any combination of the defined pulses, any order of delivery of the defined pulses, multiple instances of any defined pulse(s), any frequency of stimulation, and/or any delay between pulses (interpulse delay).
  • Each pulse can be independently programmable (e.g., frequency, amplitude, duration, etc.).
  • the stimulation pulse(s) and/or train(s) may or may not generate a repeatable pattern.
  • Each pulse includes a charge injection phase and a charge balance phase (biphasic).
  • the balance phase duration and amplitude is programmable as a ratio of the charge phase duration and amplitude so that zero net charge is maintained, as shown in FIG. 6 .
  • This ratio denominated as the Charge:Balance Ratio (C:B Ratio)
  • C:B Ratio Charge:Balance Ratio
  • each pulse is programmable via the following parameters: ratio of charge phase duration to balance phase duration; pulse width range; stimulation amplitude (current level); and delay between the charge phase and the balance phase.
  • Stimulation amplitude may be changed during the same phase (i.e., generate a gradually decreasing current for the charge pulse width). While zero net change is preferred, non-netzero charges may be used.
  • pacing may be accomplished by delivering one or more stimulation signals to produce a mechanically effective contraction of the diaphragm.
  • the stimulation signals may include a plurality of pulses that are grouped in stimulation trains.
  • a stimulation train is defined as a collection of stimulation pulses. This definition does not imply a specific composition, order of delivery, and/or shape profile or envelope.
  • FIGS. 7 and 8 illustrate examples of stimulation trains generated by the stimulator 24 and delivered to the electrodes 28 for stimulating the phrenic nerves.
  • the stimulation trains may start with a doublet (pair of pulses) or a triplet, which can be physiologically relevant; two or three pulses in quick succession at the beginning of recruitment has been shown to increase the overall force profile by shifting the baseline up during the initial onset of recruitment, as demonstrated in FIG. 5 .
  • a doublet or triplet delivered part-way through a train can cause a sustained force increase.
  • the upward shift in early force production infers that fewer stimulation pulses can be used to generate the same amount of force from the diaphragm in a comparable period of time.
  • Stimulation or pulse trains are typically characterized by the rate, the duration, the pulse width, the frequency, and the amplitude of the signals.
  • the rate of the stimulation train corresponds to the number of stimulation trains delivered per minute, which can correlate with the patient's respiratory rate or mechanical ventilator rate.
  • the duration of the stimulation train refers to the length of time the stimulation train is delivered.
  • the pulse width indicates the duration of each individual pulse creating the stimulation train.
  • the frequency indicates the number of individual pulses delivered per second.
  • the amplitude refers to the voltage of each pulse delivered. The parameters of amplitude, frequency, and pulse width determine the strength of the induced diaphragmatic pacing.
  • the stimulation trains form ramp trains.
  • ramp trains can be formed by linearly increasing (or decreasing) either the instantaneous frequency of consecutive pulses in a train, the durations (pulse widths) of consecutive pulses in a train, or both.
  • Ramp trains indicate that a change in injected charge is induced by the programmed stimulation parameters and any applied modulation.
  • ramp envelopes can be generated during a single pacing ramp in pulse width alone, frequency alone or both in pulse width and frequency.
  • Pulse width and stimulus frequency envelopes can be modulated together or combined, as shown in the examples of FIG. 10 , during pacing to generate a desired ramp train.
  • combination AF will cause a graded recruitment of the phrenic motoneurons at a constant frequency (no rate coding) and Combination BA will gradually recruit and de-recruit the motoneurons, with a steadily increasing rate coding; although any combination is possible.
  • pulse width and frequency modulation can be defined mathematically as piecewise functions in time, thereby allowing any desired ramp envelope to be generated while remaining within the scope of the present disclosure.
  • the ramp trains aim to achieve one or more of the following: 1) mimic physiological contraction of the diaphragm by independently controlling recruitment and rate coding by means of pulse width and frequency modulation, respectively; 2) delay the onset of neuromuscular fatigue; 3) maintain the native fiber composition of the healthy diaphragm; 4) condition the diaphragm towards a specific fiber type, for e.g. Type I (Slow Twitch, Fatigue Resistant).
  • a therapy plan can be constructed by the clinician with or with the aid of the system 20 .
  • the therapy plan constructed by the clinician is patient dependent in order to achieve various goals.
  • the therapy plan may include one or more of the following: timing of delivery of pacing in relation to ventilator breaths (e.g., every breath, every other breath, every five breaths, etc.); intermittent stimulation segments (e.g., stimulation delivery for 15 minutes every hour), etc.
  • timing of delivery of pacing in relation to ventilator breaths (e.g., every breath, every other breath, every five breaths, etc.); intermittent stimulation segments (e.g., stimulation delivery for 15 minutes every hour), etc.
  • a therapy plan would take into consideration both major objectives of minimizing VIDD and minimizing risk of VILI.
  • the therapy plan includes the ability to skip stimulation, sometimes referred to as skipped breaths, which allows for a ventilator breath to be delivered without being accompanied by stimulation from the system 20 .
  • the therapy plan may include sigh breaths. Sigh breaths are characterized as intermittently programmable breaths that inject more charge than a normal breath (i.e. a higher magnitude stimulation train). Physiologically, this results in a more forceful contraction of the diaphragm. Both functions are programmable independently and can be repeatable. For sigh breaths only, the percentage increase in amplitude is programmable based on the amplitude of a typical paced breath. It is possible to implement these features independently or combined.
  • FIG. 13A-C illustrate an example of skipped breaths, sigh breaths, and a combination of skipped breaths and sigh breaths, respectively.
  • FIG. 13A is an example of skipped breaths, where the system 20 skips every 3rd breath. This means that during the skipped breath, the patient receives the ventilatory support entirely from the ventilator 32 . During the skipped breaths, respiratory mechanics such as tidal volume, compliance of the lungs, resistance to airflow or the recruitment of the lung regions may vary.
  • FIG. 13B is an example of sigh breaths generated by the system 20 while operating in synchrony with the ventilator 32 . In this example, a sigh breath is delivered every 3 rd breath.
  • FIG. 13C is an example of both skipped and sigh breaths being administered in a periodic manner by the system 20 .
  • the stimulator 24 in some embodiments is configured to generate constant-amplitude current pulses with pulse duration in the range from 50-300 microsec, controllable in increments of 10 microsec.
  • the amplitude and duration of each pulse in a train can be independently programmed.
  • the amplitude of pulses can be selected between 0.1 and 10 mA in 0.1 mA increments.
  • the stimulator 24 can produce pulses in the range from 5 nC to 3000 nC and the charge per pulse can be specified in increments of 1 nC.
  • FIG. 4 shows a schematic diagram of one embodiment of the stimulator 24 .
  • the stimulator 24 includes a controller 60 , which receives signals sensed from one or more sensors 48 and/or the breath sensor 50 .
  • the stimulator 24 may also include a timer 64 coupled to controller 60 , and a power source 68 .
  • the controller 60 is coupled to a pulse generation circuit 70 , which delivers stimulation signals to one or more of the electrodes 28 via leads 40 .
  • the components described above are coupled via bus 72 .
  • the power source 68 of the stimulator 24 includes one or more batteries.
  • the power source 68 includes a power regulation section that receives power from standard “mains,” and transforms it into appropriate power for the circuitry of the stimulator 24 .
  • controller 60 serves as the computational center of the stimulator 24 for carrying out logic or by supporting the execution of routines, instructions, etc., for providing functionality to the stimulator 24 .
  • the logic, routines, instructions, etc., described herein may be implemented in hardware, in software, or a combination of hardware and software.
  • the controller 60 includes one or more processors and memory.
  • the logic, routines, instructions, etc. may include a set of control algorithms, including resident program instructions and calibrations stored, for example, in the memory and executed to provide a desired functionality of the system 20 .
  • the algorithms may be executed during preset loop cycles such that each algorithm is executed at least once each loop cycle.
  • Algorithms stored in non-volatile storage medium can be executed by the processor to: 1) monitor inputs from the sensors 48 , 50 and other data transmitting devices or polls such devices for data to be used therein; 2) cause the pulse generator to generate and transmit one or more pulses to the electrodes 28 ; and 3) regulate the diaphragm output of the patient, among other functions.
  • Loop cycles are executed at regular intervals, for example each 3.125, 6.25, 12.5, 25 and 100 milliseconds during ongoing operation of the system 20 .
  • algorithms may be executed in response to the occurrence of an event.
  • the term processor is not limited to integrated circuits referred to in the art as a computer, but broadly refers to a microcontroller, a microcomputer, a microprocessor, a programmable logic controller, an application specific integrated circuit, other programmable circuits, such as programmable gate arrays, combinations of the above, among others.
  • the controller 60 may include additional components including but not limited to a high speed clock, analog to digital (A/D) and digital to analog (D/A) circuitry, input/output circuitry and devices (I/O) and appropriate signal conditioning and buffer circuitry.
  • the signals received from the sensors 48 , 50 may be processed by an optional signal processing section 80 prior to arriving at the controller 60 .
  • the signal processing section 80 may include dedicated circuits, processors, such as digital signal processors (DSP), etc., for receiving, processing and filtering electrical signals sensed by the sensors associated with the subject and/or the ventilator 32 .
  • Signal processing section 80 can include amplifiers and circuits to condition, filter and/or amplify the electrical signals supplied thereto.
  • the signal processing section 80 carries out discrete tasks, such as the determination of one or more physiological states.
  • One physiological state that can be determined by signal processing section 80 is a patient's minute volume or ventilation.
  • Minute ventilation is a respiratory related parameter that is a measure of the volume of air inhaled and exhaled during a particular period of time.
  • the minute ventilation is the product of respiration rate and tidal volume.
  • Signal processing section 80 can also be used to receive and process signals representing other respiratory activity such as intrathoracic pressure, chest wall motion, etc.
  • the determination of one or more physiological states, processing of signals, implementation of logic or processes, etc. can be carried out solely by the controller 60 .
  • the stimulator 24 includes one or more input devices 86 .
  • the input devices 86 may include switches, knobs, etc., supported by the housing of the stimulator, and/or computer style devices, such as a keyboard, a touchpad, etc.
  • the input devices 86 provide for the input of data, such as the pacing parameters, ventilator parameters, etc., into the stimulator 24 .
  • Output devices 92 such as a monitor, may also be provided.
  • one or more embodiments of the system 20 can be operated in various pacing modes.
  • the pacing modes may be alternatively employed by a clinician, depending on the clinical status and needs of each patient and on the operational properties of a ventilator, such as ventilator 32 , which may be available in a particular ICU.
  • the pacing modes can include but are not limited to Ventilator-Initiated Pacing Mode, Pacer-Initiated Ventilation Mode, and Autonomous Pacing Mode.
  • these modes may be engaged in many ways to generate different combinations of system functionality, but for reasons of brevity all possible combinations are not listed herein. Each of these modes will now be described in some detail.
  • the first mode of the system 20 to be described herein is the Ventilator Initiated Pacing Mode.
  • this mode operates the stimulator 24 in synchrony with the operation of the ventilator 32 .
  • This mode can work with any mechanical ventilator in control mode, whereby the flow or pressure is controlled by the ventilator and delivered at a pre-determined frequency (breath rate). Delivery of stimulation ramp trains generated by the stimulator 24 , such as any of those shown in FIGS. 9 and 10 , can be synchronized with the ventilator 32 in several ways, some of which are shown in FIGS. 11 and 12 .
  • stimulation can begin at any time before, during, or after the onset of the inspiratory phase of the ventilator 32 and/or can end at any time before, during, or after the end of the inspiratory phase of the ventilator 32 .
  • routine 100 configured to carry out one or more functions of the system 20 , including the Ventilator Initiated Pacing Mode.
  • the logic or routines described herein may represent one or more of any number of processing strategies such as event-driven, interrupt-driven, multi-tasking, multi-threading, and the like.
  • various acts or functions illustrated may be performed in the sequence illustrated, in parallel, or in some cases omitted.
  • the order of processing is not necessarily required to achieve the features and advantages, but is provided for ease of illustration and description.
  • one or more of the illustrated acts or functions may be repeatedly performed depending on the particular strategy being used.
  • the routine 100 begins at block 102 , where the system is initialized.
  • Initialization allows a clinician to program the system 20 , for example, by inputting via input devices 86 various system parameters according to a therapy plan.
  • the therapy plan can include a level of diaphragm contribution and the prescribed assist level if not already known by the system 20 or derivable from other data known by system 20 .
  • the level of diaphragm contribution can be entered as either a percentage of prescribed assist level or as tidal volume, pressure or both volume and pressure, or as a parameter derived from volume and pressure.
  • the clinician can input the prescribed assist level for the patient depending upon clinical status.
  • the prescribed assist level in some embodiments is programmed as tidal volume. Alternatively, it can also be programmed as: (1) a desired amount of pressure generated by the diaphragm; (2) the product of pressure and volume, referred to as Work of Breathing (WOB) shown in FIG. 21 ; (3) the integral of pressure with respect to time, referred to as Pressure-Time Product (PTP); (4) indices derived from the monitored variables, such as Pressure-Time Index (PTI); or (5) a reduction in the airway pressure attained by PPMV plus Pacing, when compared to PPMV alone.
  • the prescribed assist level can be set in terms of one of the parameters mentioned above or as a combination of one or more of these parameters, while remaining within the scope of the claimed subject matter.
  • the clinician can program the system 20 with one or more stimulation parameters, such as amplitude, duration, frequency, etc., that are capable of recruiting the diaphragm in order to satisfy the diaphragm contribution level (e.g., in volume or pressure, or both).
  • stimulation parameters such as amplitude, duration, frequency, etc.
  • some of the stimulation parameters which correspond to the diaphragm contribution level may have been previously programmed into or obtained by the system 20 .
  • the clinician may also enter the amount of therapy to be provided per 24 hour period. For example, the clinician may wish to administer therapy for eight (8) hours out of each 24 hour period.
  • the therapy can be administered consecutively for 8 hours, or can be segmented into time period blocks (e.g., 2 hrs., 1 hr., 30 minutes, 15 minutes, etc.), which can be either constant or variable. If variable, the time period blocks can form a repeatable pattern, if desired.
  • the therapy may also vary the diaphragm contribution throughout the period of administered stimulation.
  • the clinician can program sigh breaths or skipped breaths, as described above with reference to FIG. 13A-C .
  • the clinician can further enter one or more ventilation parameters, such as ventilator operating mode, breath cycle timing (i.e., breaths per minute), etc. It will be appreciated that other data may be entered by the clinician during the initialization stage for providing functionality to the system 20 .
  • the routine 100 proceeds to block 104 , where the respiratory cycle of the patient and/or the ventilator are monitored.
  • the routine 100 carries out a breath detection algorithm, which uses data from the breath sensor 50 and detects the different phases of ventilator breath or a spontaneous breath, such as inspiration phase, inspiration pause, expiration phase and expiration pause. Further, the breath detection algorithm can quantify the different attributes of a breath such as duration of any of the breath phases mentioned above.
  • the breath detection algorithm can use any of the monitored signals, such as flow, volume or pressure to evaluate a series of conditional expressions to identify and/or calculate the attributes of a breath cycle.
  • the method of identifying and/or calculating the attributes of a breath cycle may include, but is not limited to, Slope Threshold Detection, Amplitude Threshold Detection or a combination thereof.
  • the breath detection algorithm can store and/or process waveform data of the current breath or any set of previous breaths.
  • the breath detection algorithm may also facilitate the operation of the system in an event-predictive or in an event-triggered manner. In case of detection of a spontaneous breath, the system may either stop ongoing stimulation, continue stimulating so as to add to the spontaneous breath, or skip the next breath.
  • synchrony between the ventilator 32 and the administration of pacing therapy is maintained. This ensures that diaphragm pacing by stimulation signals emitted by the electrodes is synchronized with each breath administered by the ventilator 32 . If an uncoupling is suspected, pacing may be skipped and resumed as soon as the ventilatory pattern stabilizes again. In other embodiments, the pacing can continue while synchrony is reestablished. In some embodiments, synchrony is determined by comparing the attributes of at least one previous breath cycle (e.g., 12 breaths per minute, etc.) with the attributes of the current breath cycle of the ventilator 32 as determined via processing of the signals from the breath sensor 50 and/or one or more of the sensors 48 .
  • at least one previous breath cycle e.g., 12 breaths per minute, etc.
  • the routine proceeds to block 108 .
  • the diaphragm output e.g., tidal volume, pressure, or a combination of the two
  • the system 20 monitors the data from one or more of the sensors 48 and/or sensor 50 for determining the diaphragm contribution (tidal volume, pressure, or both) for each ventilator breath. This may be calculated from the measured output (i.e., the sum of diaphragm contribution and ventilator contribution) of each ventilator breath or can be calculated directly from the sensor data. If the diaphragm output (or diaphragm contribution) from the previous administered stimulation signal is within a preselected range, the programmed stimulation parameters are maintained, and will be subsequently employed to generate the stimulation train for therapy administration at the next breath.
  • the stimulation parameters may be modified (e.g., amplitude and/or duration are increased) so as to maintain the diaphragm output within a desired range.
  • a difference between the calculated diaphragm contribution responsive to the last administered stimulation signal and the programmed diaphragm contribution value can be seen as a change in either the pressure (in Volume-Controlled Modes/Ventilators) or as a change in tidal volume (in Pressure-Controlled Modes/Ventilators) or as a change in any signal sensed by one or more of the sensor(s) 48 or sensor 50 .
  • the modified stimulation parameters are then stored in memory.
  • the system 20 operates in accordance with a “closed-loop” feedback scheme to regulate the diaphragm output during operation of the system 20 , one example of which is shown in FIG. 15 .
  • an evaluation is carried out to determine the reason for such a drop in tidal volume or pressure.
  • the discrepancy in reaching the diaphragm contribution target may be due to a displacement of a stimulation electrode away from an optimal position.
  • the discrepancy or variability in tidal volume or pressure between breaths can be attributable to either changing respiratory mechanics of the patient or to time-dependent fatigue of the higher force producing fast-fatigable (Type IIb) fibers.
  • Changes in respiratory mechanics may include changes in airway resistance and/or compliance of the lungs/chest wall.
  • the tidal volume is controlled during all breaths, representing a ventilator operating in a Volume Controlled Mode. If any changes occur to the resistive load or the compliance load, these will be reflected as changes in the airway pressure represented in the plot below the tidal volume.
  • the first two breaths illustrate the baseline level of airway pressure when pacing the diaphragm in synchrony with the ventilator 32 .
  • the system encounters a change in compliance load, which can be inferred from the increased peak airway pressure and change in slope of the airway pressure waveform.
  • the system 20 can validate the measured drop in compliance and assumes it is due, for example, to a reduction in force contribution of fast fatigable Type IIb fibers.
  • the system 20 has adjusted its pacing parameters to restore the desired level of diaphragm contribution (negative pressure) to the overall ventilatory assist system, thereby returning the airway pressure to the prescribed assist level.
  • the system 20 may be configured to adaptively modify the pacing parameters to return the tidal volume to the prescribed assist level.
  • FIG. 17A illustrates a natural progressive decline in the percentage of Type IIb Fast Fatigable Motor Units contributing to force development.
  • Type IIb Motor Units can produce much larger forces than Type I Motor Units and their larger diameter axons are also easiest to be recruited by electrical stimulation. Therefore, a low level of intensity of phrenic nerve stimulation is initially sufficient to produce the diaphragm contribution level, as illustrated by FIG. 17B .
  • FIG. 18 As shown schematically in FIG. 18 , initially perhaps only 15% of all motor units in a phrenic nerve need to be recruited by the system 20 to meet the prescribed force/pressure levels of the diaphragm contribution.
  • Type IIb Motor Units tend to fatigue and produce less force with the passage of time, leading to a decline in the force (Diaphragm Contribution) below the programmed level of diaphragm contribution.
  • the intensity of stimulation can be progressively increased so as to recruit additional Type I and Type IIa Motor Units.
  • the stimulation spreads across a higher cross-sectional area (e.g. 30%) of the phrenic nerve to recruit more Type I and Type II Motor Units and the prescribed force is produced.
  • the force declines again as the Type IIb Motor Units present in the newly activated cross-section of the phrenic nerves, fatigue in turn.
  • the pacing intensity is increased again by the pacing control system in order to activate an even larger cross-sectional area of the phrenic nerve, recruiting more Motor Units to reestablish the force output.
  • This progressively increasing activation of the phrenic nerve continues and finally up to 100% of the phrenic nerve motor units may be recruited.
  • the increase in the stimulation may be a simple linear equation or a complex equation with weights assigned to the proportion of available fibers and their fatigue resistant properties.
  • the loss of force may be attributed specifically to the fatigue of the fast fatigable fibers, using parameters such as Maximum Relaxation Rate and half-relaxation time.
  • the changes in slope of the first half of the diaphragm relaxation curve indicative of the relative contribution of Type I and Type II fibers to force development may also be used.
  • Other parameters specific to fatigue such as Pressure-Time Index, Expiratory Time Constant, EMG (and any derived parameters thereof such as power spectrum), Ratio between slow and fast twitch amplitudes, may also be employed to infer the varying conditions and to determine the modified stimulation parameters.
  • the closed-loop control strategy may include using doublets/triplets in response to contractile slowing accompanying fatigue of the diaphragm Motor Units.
  • the stimulation pattern is automatically changed to include doublet/triplets and otherwise lower stimulation frequency, as this form of stimulation is known in the art to optimize force production in fatiguing/fatigued motor units.
  • the stimulation pattern can again be changed to moderate stimulation frequency with or without doublets.
  • This closed-loop scheme allows for continuous pacing of the diaphragm irrespective of the onset or progression of fatigue, also reduces the number of stimulation pulses delivered and protects the muscle from potential injury that could be caused by over-stimulation.
  • the stimulation therapy is administered at block 110 .
  • Administration of the stimulation therapy includes generation of a stimulation signal, such as a stimulation or ramp train.
  • the stimulation signal is generated in accordance with either the original stimulation perimeters or the stimulation parameters as modified in block 108 described above.
  • Delivery timing of the stimulation ramp train is also determined at block 110 .
  • the routine can determine the appropriate timing for phrenic nerve stimulation in relation to the actual breath cycle of the ventilator 32 .
  • the routine controls the timing of stimulation according to pre-defined rules, based on parameter estimates from the breath detection algorithm, etc.
  • the pre-defined rules can include whether stimulation begins at any time before, during, or after the onset of the inspiratory phase of the ventilator 32 , which is shown in FIGS. 11 and 12 , or whether stimulation begins during the expiratory phase, as shown in FIG. 24 .
  • the system 20 can trigger off pressure or airflow signals.
  • the stimulation train can either be started by triggering off the start of the expiration phase followed by a delay or the start of the inspiration phase, as shown in FIG. 23 . Triggering off the start of the expiration phase allows stimulation to be generated prior to the start of the inspiration phase to maximize diaphragmatic force during the inspiration phase.
  • stimulation during the expiration phase can be achieved by triggering off the start of the expiration phase or the start of the inspiration phase with a delay, as shown in FIG. 24 . While using the inspiration or expiration start is preferred, the end of the inspiration/expiration periods could conceivably be used as well. Furthermore, it is also possible to provide delayed stimulation such that stimulation would begin in the middle of the inspiration phase for example.
  • the routine at block 110 delivers the stimulation pulses to the stimulating electrodes 28 at the appropriate time for transmission therefrom.
  • the routine returns to block 104 until the time period for therapy has expired or a clinician halts operation of the system 20 .
  • the system 20 may assist the clinician in determining the appropriate level of diaphragm contribution to be input into the system 20 .
  • the diaphragm contribution can be dependent on the condition of the patient's diaphragm. For example, in a patient that has only a maximum diaphragm output of 750 mL and the clinician intends to target an assist level of 500 mL, the clinician may unknowingly choose a diaphragm contribution level that would require delivery of the maximum stimulation charge, which will cause premature fatigue, etc. Given this patient's present diaphragm condition, the clinician may wish to choose a much lower percentage so that the stimulation charge is in-between the threshold charge and the supra-maximal charge.
  • the condition of the diaphragm and the respiratory system is first assessed by the system 20 .
  • the system 20 is configured to run one or more assessments on the patient's diaphragm and/or respiratory mechanics.
  • the assessment determines the maximum diaphragm output (in volume, pressure, or both) and other parameters such as the fatigue characteristics of the diaphragm, the resistance, compliance and relaxation characteristics of the respiratory system and its components, etc.
  • the assessment can be also run in-between or during periods of the operation of the system 20 in synchrony with the ventilator 32 .
  • These tests can either be run by shortly disconnecting the patient from the ventilator 32 and pacing the diaphragm in isolation or can be run with the patient connected to the ventilator 32 by employing a sequence of pauses in the operation of the ventilator 32 during which the diaphragm is paced in isolation.
  • the sequence of pauses may either be employed manually by the clinician, or natural pauses that are part of a regular ventilator breath cycle (such as an End-Inspiratory Pause or an End-Expiratory Pause) may be automatically identified and used by the system 20 .
  • the maximal static pressures generated by the diaphragm in response to supramaximally stimulating the phrenic nerves to elicit twitch, ramp, or tetanic contractions of the diaphragm are measured as well as the diaphragm relaxation characteristics during the inspiration and expiration phases.
  • the assessment can pace the diaphragm in isolation with a preset duty cycle to assess diaphragm function with regard to its strength and endurance properties.
  • measures and/or indices can be derived that include, but are not limited to, Maximum Static/Dynamic Inspiratory Pressures, Inspiratory Capacity, Pressure-Volume loop relationships, Work of Breathing, Pressure-Time Product, Pressure-Time Index, EMG, Maximum Relaxation Rate, and Expiration Time Constant.
  • Diaphragm fatigue can be induced by continuous or intermittent stimulation of the phrenic nerves to assess endurance limits and to detect the presence of low frequency and/or high frequency fatigue.
  • serial measurements set apart in time ranging from a few minutes to days can be done on a patient by the pacing system to provide a complete picture of evolving changes in the diaphragm strength and endurance of the patient.
  • a knowledge-based algorithm may be used to monitor instantaneous and/or trend data of the monitored signals. Such instantaneous and/or trend data may allow the assessment to predict weaning readiness of the patient and/or a time course for weaning. Such capability can also be extended to make the diaphragm assessment tests as a standalone screening and/or confirmatory tool by clinicians in the ICU, as the method of transvascular pacing of the diaphragm enables the clinician to assess the true status of the diaphragm in the absence of confounding factors (such as decreased central drive) usually associated with voluntary breathing maneuvers.
  • confounding factors such as decreased central drive
  • the diaphragm contribution level can be chosen with knowledge of the relationship between the prescribed assist level and the maximum diaphragm output.
  • the controller 60 in some embodiments, via one or more subroutines, can recursively estimate the percentage of maximum diaphragm output required to generate 100% of the prescribed assist level.
  • this and other calculations can be made on a separate computer system and imported or otherwise inputted into the controller 60 prior to operation of the system 20 .
  • FIG. 19 One example of this recursive estimate is shown in FIG. 19 .
  • the clinician has the option to adjust the diaphragm contribution during operation of the system 20 from 0 to 100% of the prescribed assist level, as illustrated by the dial of FIG. 20 , depending upon the status of the patient and the therapeutic goal.
  • FIG. 20A illustrates an example of setting the desired diaphragm contribution to 75% of the prescribed assist level (i.e., the target diaphragm contribution level).
  • the remaining 25% of the ventilatory work is carried out by the ventilator 32 .
  • the clinician can therefore adjust the ventilator settings to contribute 25% of the ventilatory work, either as tidal volume or as pressure assist, as illustrated by the bottom plot of FIG. 20A .
  • FIG. 20B illustrates another example of setting the desired diaphragm contribution to only 25% of the prescribed assist level (i.e., the target diaphragm contribution level).
  • the remaining 75% of the ventilatory work is carried out by the ventilator 32 .
  • the clinician can therefore adjust the ventilator settings to contribute 75% of the ventilatory work, either as tidal volume or as pressure assist, as illustrated by the bottom plot of FIG. 20B .
  • the PPMV can be set to a mode where the remaining portion of the prescribed assist level is determined and adjusted automatically by the ventilator on an Inter-Breath or Intra-Breath basis (e.g. Pressure Regulated Volume Control Mode).
  • the system 20 also calculates or otherwise obtains the stimulation characteristics that correspond to the diaphragm contribution.
  • the clinician can enter data indicative of these stimulation characteristics.
  • the condition of the diaphragm is periodically reassessed after the therapy has been administered for a period of time (e.g. 12 hours, 1 day, etc.).
  • a period of time e.g. 12 hours, 1 day, etc.
  • the variability in volume or pressure between breaths in some instances is attributable to changing respiratory mechanics of the patient, including changes to airway resistance and/or compliance of the lungs/chest wall.
  • the diaphragm muscle, through the administration of the therapy has strengthened, and thus, the diaphragm contribution can be increased or the intensity of stimulation can be decreased to adjust the diaphragm contribution. In these cases, it may be beneficial to periodically reassess the diaphragm and optimize pacing therapy accordingly, after therapy has been initiated.
  • FIG. 22 One example of a routine for measuring changes in the diaphragm condition without removing the patient from the ventilator 32 is shown in FIG. 22 . Similar to the diaphragm assessment described above, a successive approximation routine in some embodiments can be used to determine the optimal parameters of stimulation for the patient.
  • the routine 200 begins with the clinician providing the initial system parameters, which may include maximum allowable stimulation parameters.
  • Stimulation parameters can be provided either as a predefined stimulation train with fixed duration such that the stimulation train is fully defined by the user using methods as previously described or as a stimulation train in which the number of pulses and the train duration are based on the detected ventilator inspiration time.
  • the routine carries out the breath detection algorithm to detect the inspiration and expiration phases using the flow/pressure data sensed by breath sensor 50 .
  • the flow and pressure data for one or more breaths without stimulation are collected and stored.
  • the system 20 can trigger off pressure or airflow signals.
  • the stimulation train can either be started by triggering off the start of the expiration phase followed by a delay or the start of the inspiration phase, as shown in FIG. 23 . Triggering off the start of the expiration phase allows stimulation to be generated prior to the start of the inspiration phase to maximize diaphragmatic force during the inspiration phase.
  • stimulation during the expiration phase can be achieved by triggering off the start of the expiration phase or the start of the inspiration phase with a delay, as shown in FIG. 24 . While using the inspiration and expiration start are preferred, the end of the inspiration/expiration periods could conceivably be used as well. Furthermore, it is also possible to provide delayed stimulation such that stimulation would begin in the middle of the inspiration phase for example.
  • Flow, volume, and/or pressure data, or derived parameters thereof, for at least one breath with stimulation is recorded.
  • the data with stimulation as well as without, if more than one breath of information has been recorded the data can be averaged together.
  • the collected flow/volume/pressure data with stimulation is then subtracted from the collected flow/volume/pressure data without stimulation.
  • the difference calculated as an area (and shown as the blacked-out area), can be used as a relative measurement of force generated by the diaphragm, and is shown in FIG. 26 .
  • the difference in volume area under flow curve
  • the area under the pressure graph would be used as the measurement.
  • FIG. 27 is one example of another assessment routine 300 carried out by the system 20 .
  • the assessment routine 300 can be used to guide the placement of endovascular electrodes during normal ventilator operation (i.e., without interference to the ventilator operation or disconnecting the ventilator), and can assess the diaphragm recruitment in response to varying (decreasing or increasing) stimulation charges.
  • the system 20 can administer low-frequency stimulation (such as 1 Hz to 5 Hz), during one or more quiet expiratory periods, to elicit unfused diaphragm contractile responses in the form of single twitches.
  • the charge delivered can be progressively increased to build a complete nerve recruitment curve for each endovascular location, and the operator can define across how many breath periods this stimulation is delivered.
  • the system 20 can analyze this stimulation and response information to algorithmically estimate the best position of the electrodes to stimulate one or both phrenic nerves using minimal amounts of charge (highest degree of efficiency). During this assessment routine, the system 20 can also gather information regarding the relationship between the stimulation train profiles and the corresponding diaphragm response, including diaphragm output (in volume, pressure, or both). Some stimulation parameters that may be obtained include but are not limited to Threshold Pulse Width and Supra-maximal Pulse Width required to recruit each phrenic nerve from appropriate endovascular electrode locations.
  • the stimulation charges in routine 300 can be programmed to periodically occur during periods of baseline flow/volume, which can occur at the end-expiratory pause of the ventilator breath cycle, which can also be referred to as the end-expiratory delay.
  • the benefit of selective stimulation during the end-expiratory pause is that the length of the diaphragm muscle fibers is the same before each stimulus is delivered and thereby establishes standardized conditions for obtaining comparable results. This provides a standard baseline to compare the diaphragm twitch responses and can guide the placement of the endovascular electrodes.
  • FIG. 29 illustrates one example of a routine 400 for determining the duration of the end-expiratory pause.
  • this routine flow data is collected and the end expiratory pause is estimated.
  • volume of the inspiration and expiration phases are calculated. The point at which the expired volume reaches a user-programmable percentage of the inspiration volume is used as the start time for the end-expiratory pause. In one embodiment, the percentage used as a default is 85% of the inspired volume. In some embodiments, volume is used as it is less influenced by noise than other measures.
  • volume data in some embodiments is one technique, this does not preclude using other measures of the end expiratory phase such as a slope close to zero or simply using a fixed time interval at the end of the expiration phase as the end expiratory pause.
  • the system 20 can compute relaxation characteristics of the respiratory system, such as Expiratory-Time Constant (i.e. time required to exhale a certain percentage of the air from the lungs) to determine the ideal end-expiratory pause duration and prompt the clinician to adjust the ventilator settings accordingly.
  • Expiratory-Time Constant i.e. time required to exhale a certain percentage of the air from the lungs
  • Routine 300 begins at block 302 with the clinician providing the initial system parameters or accepting internal default values, which may include the characteristics of a low-level starting stimulation signal, the maximum stimulation level, the estimated duration of the end-expiratory pause, one or more ventilator parameters, etc. In some embodiments, the characteristics of the low-level starting stimulation signal are based on the estimated duration of the end-expiratory pause.
  • the breath detection algorithm described above can be employed to synchronize the administered stimulation with the end-expiratory pause period of the ventilator 32 .
  • the breath detection algorithm can be employed to identify the period of interest during a breath cycle when stimulation can be delivered, as shown in FIG. 28 .
  • the diaphragm being a skeletal muscle, its force output changes with its length, as described by its length-tension relationship. Therefore, it is beneficial to stimulate the diaphragm near its resting length, as it provides a standard baseline to compare the diaphragm twitch responses.
  • the resting length of the diaphragm is reached at the end of every expiration phase, as the lungs reach their Functional Residual Capacity.
  • signals from one or more of the sensors 48 and/or sensor 50 can be used to confirm that the lungs have reached Functional Residual Capacity.
  • the system 20 administers a starting stimulation signal at block 308 and then monitors and measures the diaphragm response to the administered stimulation at block 310 .
  • Signals that can be monitored and measured to quantify the diaphragm response may include, but are not limited to, EMG, Airway Pressure, Airway Flow, Intra-Thoracic Pressure, Pleural Pressure, Central Venous Pressure, Thoraco-abdominal motion, various patient impedances, etc.
  • the system can also employ validation checks to confirm that the functional residual capacity (and therefore the diaphragm resting length) has not changed between breaths.
  • One of the means to perform this validation is to analyze the trend data of the end-expiratory volume, before stimulating the diaphragm.
  • FIG. 30 illustrates one example of a routine 500 executed by the system 20 to carry out one or more functions, including the Pacer-Initiated Ventilation Mode.
  • many mechanical ventilators have an assist/support mode, whereby ventilation is provided when the patient attempts to breathe on their own.
  • the system 20 can be programmed to trigger the ventilator 32 working in assistive modes by using stimulation shown by “D” in FIG. 31 (and resultant response from the diaphragm) to mimic spontaneous effort by the patient, as shown in FIG. 31 .
  • the ventilator 32 responds to this trigger signal/event and delivers a breath to the patient (based on parameters set by the clinician) shown by “B” in FIG. 31 .
  • the system 20 drives breath delivery from the ventilator 32 (which is opposite from the Ventilator-Initiated Pacing Mode described above) shown by “C” in FIG. 31 .
  • the system 20 does not perform breath detection, and thus, the breath sensor 50 can be omitted.
  • the breath sensor 50 may be used to carry out various assessment routines and feedback schemes.
  • the system 20 can control the rate of pacing via the programmable parameters such as breath rate (in Breaths per minute), skipped breaths and sigh breaths.
  • the Pacer-Initiated Ventilation Mode can also include one or more of the adaptive functionality, closed loop control, diaphragm assessment, successive approximation features described above with reference to Ventilator-Initiated Pacing Mode are also applicable to this mode.
  • the system 20 can use feedback to ensure proper diaphragm contribution.
  • Some ventilator modes suitable for this embodiment are Pressure Support Ventilation (PSV), Pressure Regulated Volume Control (PRVC), Proportional Assist Ventilation (PAV) and Adaptive Support Ventilation (ASV).
  • PSV Pressure Support Ventilation
  • PRVC Pressure Regulated Volume Control
  • PAV Proportional Assist Ventilation
  • ASV Adaptive Support Ventilation
  • Embodiments of the system 20 can also be operated in Autonomous Mode, or A-Mode.
  • A-Mode is a life-sustaining mode that can operate independently of the ventilator 32 .
  • FIG. 32 illustrates one example of a routine 600 executed by the system 20 for carrying out one or more functions, including the Autonomous Mode.
  • the A-Mode operates in closed-loop control fashion using feedback from various sensors, such as one or more of the sensors 48 , 50 . These sensors can be used to monitor physiological variables that can include, but are not limited to: central venous pressure, mixed venous oxygen saturation, heart rate and movement activity levels.
  • A-Mode provides adjustable diaphragmatic pacing to a patient retaining none, some or all of his/her spontaneous breathing and requiring assisted breathing and can automatically adjust to the patient's physiological needs and changed activity levels, as needed.
  • A-mode can be a life-sustaining mode, it may or may not be used in this capacity (i.e. could be interfaced with a backup ventilator).
  • A-Mode may be applicable to patients who are permanently dependent on mechanical ventilators or otherwise in need of continuous pacing from the system 20 .
  • embodiments of the system 20 carrying out the A-Mode can be totally implanted under the skin of the patient in the upper chest area.
  • the system 20 is powered by a power storage source, such as either primary or rechargeable implantable batteries, and may be integrated with other implantable devices that support heart or other functions to a patient.
  • the system 20 operating in A-Mode involves a closed-loop operation to autonomously pace the diaphragm.
  • This mode may make use of any patient response signal (feedback) that will help indicate that pacing is required; these signals include, but are not limited to: oxygen saturation, end-tidal CO2 (EtCO2), airflow, heart rate, movement-detecting accelerometer signals, etc.
  • Pacing is administered continuously in A-mode, and an algorithm is used to detect and/or modify physiological response signals to determine whether a change in stimulation pattern, frequency, breath rate, intensity, type, and/or shape profile is required to elicit the expected response.

Abstract

Transvascular diaphragm pacing systems (TDPS) and methods are disclosed for providing respiratory therapy to a patient. The TDPS can provide rapid insertion and deployment of endovascular pacing electrodes in critically ill patients who require intubation and invasive PPMV in order to support the physiological requirements of the human ventilatory system. The systems and methods make best use of the contractile properties of the diaphragm muscle and prevent muscle disuse and muscle atrophy. This can be carried out by engaging the phrenic nerves using patterned functional electrical stimulation applied to endovascular electrodes that are temporarily and reversibly inserted in central veins of the patient, such as the left subclavian vein and the superior vena cava. The TDPS can be designed to seamlessly interface with any commercially available positive-pressure ventilatory assistance/support equipment such as is commonly in use in hospital intensive care units (ICU) for treating critically ill patients with breathing insufficiencies, pain, trauma, sepsis or neurological diseases or deficits.

Description

    CROSS-REFERENCE TO RELATED APPLICATION
  • This applicant claims the benefit of U.S. Provisional Application No. 61/662,579, filed Jun. 21, 2012, the disclosure of which is expressly incorporated by reference herein.
  • BACKGROUND
  • Patients in hospital Intensive Care Units (ICU) may experience impairment in their ability to breathe volitionally due to their underlying disease condition and require positive pressure mechanical ventilation (PPMV) to provide ventilatory assistance. PPMV is routinely used in combination with sedation in the ICU to provide artificial ventilation for these critically ill individuals. Additionally, many patients undergoing surgery under general anesthesia, for example in hospital Operating Rooms (OR), or procedures under anesthesia or sedation, for example in hospital Emergency Rooms (ER), commonly require PPMV for ventilatory assistance while anesthetized or sedated.
  • Although mechanical ventilation is a life-sustaining modality, when combined with sedation or anesthesia it interferes with active contraction of the diaphragm. Prolonged totally controlled mechanical ventilation can result in the complete absence of neural activation and mechanical activity of the diaphragm and has been shown to induce muscle atrophy, proteolysis, and reactive oxygen species liberation, leading to rapid loses in diaphragmatic function, a syndrome known as Ventilator-Induced Diaphragmatic Dysfunction (VIDD).
  • The onset of diaphragm disuse atrophy is rapid, leading to slower patient recovery, which often results in ventilator dependence and translates into higher incidence of ventilator-acquired pneumonia and nosocomial infections, longer stays in the ICU, and escalating hospitalization costs.
  • In addition to ICU patients, mechanical ventilation is the primary modality of ventilatory assistance for individuals with disease conditions that adversely affect neurological function, such as Spinal Cord Injury (SCI). These individuals may experience impairment in their ability to breathe volitionally due to partial or complete loss of control of the diaphragm, and are prone to lifelong dependence on a mechanical ventilator.
  • Several viable alternatives to PPMV for assisting breathing are currently available, and have been indicated for use in patients requiring long-term ventilatory assistance such as Spinal Cord Injury (SCI) patients or patients with Congenital Central Hypoventilation Syndrome (CCHS). They include phrenic nerve stimulation and diaphragmatic pacing. These methods use electrical stimulation to induce contraction of the diaphragm using an electrode and an external pacing control box or an implanted pacemaker device.
  • The two phrenic nerves, which control activation of the diaphragm, run through the thorax, along the left and right sides of the heart, and then to the diaphragm. Phrenic nerve stimulation is performed by electrically stimulating the phrenic nerve to control the patient's diaphragm, which may induce a respiratory cycle. Conventional techniques include surgically implanting a nerve cuff around the phrenic nerve (at the neck or chest level), and then delivering an electrical stimulus from an externally located controller through the cuff to the phrenic nerve. This procedure is quite invasive, requiring incisions when deploying the nerve cuffs, and quite expensive, so it is only selectively used in patients with a life-long requirement for assisted ventilation. In addition, the direct placement of the nerve cuffs around the phrenic nerves may damage the phrenic nerves. These phrenic nerve stimulation systems have not heretofore been prescribed for temporary use in critically ill ICU patients.
  • Other phrenic nerve stimulation techniques are known, such as that described in U.S. Pat. No. 8,195,297. However, the system disclosed in the '297 Patent does to allow for rapid, short term use in an ICU environment for the management of ICU patients particularly in the first few days after start of PPMV.
  • Another method for electrically stimulating the diaphragm is known as diaphragmatic pacing. Conventionally, diaphragmatic pacing is performed by laparoscopically implanting four electrodes directly on the diaphragm (two on each side), with electrical leads connected to a controller residing external to the body. Conventional diaphragmatic pacing procedures are also quite time consuming and relatively invasive, requiring incisions during implantation, presenting risk during the implantation procedure and risk of chronic infection at the lead entrance sites to the body. Accordingly, these diaphragmatic pacing systems have not heretofore been prescribed for temporary use in critically ill ICU patients.
  • One such diaphragmatic pacing system is described in U.S. Pat. No. 7,962,215. In addition to being surgically demanding, the diaphragmatic pacing system of the '215 Patent is employed to administer therapy to convert Type IIa (fast-type) muscle fibers to Type I (slow-type) muscle fibers in patients who have been ventilated for prolonged periods, whose muscle fibers have all atrophied and converted to Fast-type (VIDD). The therapy described in the '215 Patent, however, will not be desirable in the treatment of critical care patients that still have both Type IIa (fast-type) muscle fibers and Type I (slow-type) and will need to have both types to successfully wean off of PPMV.
  • Accordingly, there exists a need for minimally invasive diaphragm pacing systems and methods for rapid, short term use, as appropriate in the ICU environment, for the management of ICU patients particularly in the first few days or weeks after start of PPMV.
  • SUMMARY
  • Examples of systems and methods disclosed herein address this need and others by providing a minimally invasive nerve stimulation system that paces the phrenic nerves transvascularly via disposable endovascular electrodes that can be percutaneously placed under local anesthesia. As will be described in the Detailed Description, such pacing systems and methods can be employed to provide short periods of electrical stimulation for preventing diaphragm disuse atrophy in patients at risk of becoming ventilator-dependent and/or to rehabilitate diaphragm disuse atrophy in ventilator-dependent patients.
  • The system is designed to work either in conjunction with a mechanical ventilator, causing diaphragmatic contractions in synchrony with each ventilator administered breath, intermittently synchronized to some ventilator breaths, or as a stand-alone system. In some embodiments, the systems and methods may be employed just minutes or hours after first intubation of the subject. Such diaphragm pacing therapy is expected to prevent, reduce or reverse diaphragm disuse atrophy that typically occurs in patients who are on PPMV or are expected to require PPMV and sedation for prolonged periods and by extension, the adverse effects associated with PPMV will be avoided or reduced. As a result, patients may be successfully weaned from PPMV earlier than currently known methods, providing drastic health benefits to patients not to mention substantial reductions in total in-patient costs.
  • In accordance with one aspect of the present disclosure, a method is provided for administering a treatment plan designed for preventing or reversing diaphragm disuse atrophy in a patient receiving respiratory assistance from a ventilator. The ventilator is employed to provide a breath cycle to the patient, the patient having a prescribed assist level. The method comprises monitoring the breath cycle of the ventilator, administering a pre-programmed stimulation signal to the patient to recruit the phrenic nerve of the patient, and regulating the diaphragm output of the patient for each breath cycle. In some embodiments, the stimulation signal is administered via one or more endovascular electrodes.
  • In accordance with a first embodiment, the administration of the stimulation signal can occur within a time period, such as 1 hour, 3 hours, 6 hours, 12 hours, 1 day, 3 days, and 1 week, of the patient's first reception of respiratory assistance from the ventilator.
  • In accordance with a second embodiment, the method also includes obtaining data indicative of at least one of: one or more ventilator breath parameters; one or more pacing parameters; and a prescribed assist level for the patient.
  • In accordance with a third embodiment, the one or more ventilator breath parameters includes timing data indicative of the duration of a ventilated breath.
  • In accordance with a fourth embodiment, the method also includes maintaining synchrony between the delivery of the stimulation signal and the ventilator breath cycle.
  • In accordance with a fifth embodiment, maintaining synchrony includes determining the current breath cycle via data from one or more sensors, and comparing the current breath cycle with the timing data from at least one previous breath cycle.
  • In accordance with a sixth embodiment, recruitment of the diaphragm provides at least a portion of the prescribed assist level.
  • In accordance with a seventh embodiment, the method further comprises determining a diaphragm contribution level attributable to the administration of the stimulation signal, wherein the prescribed assist level is the sum of the diaphragm contribution level and a ventilator contribution level.
  • In accordance with an eight embodiment, the simulation signal includes stimulation signal characteristics that cause the stimulation signal, when delivered to the patient, to satisfy the diaphragm contribution level.
  • In accordance with a ninth embodiment, the diaphragm contribution level is measured in tidal volume or pressure, individually, in combination, and including components thereof.
  • In accordance with a tenth embodiment, the prescribed diaphragm contribution level is dependent on the condition of the patient and the contractile capacity and/or functional status of the diaphragm.
  • In accordance with a eleventh embodiment, determining the contractile capacity includes measuring strength and endurance from the response of the diaphragm to test stimulation patterns.
  • In accordance with a twelfth embodiment, the condition of the patient and contractile capacity of the diaphragm and/or functional status of the phrenic nerves are assessed prior to the administration of the treatment plan and/or during administration of the treatment plan.
  • In accordance with a thirteenth embodiment, determining the strength and endurance of the patient's diaphragm includes measuring maximum diaphragm output and fatigue characteristics of the diaphragm.
  • In accordance with a fourteenth embodiment, monitoring the breath cycle includes sensing breath cycle data via a breath sensor discrete from and interfaced with a breathing circuit of the ventilator and the patient airway, and determining the inspiration phase and the expiration phase of the breath cycle and the duration of each phase from the sensed breath cycle data.
  • In accordance with a fifteenth embodiment, monitoring the breath cycle further includes determining at least one of the amplitude and rate of change of ventilator output signals for each breath.
  • In accordance with a sixteenth embodiment, administering a stimulation signal includes generating a stimulation signal in accordance with one or more pacing parameters; and delivering the stimulation signal in relation to a ventilator breath cycle.
  • In accordance with a seventeenth embodiment, regulating the diaphragm output of the patient for each breath cycle, such as a paced breath cycle, includes monitoring the diaphragm output in response to the last administered stimulation signal; and comparing the diaphragm output of the last administered stimulation signal to a preset target range. Alternatively, the method can skip pacing for one breath cycle (MV-Only), but stimulate the at the next breath cycle (i.e., mechanical ventilation and diaphragm pacing. The method can then compare both of these values and regulate the next paced breath.
  • In accordance with an eighteenth embodiment, monitoring the diaphragm output in response to the last administered stimulation signal includes sensing diaphragm output data via one or more sensors, wherein the diaphragm output data is indicative of one or more of: air flow, tidal volume, pressure, and/or parameters derived from combinations of flow, tidal volume and/or pressure; and processing the sensed diaphragm data to determine the diaphragm output.
  • In accordance with a nineteenth embodiment, regulating the diaphragm output of the patient for each breath cycle further includes modifying the stimulation signal to be administered with the next ventilator breath if the diaphragm output of the last administered stimulation signal is outside of the preselected target range.
  • In accordance with a twentieth embodiment, the preselected target range includes a diaphragm contribution level.
  • In accordance with a twenty-first embodiment, the method further comprises determining a cause if the diaphragm output of the last administered stimulation signal is outside of the preselected target range.
  • In accordance with a twenty-second embodiment, if the cause is due to a variation in the respiratory mechanics of the patient, then the condition of the patient's diaphragm and respiratory system during administration of the treatment plan is assessed.
  • In accordance with a twenty-third embodiment, the method further comprises reprogramming the stimulation signal based on the condition of the assessed diaphragm.
  • In accordance with a twenty-fourth embodiment, assessing the diaphragm includes monitoring data indicative of flow and pressure of the ventilator breath cycle to determine timing of the end expiration delay; progressively stimulating the diaphragm with stimulating signals based on the monitored data of the ventilator breath cycle; and determining one or more functional characteristics of the diaphragm and respiratory system, wherein the one or more functional characteristics includes one or more of Maximum Static Inspiratory Pressure, Inspiratory Capacity, Work of Breathing, Pressure-Time Product, Pressure-Time Index, Electromyogram (EMG), Maximum Relaxation Rate, and Expiration Time Constant.
  • In accordance with a twenty-fifth embodiment, the diaphragm stimulation is targeted to take place during each ventilator breath in order to reduce positive pressure and reduce the risk of Ventilator Induced Lung Injury (VILI).
  • In accordance with a twenty-sixth embodiment, monitoring the breath cycle of the ventilator includes sensing signals indicative of ventilator inspiration and expiration; and calculating one or more of: inspiration phase; expiration phase; inspiration pause; expiration pause.
  • In accordance with a twenty-seventh embodiment, administering the stimulation signal includes delivery of the stimulation signal contemporaneously with inspiration phase.
  • In accordance with anther aspect of the present disclosure, a transvascular diaphragm pacing system is provided for preventing or reversing diaphragm disuse atrophy in a patient receiving respiratory assistance from a ventilator. The system comprises at least one endovascular electrode configured to transmit a stimulation signal delivered thereto. The stimulation signal in some embodiments is configured to recruit a phrenic nerve of the patient, the stimulation signal in some embodiments have one or more stimulation parameters. The system also includes one or more sensors configured to sense breath cycle signals from an associated ventilator and diaphragm response from recruitment of the phrenic nerve, and a pulse generator coupled in electrical communication with the at least one endovascular electrode, and at least one input device configured to input data indicative of one or more aspects of a therapy plan. The system further includes a controller coupled in electrical communication with the one or more sensors, the at least one input device, and the pulse generator. The controller is some embodiments is programmed to: receive input data indicative of one or more aspects of the therapy plan, wherein the input data includes sensed signals indicative of ventilator operation and one or more pacing parameters; monitor the breath cycle signals and determine the inspiration phase and expiration phase of the breath cycle; generate the stimulation signal according to the one or more pacing parameters and delivering the generated stimulation signal to the at least one transvascular electrode at a preselected time of the ventilator breath cycle; and regulate the diaphragm output of the patient for each breath cycle.
  • In accordance with a twenty-eighth embodiment, the controller is further programmed to regulate the diaphragm output of the patient to satisfy a prescribed assist level of the patient.
  • In accordance with a twenty-ninth embodiment, the controller is further programmed to maintain synchrony of the delivery of the stimulation signal with the ventilator breath cycle.
  • In accordance with a thirtieth embodiment, the controller is further programmed to: monitor the diaphragm output in response to the last administered stimulation signal; and compare the diaphragm output of the last administered stimulation signal to a preselected target range.
  • In accordance with a thirty-first embodiment, the controller is programmed to monitor the diaphragm output by sensing diaphragm output data via one of said one or more sensors and processing the sensed diaphragm data to determine the diaphragm output, wherein the diaphragm output includes flow, tidal volume and/or pressure and/or parameters derived from combinations of flow, tidal volume and/or pressure.
  • In accordance with a thirty-second embodiment, the controller is further programmed to modify the stimulation signal to be administered with the next ventilator breath if the diaphragm output of the last administered stimulation signal is outside a preselected range. Alternatively, the signal could be modified and administered at the next breath with programmed pacing (i.e., a combined breath) as some ventilator breaths may be skipped between stimulations.
  • In accordance with a thirty-third embodiment, the controller is further programmed to determine a cause if the diaphragm output of the last administered stimulation signal is outside of the preselected target range.
  • In accordance with a thirty-fourth embodiment, if the controller determines that the cause is due to a variation in the respiratory mechanics of the patient, then the controller is further programmed to assess the condition of the patient's diaphragm and respiratory system during administration of the treatment plan.
  • In accordance with a thirty-fifth embodiment, the controller is further programmed to reprogram the stimulation signal based on the condition of the assessed diaphragm.
  • In accordance with a thirty sixth embodiment, the controller is further programmed to assess the diaphragm by monitoring data indicative of flow and pressure of the ventilator breath cycle to determine timing of the end expiration delay, progressively stimulating the diaphragm with stimulating signals based on the monitored data of the ventilator breath cycle, and determining one or more functional characteristics of the diaphragm and respiratory system. In some embodiments, the one or more functional characteristics includes one or more of Maximum Static Inspiratory Pressure, Inspiratory Capacity, Work of Breathing, Pressure-Time Product, Pressure-Time Index, EMG, Maximum Relaxation Rate, and Expiration Time Constant.
  • In accordance with a thirty-seventh embodiment, the controller is further programmed to determine the readiness to wean from the ventilator based on the assessment of the diaphragm.
  • In accordance with a thirty-eighth embodiment, the stimulation signal includes a doublet or triplet pulse at the beginning of the stimulation train or in the middle of the simulation train.
  • In accordance with another aspect of the present disclosure, a method is provided for preventing respiratory disuse atrophy in a patient who is attached to a mechanical ventilator and receiving artificial breath cycle respiratory assistance and sedation. The method comprises placing a first electrode in the patient's vasculature in proximity to the left phrenic nerve, placing at second electrode in the patient's vasculature in proximity to the right phrenic nerve, and within hours of attaching the patient to the ventilator, delivering a pre-programmed stimulation signal to the first and second electrodes in order to stimulate the diaphragm in synchrony with the ventilator breath cycle.
  • In accordance with a thirty-ninth embodiment, within hours includes one of the following: within twelve hours; within six hours, within five hours; within four hours, within three hours; and within one hour.
  • In accordance with a yet another aspect of the present disclosure, a method is provided for administering a treatment plan for preventing or speeding up reversal of diaphragm disuse atrophy in a patient receiving respiratory assistance from a ventilator. The ventilator provides a breath cycle to the patient and the patient has a prescribed assist level. The method comprises storing a measurement value indicative of a preselected range of diaphragm output, wherein the diaphragm output is at least a portion of the prescribed assist level, monitoring the breath cycle of the ventilator, administering a stimulation signal to the patient in synchrony with the breath cycle of the ventilator to recruit the diaphragm of the patient, the recruitment of the diaphragm causing a level of diaphragm output, and regulating the diaphragm output of the patient attributable to phrenic recruitment for each stimulated breath cycle in order to fall within the preselected range of diaphragm output.
  • In accordance with a fortieth embodiment, regulating the diaphragm output of the patient for each breath cycle includes monitoring the diaphragm output in response to the last administered stimulation signal, and comparing the diaphragm output of the last administered stimulation signal to the preselected range of diagram output.
  • In accordance with a forty-first embodiment, monitoring the diaphragm output in response to the last administered stimulation signal includes sensing diaphragm output data via one or more sensors, and processing the sensed diaphragm output data to determine the diaphragm output. In some embodiments, the diaphragm output includes one or more of: air flow, tidal volume, pressure, and/or parameters derived from combinations of flow, tidal volume and/or pressure.
  • In accordance with a forty-second embodiment, regulating the diaphragm output of the patient for each breath cycle further includes comparing the determined diaphragm output to the preselected range of diagram output, and modifying the stimulation signal to be administered with the next ventilator breath if the diaphragm output from the last administered stimulation signal fell outside of the preselected range of diagram output.
  • In accordance with a forty-third embodiment, modifying the stimulation signal includes increasing the intensity of the stimulation signal.
  • In accordance with a forty-fourth embodiment, increasing the intensity includes one or more of: increasing the frequency of stimulation signal pulses; increasing the amplitude of stimulation signal pulses; and/or increasing the duration of stimulation signal pulses.
  • In accordance with a forty-fifth embodiment, diaphragm output includes tidal volume, pressure, or combinations thereof.
  • In accordance with a still another aspect of the present disclosure, a method is provided for preventing diaphragm disuse atrophy in a critically ill patient. The method comprises attaching a patient to a ventilator, monitoring the breath cycle of the ventilator; administering, within one of twelve hours or six hours of attaching the patient to the ventilator, a pre-programmed stimulation signal to the patient to recruit the diaphragm of the patient for outputting a level of diaphragm output, and regulating the level of diaphragm output of the patient for each breath cycle based on the administration of the stimulation signal to match or exceed a preselected threshold.
  • In accordance with yet still another aspect of the present disclosure, a method is provided for constructing a therapy plan for a patient. The therapy plan attempts to prevent disuse atrophy or rehabilitate the patient's diaphragm. The method comprises assessing the diaphragm for maximum diaphragm output and fatigue characteristics, and determining one or more stimulation signals that cause diaphragm output to be a preselected percentage of the maximum diaphragm output.
  • In accordance with a forty-sixth embodiment, the method further comprises creating a stimulation administration plan including a series of discrete stimulation signals, wherein the series of stimulation signals can vary by rate, duration, pulse width, frequency, and amplitude.
  • In accordance with still yet another aspect of the present disclosure, a method is provided for assessing a diaphragm. The method comprises monitoring data indicative of flow and pressure of a ventilator breath cycle, stimulating the diaphragm with stimulating signals based on the monitored data of the ventilator breath cycle, and determining one or more functional characteristics of the diaphragm from the response generated from the stimulation of the diaphragm with the stimulation signals. In some embodiments, the one or more functional characteristics including one or more of Maximum Static Inspiratory Pressure, Inspiratory Capacity, Work of Breathing, Pressure-Time Product, Pressure-Time Index, EMG, Maximum Relaxation Rate, and Expiration Time Constant.
  • In accordance with still another aspect of the present disclosure, a transvascular diaphragm pacing system is provided for constructing a therapy plan for a patient. The therapy plan in some embodiments prevents diaphragm disuse atrophy or rehabilitates the patient's diaphragm. The system includes at least one endovascular electrode configured to transmit a stimulation signal delivered thereto. The stimulation signal in some embodiments is configured to recruit a phrenic nerve of the patient and the stimulation signal has one or more stimulation parameters. The system also includes one or more sensors configured to sense breath cycle signals from an associated ventilator and diaphragm response from recruitment of the phrenic nerve, a pulse generator coupled in electrical communication with the at least one endovascular electrode, and at least one input device configured to input data indicative of one or more aspects of a therapy plan. The system further includes a controller coupled in electrical communication with the one or more sensors, the at least one input device, and the pulse generator. The controller is some embodiments is programmed to assess the diaphragm for maximum diaphragm output and fatigue characteristics, and determine one or more stimulation signals that cause diaphragm output to be a preselected percentage of the maximum diaphragm output.
  • In accordance with yet still another embodiment, a transvascular diaphragm pacing system is provided for assessing a diaphragm. The system includes at least one endovascular electrode configured to transmit a stimulation signal delivered thereto. The stimulation signal in some embodiments is configured to recruit a phrenic nerve of the patient and the stimulation signal has one or more stimulation parameters. The system also includes one or more sensors configured to sense breath cycle signals from the ventilator and the diaphragm response from recruitment of the phrenic nerve, a pulse generator coupled in electrical communication with the at least one endovascular electrode, and at least one input device configured to input data indicative of one or more aspects of a therapy plan. The system further includes a controller coupled in electrical communication with the one or more sensors, the at least one input device, and the pulse generator. The controller is some embodiments is programmed to: monitor data indicative of flow and pressure of a ventilator breath cycle; stimulate the diaphragm with stimulating signals based on the monitored data of the ventilator breath cycle; and determine one or more functional characteristics of the diaphragm from the response generated from the stimulation of the diaphragm with the stimulation signals. In some embodiments, the one or more functional characteristics include one or more of Maximum Static Inspiratory Pressure, Inspiratory Capacity, Work of Breathing, Pressure-Time Product, Pressure-Time Index, EMG, Maximum Relaxation Rate, and Expiration Time Constant.
  • This summary is provided to introduce a selection of concepts in a simplified form that are further described below in the Detailed Description. This summary is not intended to identify key features of the claimed subject matter, nor is it intended to be used as an aid in determining the scope of the claimed subject matter.
  • DESCRIPTION OF THE DRAWINGS
  • The foregoing aspects and many of the attendant advantages of the claimed subject matter will become more readily appreciated as the same become better understood by reference to the following detailed description, when taken in conjunction with the accompanying drawings, wherein:
  • FIG. 1 is a schematic diagram of one example of a transvascular diaphragm pacing system formed in accordance with aspects of the present disclosure;
  • FIG. 2 is a schematic diagram of the location of the left and right phrenic nerves in a patient in relation to the heart and diaphragm of the patient;
  • FIG. 3A is one example of one pair of catheter-mounted phrenic nerve stimulating electrodes positioned within the left subclavian vein of the patient;
  • FIG. 3B is one example of one pair of catheter-mounted phrenic nerve stimulating electrodes positioned within the superior vena cava of the patient;
  • FIG. 4 is a block diagram of the components of one embodiment of the system of FIG. 1;
  • FIG. 5 illustrates the shift in force generated when stimulating with a train that begins with a doublet/triplet;
  • FIG. 6 illustrates one example of the programmable parameters of each stimulation pulse as well as the ratiometric relationship between the charge injection pulse and charge balance pulse when exemplifying net-charge;
  • FIG. 7 illustrates one example of three stimulation trains, in each of which the pulse width and frequency are modulated to increase from the start to end of the stimulation train to cause graded contraction of the diaphragm;
  • FIG. 8 illustrates one example of three stimulation trains, in each of which the pulse width and frequency are modulated to first increase and then decrease from the start to end of the stimulation train to cause graded contraction of the diaphragm;
  • FIG. 9 illustrates examples of representative ramp envelopes where the ramp slopes represent the modulations in pulse width and/or pulse frequency within a train;
  • FIG. 10 illustrates examples of representative pulse width ramp envelopes and stimulus frequency envelopes, which can be combined together to form a single pacing ramp;
  • FIG. 11 illustrates examples of timing for the start time and end time of stimulation trains generated and delivered to the phrenic nerves, relative to a ventilator breath;
  • FIG. 12 illustrates other examples of timing for the stimulation trains generated and delivered to the phrenic nerves;
  • FIG. 13 illustrates yet other examples of timing as well as amplitude modulations for the stimulation trains generated and delivered to the phrenic nerves;
  • FIG. 14 illustrates one example of a process configured to carry out one or more functions of the system 20, including but not limited to the Ventilator Initiated Pacing Mode;
  • FIG. 15 illustrates one feedback scheme that may be practiced by the process of FIG. 14 and the system of FIG. 1;
  • FIG. 16 illustrates one example of a change in respiratory mechanics during pacing in synchrony with a volume controlled mechanical ventilator;
  • FIG. 17A-B illustrate examples of maintaining the diaphragm output at a prescribed level despite a time dependent fatiguing and drop-out of stimulated Type IIb fibers;
  • FIG. 17C illustrates a process for using doublets to enhance force in fatiguing muscle;
  • FIG. 18 illustrates one example of progressive recruitment of nerve axons across the cross-section of the phrenic nerve and their associated motor units by increasing the pacing intensity;
  • FIG. 19 is a graphical representation for scaling the contribution of the system of FIG. 1 to prescribed assist level and determining one or more initial pacing parameters using, for example, a binary algorithm;
  • FIG. 20A is a schematic representation of one example of scaling the contribution of the system of FIG. 1 to diaphragm response;
  • FIG. 20B is a schematic representation of another example of scaling the contribution of the system of FIG. 1 to diaphragm response;
  • FIG. 21 is a graphical representation of one example of calculating the Work of Breathing (WOB), the calculation in turn used to regulate diaphragm contribution;
  • FIG. 22 is one example of a routine for assessing the diaphragm without disconnecting the patient from the ventilator;
  • FIGS. 23 and 24 illustrate examples of the timing of administered stimulus in relation to the phases of the breath cycle;
  • FIG. 25 is a graphical representation of airway pressure data obtained from a volume controlled ventilator with and without stimulation;
  • FIG. 26 is a graphical representation of one example of calculating the Pressure-Time Product, the calculation in turn used to regulate diaphragm contribution.
  • FIG. 27 is one example of an assessment routine carried out by the system of FIG. 1;
  • FIG. 28 is a graphical representation of end expiratory pauses, sometimes referred to as quiet periods;
  • FIG. 29 is one example of a routine for determining the duration of the end-expiratory pause;
  • FIG. 30 is a schematic diagram showing one example of a Pacer-Initiated Ventilation Mode that can be carried out by one or more embodiments of the system shown in FIG. 1;
  • FIG. 31 illustrates the relationship between the pacing system and the ventilator in Pacer-Initiated Ventilation Mode;
  • FIG. 32 is a schematic diagram showing one example of a pacing system operating in an Autonomous Mode; and
  • FIG. 33A-C graphically represent the benefits of examples of the system of FIG. 1 in preventing diaphragm disuse atrophy or rehabilitating the diaphragm for successful weaning from respiratory assistance.
  • DETAILED DESCRIPTION
  • The detailed description set forth below in connection with the appended drawings where like numerals reference like elements is intended as a description of various embodiments of the disclosed subject matter and is not intended to represent the only embodiments. Each embodiment described in this disclosure is provided merely as an example or illustration and should not be construed as preferred or advantageous over other embodiments. The illustrative examples provided herein are not intended to be exhaustive or to limit the claimed subject matter to the precise forms disclosed.
  • The following discussion provides examples of transvascular diaphragm pacing systems (TDPS) and methods for providing respiratory therapy to a patient. Some examples of the TDPS provide rapid insertion and deployment of endovascular pacing electrodes in critically ill patients who require intubation and invasive PPMV in order to support the physiological requirements of the human ventilatory system. Examples described herein make best use of the contractile properties of the diaphragm muscle and prevent muscle disuse and muscle atrophy. This can be carried out by engaging the phrenic nerves using patterned functional electrical stimulation applied to endovascular electrodes that are temporarily and reversibly inserted in central veins of the patient, such as the left subclavian vein and the superior vena cava. In some examples, the TDPS is designed to seamlessly interface with any commercially available positive-pressure ventilatory assistance/support equipment such as is commonly in use in hospital intensive care units (ICU) for treating critically ill patients with breathing insufficiencies, pain, trauma, sepsis or neurological diseases or deficits.
  • Rapid insertion and deployment of the disclosed systems can be effected via employment of minimally invasive central line catheter-based electrodes, such as those described in U.S. application Ser. No. 12/524,571, filed Jul. 25, 2009, which can be quickly installed in the patient under local anesthesia and rapidly activated, such that a pacing therapy can be initiated within one or a few hours of admission/intubation. If indicated by the patient clinical status, pacing via electrical stimulation can proceed in synchrony with ventilator breaths provided by virtually any brand or model of commercially available positive-pressure ventilator operating in typical modes such as Control Mode, Support Mode or Assist Mode. Once therapy is complete, the pacing catheter electrodes can be easily removed. In some embodiments, system pacing follows the operation of a ventilator while in other embodiments, the ventilator initiates and/or assists a breath cycle based on physiological responses generated by the pacing system.
  • Rapid deployment, i.e., within a few hours of admission/intubation, is advantageous in preventing the ill effects of muscle disuse atrophy, which are known to occur very quickly in ventilated and sedated patients, and to maintain diaphragm muscle strength and endurance during the critical period when a patient is unable to breathe independently. FIG. 33A-C illustrate examples of employing the TDPS to prevent diaphragm disuse atrophy or rehabilitate the diaphragm for successful weaning from respiratory assistance. As a result, early and successful weaning from the ventilator can be realized. Another advantage stemming from the rapid deployment capability of the systems described herein and a rapid initiation of a diaphragm pacing therapy is that this intervention will help prevent/reduce the deleterious effects of high positive airway/lung pressures (such as Ventilator Induced Lung Injury, VILI) that are commonly encountered in patients subjected to mechanical ventilation and contribute to failure to wean and protracted dependence on ventilation in many cases. Patients who remain on mechanical ventilation have high risk of ventilator-associated pneumonia (VAP) and of contracting nosocomial (hospital-borne) infections. It is therefore important to ensure that a patient on mechanical ventilation is liberated (weaned) from ventilation as soon as medically possible. Examples of the pacing systems and methods described herein address this need and others.
  • As will be described in more detail below, the systems of the present disclosure are designed to stimulate the right phrenic nerve (to recruit the right hemi-diaphragm), the left phrenic nerve (to recruit the left hemi-diaphragm), or both phrenic nerves in order to recruit the entire diaphragm muscle. Furthermore, each phrenic nerve may be recruited using a single channel of stimulation or two or more channels of stimulation per nerve. An example showing one embodiment employing two channels of stimulation per phrenic nerve is shown in FIG. 3. In some examples that employ two channels of stimulation per nerve, the stimulation pulses can be delivered 180 degrees out of phase.
  • In the following description, numerous specific details are set forth in order to provide a thorough understanding of one or more embodiments of the present disclosure. It will be apparent to one skilled in the art, however, that many embodiments of the present disclosure may be practiced without some or all of the specific details. In some instances, well-known process steps have not been described in detail in order not to unnecessarily obscure various aspects of the present disclosure. Further, it will be appreciated that embodiments of the present disclosure may employ any combination of features described herein.
  • Turning now to FIG. 1, one example is shown of a transvascular diaphragm pacing system, generally designated 20, formed in accordance with aspects of the present disclosure. As best shown in FIGS. 1 and 4, the system 20 includes a stimulator 24 coupled in electrical communication (e.g., wired or wireless) with one or more transvascular electrodes 28 suitable for placement in-vivo near the left and/or right phrenic nerves. In use, the stimulator 24 is configured to transmit a stimulatory signal in the form of stimulation pulses to one or more of the electrodes 28. The electrodes 28, in turn, emit the stimulatory signal in the vicinity of a left and/or right phrenic nerve. Stimulation of the left and/or right phrenic nerve, in turn, aims to cause recruitment of the subject's diaphragm.
  • As will be described in more detail below, the parameters (amplitude, duration, frequency, etc.) of stimulation pulses affect the amount of diaphragm recruitment, and the resulting output (such as tidal volume, pressure) therefrom. In that regard, and as will be described in more detail below, sensors 48 configured to sense various physiological parameters of the patient, some indicating diaphragm output, can provide feedback to the stimulator 24 for regulation of the administered therapy.
  • As described herein, the system 20 can be the sole respiratory aid for the patient. In other embodiments, the system 20 operates in conjunction with a positive pressure mechanical ventilator 32 (“ventilator 32”) in order to satisfy the respiratory needs of the patient. In some embodiments, signals sensed from a breath sensor 50 that monitors the breath cycle of the ventilator 32 can be employed to synchronize the delivery of the stimulation signals with the ventilator breath cycle.
  • The respiratory needs of the patient are sometimes referred to as the patient's prescribed assist level. The prescribed assist level is generally quantified as the amount of tidal volume or pressure (or a combination of the two) provided to the patient during one breath cycle that satisfies the minimum physiological functions of the patient. Generally, the prescribed assist level in terms of tidal volume is approximately 7-10 mL per Kg of patient weight. In some embodiments, the prescribed assist level is satisfied solely via artificial means (e.g., via system 20, via ventilator 32, or a combination of the two). This may occur in patients that are heavily sedated and/or unconscious. In other embodiments, the prescribed assist level may include some patient initiated respiratory effort.
  • As will be described below, in some embodiments, the clinician, as part of a therapy plan, can program the system 20 in order to satisfy the prescribed assist level (i.e., in tidal volume, pressure, or both) via recruitment of the diaphragm. In other embodiments, the clinician can program the system 20 to contribute only a percentage of the prescribed assist level (in volume, pressure, or both), referred to herein as the diaphragm contribution or diaphragm contribution level, via electrical recruitment of the phrenic nerve or nerves. The percentage can vary, and is patient-dependent based on a variety of factors, such as the condition of the patient, the ailment afflicting the patient, time elapsed preceding any stimulation therapy, etc. In this embodiment, the remaining percentage of the prescribed assist level can then be satisfied by the ventilator 32, which can be appropriately programmed by the clinician at the onset of or during administration of the therapy plan.
  • In some embodiments, as will be described in more detail below, the system 20 carries out one or more assessments of the patient in order to determine, for example, the current condition of the patient's diaphragm, the stimulation signal characteristics that relate to the recruitment of the diaphragm, such as threshold pulse width, pulse amplitude, pulse frequency, sub-maximal pulse width, and supra-maximal pulse width, etc. Threshold Pulse Width refers to a minimum pulse width at and above which there is a diaphragmatic response. Threshold Frequency refers to a minimum frequency at and above which partly or completely fused Tetanic contractions are produced, so as to generate useful diaphragmatic force and/or work.
  • Turning now to FIG. 2, placement of the electrodes 28 will now be described with reference to a heart H and diaphragm D of a patient P. As shown in FIG. 2, the left and right phrenic nerves run along the lateral and medial side of the heart to a diaphragm D. The left subclavian vein traverses in proximity to the left phrenic nerve and transmits blood from the upper extremities to the heart H. The superior vena cava traverses near the right phrenic nerve and carries deoxygenated blood from the upper half of the body to the heart's right atrium. As known in the art, when either left or right phrenic nerve receives a high enough electric stimulus as a voltage (V), current (mA) or charge (nano-coulombs) the phrenic nerve is activated and causes the diaphragm D to contract.
  • FIG. 3 illustrates one embodiment showing two channels of transvascular stimulation delivered to the left phrenic nerve by endovascular electrodes placed in the left subclavian vein and two channels of transvascular stimulation delivered to the right phrenic nerve by endovascular electrodes placed along the lateral wall of the superior vena cava. Each phrenic nerve can be partially or fully recruited from more than one endovascular electrode combination. Partial nerve recruitment from more than one electrode combination is useful to reduce muscle fatigue over time.
  • Turning now to FIG. 4, the components of the system will now be described in detail. As shown in FIG. 4, the system 20 includes a first electrode 28A having anodal and cathodal electrode contacts 30A, 32A placed within the left subclavian vein and positioned in the vicinity of the left phrenic nerve. In the embodiment shown, a second electrode 28B having anodal and cathodal electrode contacts 30B, 32B may be also placed within the left subclavian vein and positioned in the vicinity of the left phrenic nerve.
  • The system 20 further includes a third electrode 28C having anodal and cathodal electrode contacts 30C, 32C placed within the superior vena cava and positioned in the vicinity of the right phrenic nerve. In the embodiment shown, a fourth electrode 28D having anodal and cathodal electrode contacts 30D, 32D may be also placed within the superior vena cava and positioned in the vicinity of the right phrenic nerve.
  • While two electrodes are shown and described for stimulating each of the left and right phrenic nerves, it will be appreciated that other numbers of electrodes may be practiced with embodiments of the present disclosure. For example, four electrodes can be used for stimulating each phrenic nerve. For more information regarding the placement of a plurality of electrodes endovascularly as well as the configuration of one type of electrode structure that can be practiced with embodiments of the present disclosure, please see U.S. application Ser. No. 12/524,571, filed Jul. 25, 2009, the disclosure of which is hereby expressly incorporated in its entirety. Additionally, while electrodes with anodal and cathodal electrode contacts are utilized to emit the stimulation pulses into the phrenic nerves, other configurations are possible. For example, several cathodal electrode contacts may be used in conjunction with a single anodal electrode contact, and vice versa.
  • Each electrode 28 is connected in electrical communication with the stimulator 24. In the embodiment shown, each electrode 28 is electrically connected to the stimulator 24 via lead(s) 40.
  • The system 20 further includes one or more sensors 48 configured to monitor the response to phrenic nerve stimulation and/or other physiological characteristics of the patient. As will be described in more detail below, the one or more sensors 48 can be part of a feedback control scheme for regulating the stimulation administered to the patient. The plurality of sensors 48 can transmit data to the stimulator 24 indicative of one or more of the following: electromyographic activity (intramuscular, surface, and/or intraesophageally monitored), central venous pressure (any specific component of this signal), heart rate, chest wall acceleration, blood oxygen saturation, carbon dioxide concentration, catheter position/depth within vein, mechanical movement (i.e., from accelerometers, length gauges, and/or strain gauges) resistance (.e., from impedance pneumographs, and/or piezoresistive sensors) and/or other physiological or mechanical parameters. It will be appreciated that the information can be appropriately processed (e.g., filtered, conditioned, amplified, etc.) prior to use by the stimulator 24.
  • The term “volume” as used herein includes, but is not limited to, Inspired Tidal Volume, Expired Tidal Volume or Minute Volume. The term “pressure” as used herein includes, but is not limited to, Airway Pressure, Alveolar Pressure, Ventilator Pressure, Esophageal Pressure, Gastric Pressure, Transdiaphragmatic Pressure, Intra-Thoracic Pressure Positive End-Expiratory Pressure or Pleural Pressure. Any pressure may be Peak Pressure, Mean Pressure or Baseline Pressure. The term “flow” as used herein includes, but is not limited to, Inspiratory Flow or Expiratory Flow.
  • In some embodiments, the electrodes 28 can also monitor physiological variables of the subject by virtue of their placement in the central veins. Such monitored physiological variables can include, but are not limited to: central venous pressure, electrocardiogram, and mixed venous oxygen saturation. It will be appreciated that one or more sensors discrete from the electrodes, such as one or more of the sensors 48, may be used to monitor such physiological variables.
  • In some embodiments, the system 20 can additionally or alternatively include a breath sensor 50 for sensing parameters of the ventilator 32. In that regard, the breath sensor 50 can be configured to interface with any standard breathing circuit used in critical care ventilators and therefore the pacing system is independent of the brand of ventilator used. The breath sensor 50, by virtue of its location in the breathing circuit, can monitor and/or measure several ventilation parameters and communicate such parameters to the stimulator 24. As will be described in more detail below, the breath sensor 50 can be part of or used solely as a feedback control scheme for regulating the stimulation administered to the patient. The sensed ventilation parameters may include, but not limited to, airflow (inspired and/or expired), volume, pressure (airway, esophageal, gastric, and/or some combination/derivative of the former). In some embodiments, other sensors may aid in the procurement of one or more ventilation parameters.
  • In some embodiments, the example parameters are being measured both to and from the ventilator 32. In the embodiment shown, the breath sensor 50 is external to the ventilator 32 so that the system is independent of ventilator model. However, the system 20 could also be integrated to use a ventilator's internal sensors or signals externally supplied by the ventilator can provide the information to the system 20 for proper operation so that an external breath sensor can be omitted.
  • The stimulator 24 functions, in part, as a signal generator for providing therapy to the diaphragm in response to information received from the one or more of the sensors 48 and 50 and/or information programmed into the system 20 by the clinician. In that regard, the stimulator 24 delivers pulses to the endovascular electrodes 28 in accordance with one or more protocols described herein. As will be described in more detail below, the pulses in some embodiments are generated by the stimulator 24 with characteristics that deliver a suitable charge to the phrenic nerves in order to provide enough diaphragm recruitment to satisfy the selected diaphragm contribution (e.g., in volume, pressure, both, or derived parameters from volume and pressure) of the prescribed assist level described above.
  • Towards that end, the stimulator 24 is configured to deliver fully programmable stimulation, including, but not limited to, the following: any number of pulses, any combination of the defined pulses, any order of delivery of the defined pulses, multiple instances of any defined pulse(s), any frequency of stimulation, and/or any delay between pulses (interpulse delay). Each pulse can be independently programmable (e.g., frequency, amplitude, duration, etc.). The stimulation pulse(s) and/or train(s) may or may not generate a repeatable pattern.
  • Each pulse includes a charge injection phase and a charge balance phase (biphasic). In some embodiments, the balance phase duration and amplitude is programmable as a ratio of the charge phase duration and amplitude so that zero net charge is maintained, as shown in FIG. 6. This ratio, denominated as the Charge:Balance Ratio (C:B Ratio), is applied so that the product of amplitude and duration (charge) is equal in both the charge phase and the balance phase. In some embodiments, each pulse is programmable via the following parameters: ratio of charge phase duration to balance phase duration; pulse width range; stimulation amplitude (current level); and delay between the charge phase and the balance phase. Stimulation amplitude may be changed during the same phase (i.e., generate a gradually decreasing current for the charge pulse width). While zero net change is preferred, non-netzero charges may be used.
  • Because the diaphragm is skeletal muscle, pacing may be accomplished by delivering one or more stimulation signals to produce a mechanically effective contraction of the diaphragm. In that regard, the stimulation signals may include a plurality of pulses that are grouped in stimulation trains. As used herein, a stimulation train is defined as a collection of stimulation pulses. This definition does not imply a specific composition, order of delivery, and/or shape profile or envelope. FIGS. 7 and 8 illustrate examples of stimulation trains generated by the stimulator 24 and delivered to the electrodes 28 for stimulating the phrenic nerves. The stimulation trains may start with a doublet (pair of pulses) or a triplet, which can be physiologically relevant; two or three pulses in quick succession at the beginning of recruitment has been shown to increase the overall force profile by shifting the baseline up during the initial onset of recruitment, as demonstrated in FIG. 5. Similarly, a doublet or triplet delivered part-way through a train can cause a sustained force increase. The upward shift in early force production infers that fewer stimulation pulses can be used to generate the same amount of force from the diaphragm in a comparable period of time. This can be quite beneficial since over-activating the diaphragm with excessive numbers of stimulation pulses may induce fatigue, and may also cause conversion of fibers from fast-twitch (powerful, but fatigued easily) to slow-twitch (fatigue-resistant but unable to produce large amounts of force).
  • Stimulation or pulse trains are typically characterized by the rate, the duration, the pulse width, the frequency, and the amplitude of the signals. The rate of the stimulation train corresponds to the number of stimulation trains delivered per minute, which can correlate with the patient's respiratory rate or mechanical ventilator rate. The duration of the stimulation train refers to the length of time the stimulation train is delivered. The pulse width indicates the duration of each individual pulse creating the stimulation train. Similarly, the frequency indicates the number of individual pulses delivered per second. Finally, the amplitude refers to the voltage of each pulse delivered. The parameters of amplitude, frequency, and pulse width determine the strength of the induced diaphragmatic pacing.
  • In some embodiments, the stimulation trains form ramp trains. For example, ramp trains can be formed by linearly increasing (or decreasing) either the instantaneous frequency of consecutive pulses in a train, the durations (pulse widths) of consecutive pulses in a train, or both. Ramp trains indicate that a change in injected charge is induced by the programmed stimulation parameters and any applied modulation.
  • Variations in pulse width and frequency modulation allow different ramp train envelopes to be designed. Referring to FIG. 9, ramp envelopes can be generated during a single pacing ramp in pulse width alone, frequency alone or both in pulse width and frequency. Pulse width and stimulus frequency envelopes can be modulated together or combined, as shown in the examples of FIG. 10, during pacing to generate a desired ramp train. For example, combination AF will cause a graded recruitment of the phrenic motoneurons at a constant frequency (no rate coding) and Combination BA will gradually recruit and de-recruit the motoneurons, with a steadily increasing rate coding; although any combination is possible. It will also be possible to alter the rate of recruitment and de-recruitment (slope) of motoneurons, independent of the rate coding, by adjusting the relative percentage of pulse width increase and decrease duration within a single pacing ramp. Further, the pulse width and frequency modulation can be defined mathematically as piecewise functions in time, thereby allowing any desired ramp envelope to be generated while remaining within the scope of the present disclosure.
  • Although a large set of ramp trains can be generated, there will be some embodiments where the ramp trains aim to achieve one or more of the following: 1) mimic physiological contraction of the diaphragm by independently controlling recruitment and rate coding by means of pulse width and frequency modulation, respectively; 2) delay the onset of neuromuscular fatigue; 3) maintain the native fiber composition of the healthy diaphragm; 4) condition the diaphragm towards a specific fiber type, for e.g. Type I (Slow Twitch, Fatigue Resistant).
  • With the various programmable stimulation trains or ramp trains, a therapy plan can be constructed by the clinician with or with the aid of the system 20. The therapy plan constructed by the clinician is patient dependent in order to achieve various goals. The therapy plan may include one or more of the following: timing of delivery of pacing in relation to ventilator breaths (e.g., every breath, every other breath, every five breaths, etc.); intermittent stimulation segments (e.g., stimulation delivery for 15 minutes every hour), etc. As an example, in a patient who requires PPMV and sedation, a therapy plan would take into consideration both major objectives of minimizing VIDD and minimizing risk of VILI. As another example, in a therapy plan for a patient who able to remain awake during part of the day and breathe independently for some hours and will soon be attempting to wean, it may be desirable to not pace while the patient is breathing spontaneously but, conversely, to pace at a low assistive level during the night while the patient is again sedated and placed back on PPMV, in order to reduce the peak pressure required for ventilation and thus reduce risk of VILI.
  • In some embodiments, the therapy plan includes the ability to skip stimulation, sometimes referred to as skipped breaths, which allows for a ventilator breath to be delivered without being accompanied by stimulation from the system 20. Additionally or alternatively, the therapy plan may include sigh breaths. Sigh breaths are characterized as intermittently programmable breaths that inject more charge than a normal breath (i.e. a higher magnitude stimulation train). Physiologically, this results in a more forceful contraction of the diaphragm. Both functions are programmable independently and can be repeatable. For sigh breaths only, the percentage increase in amplitude is programmable based on the amplitude of a typical paced breath. It is possible to implement these features independently or combined.
  • FIG. 13A-C illustrate an example of skipped breaths, sigh breaths, and a combination of skipped breaths and sigh breaths, respectively. FIG. 13A is an example of skipped breaths, where the system 20 skips every 3rd breath. This means that during the skipped breath, the patient receives the ventilatory support entirely from the ventilator 32. During the skipped breaths, respiratory mechanics such as tidal volume, compliance of the lungs, resistance to airflow or the recruitment of the lung regions may vary. FIG. 13B is an example of sigh breaths generated by the system 20 while operating in synchrony with the ventilator 32. In this example, a sigh breath is delivered every 3rd breath. Depending upon whether flow is controlled or pressure controlled, the sigh breaths can alter the respiratory mechanics. This feature mimics a feature of spontaneous breathing namely, variable tidal volume. FIG. 13C is an example of both skipped and sigh breaths being administered in a periodic manner by the system 20.
  • The stimulator 24 in some embodiments is configured to generate constant-amplitude current pulses with pulse duration in the range from 50-300 microsec, controllable in increments of 10 microsec. The amplitude and duration of each pulse in a train can be independently programmed. The amplitude of pulses can be selected between 0.1 and 10 mA in 0.1 mA increments. The main parameter that determines whether a stimulus pulse will be sufficient to activate a nerve axon (reach its threshold to fire an action potential) is the charge delivered by the stimulus, where charge (in nC)=pulse current amplitude (in mA)×pulse duration (in microsec). In this regard, the stimulator 24 can produce pulses in the range from 5 nC to 3000 nC and the charge per pulse can be specified in increments of 1 nC.
  • FIG. 4 shows a schematic diagram of one embodiment of the stimulator 24. As shown in FIG. 4, the stimulator 24 includes a controller 60, which receives signals sensed from one or more sensors 48 and/or the breath sensor 50. The stimulator 24 may also include a timer 64 coupled to controller 60, and a power source 68. The controller 60 is coupled to a pulse generation circuit 70, which delivers stimulation signals to one or more of the electrodes 28 via leads 40. In one embodiment, the components described above are coupled via bus 72. In some embodiments, the power source 68 of the stimulator 24 includes one or more batteries. In other embodiments, the power source 68 includes a power regulation section that receives power from standard “mains,” and transforms it into appropriate power for the circuitry of the stimulator 24.
  • Those skilled in the art and others will recognize that the controller 60 serves as the computational center of the stimulator 24 for carrying out logic or by supporting the execution of routines, instructions, etc., for providing functionality to the stimulator 24. In that regard, the logic, routines, instructions, etc., described herein may be implemented in hardware, in software, or a combination of hardware and software.
  • In some embodiments, the controller 60 includes one or more processors and memory. The logic, routines, instructions, etc., may include a set of control algorithms, including resident program instructions and calibrations stored, for example, in the memory and executed to provide a desired functionality of the system 20. The algorithms may be executed during preset loop cycles such that each algorithm is executed at least once each loop cycle. Algorithms stored in non-volatile storage medium can be executed by the processor to: 1) monitor inputs from the sensors 48, 50 and other data transmitting devices or polls such devices for data to be used therein; 2) cause the pulse generator to generate and transmit one or more pulses to the electrodes 28; and 3) regulate the diaphragm output of the patient, among other functions. Loop cycles are executed at regular intervals, for example each 3.125, 6.25, 12.5, 25 and 100 milliseconds during ongoing operation of the system 20. Alternatively, algorithms may be executed in response to the occurrence of an event.
  • As used herein, the term processor is not limited to integrated circuits referred to in the art as a computer, but broadly refers to a microcontroller, a microcomputer, a microprocessor, a programmable logic controller, an application specific integrated circuit, other programmable circuits, such as programmable gate arrays, combinations of the above, among others. In some embodiments, the controller 60 may include additional components including but not limited to a high speed clock, analog to digital (A/D) and digital to analog (D/A) circuitry, input/output circuitry and devices (I/O) and appropriate signal conditioning and buffer circuitry.
  • It will be appreciated that the signals received from the sensors 48, 50 may be processed by an optional signal processing section 80 prior to arriving at the controller 60. For example, the signal processing section 80 may include dedicated circuits, processors, such as digital signal processors (DSP), etc., for receiving, processing and filtering electrical signals sensed by the sensors associated with the subject and/or the ventilator 32. Signal processing section 80 can include amplifiers and circuits to condition, filter and/or amplify the electrical signals supplied thereto. In some embodiments, the signal processing section 80 carries out discrete tasks, such as the determination of one or more physiological states. One physiological state that can be determined by signal processing section 80 is a patient's minute volume or ventilation. Minute ventilation is a respiratory related parameter that is a measure of the volume of air inhaled and exhaled during a particular period of time. The minute ventilation is the product of respiration rate and tidal volume. Signal processing section 80 can also be used to receive and process signals representing other respiratory activity such as intrathoracic pressure, chest wall motion, etc. Of course, the determination of one or more physiological states, processing of signals, implementation of logic or processes, etc., can be carried out solely by the controller 60.
  • Still referring to FIG. 4, the stimulator 24 includes one or more input devices 86. The input devices 86 may include switches, knobs, etc., supported by the housing of the stimulator, and/or computer style devices, such as a keyboard, a touchpad, etc. The input devices 86 provide for the input of data, such as the pacing parameters, ventilator parameters, etc., into the stimulator 24. Output devices 92, such as a monitor, may also be provided.
  • In accordance with aspects of the present disclosure, one or more embodiments of the system 20 can be operated in various pacing modes. The pacing modes may be alternatively employed by a clinician, depending on the clinical status and needs of each patient and on the operational properties of a ventilator, such as ventilator 32, which may be available in a particular ICU. The pacing modes can include but are not limited to Ventilator-Initiated Pacing Mode, Pacer-Initiated Ventilation Mode, and Autonomous Pacing Mode. Those skilled in the art will understand that these modes may be engaged in many ways to generate different combinations of system functionality, but for reasons of brevity all possible combinations are not listed herein. Each of these modes will now be described in some detail.
  • The first mode of the system 20 to be described herein is the Ventilator Initiated Pacing Mode. As will be described in more detail below, this mode operates the stimulator 24 in synchrony with the operation of the ventilator 32. This mode can work with any mechanical ventilator in control mode, whereby the flow or pressure is controlled by the ventilator and delivered at a pre-determined frequency (breath rate). Delivery of stimulation ramp trains generated by the stimulator 24, such as any of those shown in FIGS. 9 and 10, can be synchronized with the ventilator 32 in several ways, some of which are shown in FIGS. 11 and 12. For example, stimulation can begin at any time before, during, or after the onset of the inspiratory phase of the ventilator 32 and/or can end at any time before, during, or after the end of the inspiratory phase of the ventilator 32.
  • Turning now to FIG. 14, there is shown one example of a routine 100 configured to carry out one or more functions of the system 20, including the Ventilator Initiated Pacing Mode. As will be appreciated by one skilled in the art, the logic or routines described herein may represent one or more of any number of processing strategies such as event-driven, interrupt-driven, multi-tasking, multi-threading, and the like. As such, various acts or functions illustrated may be performed in the sequence illustrated, in parallel, or in some cases omitted. Likewise, the order of processing is not necessarily required to achieve the features and advantages, but is provided for ease of illustration and description. Although not explicitly illustrated, one or more of the illustrated acts or functions may be repeatedly performed depending on the particular strategy being used. Some of the functions carried out by the routine can be combined or can be further separated into additional steps or acts.
  • As shown in FIG. 15, the routine 100 begins at block 102, where the system is initialized. Initialization allows a clinician to program the system 20, for example, by inputting via input devices 86 various system parameters according to a therapy plan. As was described in some detail above, the therapy plan can include a level of diaphragm contribution and the prescribed assist level if not already known by the system 20 or derivable from other data known by system 20. In some embodiments, the level of diaphragm contribution can be entered as either a percentage of prescribed assist level or as tidal volume, pressure or both volume and pressure, or as a parameter derived from volume and pressure.
  • In some embodiments, the clinician can input the prescribed assist level for the patient depending upon clinical status. The prescribed assist level in some embodiments is programmed as tidal volume. Alternatively, it can also be programmed as: (1) a desired amount of pressure generated by the diaphragm; (2) the product of pressure and volume, referred to as Work of Breathing (WOB) shown in FIG. 21; (3) the integral of pressure with respect to time, referred to as Pressure-Time Product (PTP); (4) indices derived from the monitored variables, such as Pressure-Time Index (PTI); or (5) a reduction in the airway pressure attained by PPMV plus Pacing, when compared to PPMV alone. The prescribed assist level can be set in terms of one of the parameters mentioned above or as a combination of one or more of these parameters, while remaining within the scope of the claimed subject matter.
  • Along with the diaphragm contribution level, the clinician can program the system 20 with one or more stimulation parameters, such as amplitude, duration, frequency, etc., that are capable of recruiting the diaphragm in order to satisfy the diaphragm contribution level (e.g., in volume or pressure, or both). In other embodiments, as will be described in detail below, some of the stimulation parameters which correspond to the diaphragm contribution level, may have been previously programmed into or obtained by the system 20.
  • The clinician may also enter the amount of therapy to be provided per 24 hour period. For example, the clinician may wish to administer therapy for eight (8) hours out of each 24 hour period. The therapy can be administered consecutively for 8 hours, or can be segmented into time period blocks (e.g., 2 hrs., 1 hr., 30 minutes, 15 minutes, etc.), which can be either constant or variable. If variable, the time period blocks can form a repeatable pattern, if desired. The therapy may also vary the diaphragm contribution throughout the period of administered stimulation. In some embodiments, the clinician can program sigh breaths or skipped breaths, as described above with reference to FIG. 13A-C. The clinician can further enter one or more ventilation parameters, such as ventilator operating mode, breath cycle timing (i.e., breaths per minute), etc. It will be appreciated that other data may be entered by the clinician during the initialization stage for providing functionality to the system 20.
  • Returning to FIG. 14, the routine 100 proceeds to block 104, where the respiratory cycle of the patient and/or the ventilator are monitored. In one embodiment, the routine 100 carries out a breath detection algorithm, which uses data from the breath sensor 50 and detects the different phases of ventilator breath or a spontaneous breath, such as inspiration phase, inspiration pause, expiration phase and expiration pause. Further, the breath detection algorithm can quantify the different attributes of a breath such as duration of any of the breath phases mentioned above. The breath detection algorithm can use any of the monitored signals, such as flow, volume or pressure to evaluate a series of conditional expressions to identify and/or calculate the attributes of a breath cycle. The method of identifying and/or calculating the attributes of a breath cycle may include, but is not limited to, Slope Threshold Detection, Amplitude Threshold Detection or a combination thereof. Furthermore, the breath detection algorithm can store and/or process waveform data of the current breath or any set of previous breaths. The breath detection algorithm may also facilitate the operation of the system in an event-predictive or in an event-triggered manner. In case of detection of a spontaneous breath, the system may either stop ongoing stimulation, continue stimulating so as to add to the spontaneous breath, or skip the next breath.
  • Next, at block 106, synchrony between the ventilator 32 and the administration of pacing therapy is maintained. This ensures that diaphragm pacing by stimulation signals emitted by the electrodes is synchronized with each breath administered by the ventilator 32. If an uncoupling is suspected, pacing may be skipped and resumed as soon as the ventilatory pattern stabilizes again. In other embodiments, the pacing can continue while synchrony is reestablished. In some embodiments, synchrony is determined by comparing the attributes of at least one previous breath cycle (e.g., 12 breaths per minute, etc.) with the attributes of the current breath cycle of the ventilator 32 as determined via processing of the signals from the breath sensor 50 and/or one or more of the sensors 48.
  • From block 106, the routine proceeds to block 108. At block 108, the diaphragm output (e.g., tidal volume, pressure, or a combination of the two) is regulated to ensure the programmed prescribed assist level is satisfied. In this regard, in some embodiments, the system 20 monitors the data from one or more of the sensors 48 and/or sensor 50 for determining the diaphragm contribution (tidal volume, pressure, or both) for each ventilator breath. This may be calculated from the measured output (i.e., the sum of diaphragm contribution and ventilator contribution) of each ventilator breath or can be calculated directly from the sensor data. If the diaphragm output (or diaphragm contribution) from the previous administered stimulation signal is within a preselected range, the programmed stimulation parameters are maintained, and will be subsequently employed to generate the stimulation train for therapy administration at the next breath.
  • If the calculated diaphragm contribution resulting from the last administered stimulation signal differs from the target diaphragm contribution value by more than a preselected amount, the stimulation parameters may be modified (e.g., amplitude and/or duration are increased) so as to maintain the diaphragm output within a desired range. Such a difference between the calculated diaphragm contribution responsive to the last administered stimulation signal and the programmed diaphragm contribution value can be seen as a change in either the pressure (in Volume-Controlled Modes/Ventilators) or as a change in tidal volume (in Pressure-Controlled Modes/Ventilators) or as a change in any signal sensed by one or more of the sensor(s) 48 or sensor 50. The modified stimulation parameters are then stored in memory. In some embodiments, the system 20 operates in accordance with a “closed-loop” feedback scheme to regulate the diaphragm output during operation of the system 20, one example of which is shown in FIG. 15.
  • In some embodiments, an evaluation is carried out to determine the reason for such a drop in tidal volume or pressure. For example, in some embodiments, the discrepancy in reaching the diaphragm contribution target may be due to a displacement of a stimulation electrode away from an optimal position. In other embodiments, the discrepancy or variability in tidal volume or pressure between breaths can be attributable to either changing respiratory mechanics of the patient or to time-dependent fatigue of the higher force producing fast-fatigable (Type IIb) fibers.
  • Changes in respiratory mechanics may include changes in airway resistance and/or compliance of the lungs/chest wall. For example, in the embodiment shown in FIG. 16, the tidal volume is controlled during all breaths, representing a ventilator operating in a Volume Controlled Mode. If any changes occur to the resistive load or the compliance load, these will be reflected as changes in the airway pressure represented in the plot below the tidal volume. In the example of FIG. 16, the first two breaths illustrate the baseline level of airway pressure when pacing the diaphragm in synchrony with the ventilator 32. On the 3rd breath, the system encounters a change in compliance load, which can be inferred from the increased peak airway pressure and change in slope of the airway pressure waveform.
  • In the 4th breath shown in FIG. 16, the system 20 can validate the measured drop in compliance and assumes it is due, for example, to a reduction in force contribution of fast fatigable Type IIb fibers. By the 5th breath, the system 20 has adjusted its pacing parameters to restore the desired level of diaphragm contribution (negative pressure) to the overall ventilatory assist system, thereby returning the airway pressure to the prescribed assist level.
  • It will be appreciated that similar principles can be applied to a pressure controlled ventilator, where changes in respiratory mechanics may be indicated by changes in tidal volume between breaths. The system 20 may be configured to adaptively modify the pacing parameters to return the tidal volume to the prescribed assist level.
  • As described above, the discrepancy or variability in tidal volume or pressure between breaths can be also attributable to time-dependent fatigue of the higher force producing fast-fatigable (Type IIb) fibers. For example, FIG. 17A illustrates a natural progressive decline in the percentage of Type IIb Fast Fatigable Motor Units contributing to force development. Initially, Type IIb Motor Units can produce much larger forces than Type I Motor Units and their larger diameter axons are also easiest to be recruited by electrical stimulation. Therefore, a low level of intensity of phrenic nerve stimulation is initially sufficient to produce the diaphragm contribution level, as illustrated by FIG. 17B. As shown schematically in FIG. 18, initially perhaps only 15% of all motor units in a phrenic nerve need to be recruited by the system 20 to meet the prescribed force/pressure levels of the diaphragm contribution.
  • As shown in FIG. 17, Type IIb Motor Units tend to fatigue and produce less force with the passage of time, leading to a decline in the force (Diaphragm Contribution) below the programmed level of diaphragm contribution. To maintain the diaphragm contribution, the intensity of stimulation can be progressively increased so as to recruit additional Type I and Type IIa Motor Units. As a result, the stimulation spreads across a higher cross-sectional area (e.g. 30%) of the phrenic nerve to recruit more Type I and Type II Motor Units and the prescribed force is produced.
  • The force declines again as the Type IIb Motor Units present in the newly activated cross-section of the phrenic nerves, fatigue in turn. At this point the pacing intensity is increased again by the pacing control system in order to activate an even larger cross-sectional area of the phrenic nerve, recruiting more Motor Units to reestablish the force output. This progressively increasing activation of the phrenic nerve continues and finally up to 100% of the phrenic nerve motor units may be recruited. Eventually all the Type IIb Motor Units are knocked out by fatigue and only the Type I and Type Ha Motor Units continue to contribute force.
  • It will be appreciated that the increase in the stimulation may be a simple linear equation or a complex equation with weights assigned to the proportion of available fibers and their fatigue resistant properties. The loss of force may be attributed specifically to the fatigue of the fast fatigable fibers, using parameters such as Maximum Relaxation Rate and half-relaxation time. The changes in slope of the first half of the diaphragm relaxation curve indicative of the relative contribution of Type I and Type II fibers to force development may also be used. Other parameters specific to fatigue such as Pressure-Time Index, Expiratory Time Constant, EMG (and any derived parameters thereof such as power spectrum), Ratio between slow and fast twitch amplitudes, may also be employed to infer the varying conditions and to determine the modified stimulation parameters.
  • In another embodiment, the closed-loop control strategy may include using doublets/triplets in response to contractile slowing accompanying fatigue of the diaphragm Motor Units. When fatigue is detected by the system 20, the stimulation pattern is automatically changed to include doublet/triplets and otherwise lower stimulation frequency, as this form of stimulation is known in the art to optimize force production in fatiguing/fatigued motor units. Once the fatigued motor units have recovered their strength, the stimulation pattern can again be changed to moderate stimulation frequency with or without doublets. This closed-loop scheme allows for continuous pacing of the diaphragm irrespective of the onset or progression of fatigue, also reduces the number of stimulation pulses delivered and protects the muscle from potential injury that could be caused by over-stimulation.
  • Returning to FIG. 14, the stimulation therapy is administered at block 110. Administration of the stimulation therapy includes generation of a stimulation signal, such as a stimulation or ramp train. Depending on the result of block 108, the stimulation signal is generated in accordance with either the original stimulation perimeters or the stimulation parameters as modified in block 108 described above. Delivery timing of the stimulation ramp train is also determined at block 110. For example, the routine can determine the appropriate timing for phrenic nerve stimulation in relation to the actual breath cycle of the ventilator 32. Generally described, the routine controls the timing of stimulation according to pre-defined rules, based on parameter estimates from the breath detection algorithm, etc. The pre-defined rules can include whether stimulation begins at any time before, during, or after the onset of the inspiratory phase of the ventilator 32, which is shown in FIGS. 11 and 12, or whether stimulation begins during the expiratory phase, as shown in FIG. 24.
  • For example, depending on the ventilator mode, the system 20 can trigger off pressure or airflow signals. Once the inspiration/expiration phases have been determined, such as in block 104, to stimulate during the inspiration phase, the stimulation train can either be started by triggering off the start of the expiration phase followed by a delay or the start of the inspiration phase, as shown in FIG. 23. Triggering off the start of the expiration phase allows stimulation to be generated prior to the start of the inspiration phase to maximize diaphragmatic force during the inspiration phase. In addition, stimulation during the expiration phase can be achieved by triggering off the start of the expiration phase or the start of the inspiration phase with a delay, as shown in FIG. 24. While using the inspiration or expiration start is preferred, the end of the inspiration/expiration periods could conceivably be used as well. Furthermore, it is also possible to provide delayed stimulation such that stimulation would begin in the middle of the inspiration phase for example.
  • Once timing is determined, the routine at block 110 delivers the stimulation pulses to the stimulating electrodes 28 at the appropriate time for transmission therefrom. The routine returns to block 104 until the time period for therapy has expired or a clinician halts operation of the system 20.
  • In some embodiments, the system 20 may assist the clinician in determining the appropriate level of diaphragm contribution to be input into the system 20. In that regard, the diaphragm contribution can be dependent on the condition of the patient's diaphragm. For example, in a patient that has only a maximum diaphragm output of 750 mL and the clinician intends to target an assist level of 500 mL, the clinician may unknowingly choose a diaphragm contribution level that would require delivery of the maximum stimulation charge, which will cause premature fatigue, etc. Given this patient's present diaphragm condition, the clinician may wish to choose a much lower percentage so that the stimulation charge is in-between the threshold charge and the supra-maximal charge.
  • Thus, in some embodiments, in order to appropriately select the diaphragm contribution level, the condition of the diaphragm and the respiratory system is first assessed by the system 20. In that regard, the system 20 is configured to run one or more assessments on the patient's diaphragm and/or respiratory mechanics. The assessment determines the maximum diaphragm output (in volume, pressure, or both) and other parameters such as the fatigue characteristics of the diaphragm, the resistance, compliance and relaxation characteristics of the respiratory system and its components, etc. The assessment can be also run in-between or during periods of the operation of the system 20 in synchrony with the ventilator 32. These tests can either be run by shortly disconnecting the patient from the ventilator 32 and pacing the diaphragm in isolation or can be run with the patient connected to the ventilator 32 by employing a sequence of pauses in the operation of the ventilator 32 during which the diaphragm is paced in isolation. The sequence of pauses may either be employed manually by the clinician, or natural pauses that are part of a regular ventilator breath cycle (such as an End-Inspiratory Pause or an End-Expiratory Pause) may be automatically identified and used by the system 20.
  • Generally described, after the flow of gas from the ventilator 32 is momentarily occluded, the maximal static pressures generated by the diaphragm in response to supramaximally stimulating the phrenic nerves to elicit twitch, ramp, or tetanic contractions of the diaphragm are measured as well as the diaphragm relaxation characteristics during the inspiration and expiration phases. The assessment can pace the diaphragm in isolation with a preset duty cycle to assess diaphragm function with regard to its strength and endurance properties. From the data sensed by one or more sensors 48 and/or the sensor 50, measures and/or indices can be derived that include, but are not limited to, Maximum Static/Dynamic Inspiratory Pressures, Inspiratory Capacity, Pressure-Volume loop relationships, Work of Breathing, Pressure-Time Product, Pressure-Time Index, EMG, Maximum Relaxation Rate, and Expiration Time Constant. Diaphragm fatigue can be induced by continuous or intermittent stimulation of the phrenic nerves to assess endurance limits and to detect the presence of low frequency and/or high frequency fatigue. As the normal values for most of the calculated or derived parameters have a wide normal range, serial measurements set apart in time ranging from a few minutes to days, can be done on a patient by the pacing system to provide a complete picture of evolving changes in the diaphragm strength and endurance of the patient.
  • In some embodiments, a knowledge-based algorithm may be used to monitor instantaneous and/or trend data of the monitored signals. Such instantaneous and/or trend data may allow the assessment to predict weaning readiness of the patient and/or a time course for weaning. Such capability can also be extended to make the diaphragm assessment tests as a standalone screening and/or confirmatory tool by clinicians in the ICU, as the method of transvascular pacing of the diaphragm enables the clinician to assess the true status of the diaphragm in the absence of confounding factors (such as decreased central drive) usually associated with voluntary breathing maneuvers.
  • Once the maximum diaphragm output is determined, the diaphragm contribution level can be chosen with knowledge of the relationship between the prescribed assist level and the maximum diaphragm output. In order to understand this relationship, the controller 60 in some embodiments, via one or more subroutines, can recursively estimate the percentage of maximum diaphragm output required to generate 100% of the prescribed assist level. Of course, this and other calculations can be made on a separate computer system and imported or otherwise inputted into the controller 60 prior to operation of the system 20. One example of this recursive estimate is shown in FIG. 19.
  • In some embodiments, and described generally above, the clinician has the option to adjust the diaphragm contribution during operation of the system 20 from 0 to 100% of the prescribed assist level, as illustrated by the dial of FIG. 20, depending upon the status of the patient and the therapeutic goal.
  • FIG. 20A illustrates an example of setting the desired diaphragm contribution to 75% of the prescribed assist level (i.e., the target diaphragm contribution level). In this example, the remaining 25% of the ventilatory work is carried out by the ventilator 32. The clinician can therefore adjust the ventilator settings to contribute 25% of the ventilatory work, either as tidal volume or as pressure assist, as illustrated by the bottom plot of FIG. 20A. FIG. 20B illustrates another example of setting the desired diaphragm contribution to only 25% of the prescribed assist level (i.e., the target diaphragm contribution level). In this example, the remaining 75% of the ventilatory work is carried out by the ventilator 32. The clinician can therefore adjust the ventilator settings to contribute 75% of the ventilatory work, either as tidal volume or as pressure assist, as illustrated by the bottom plot of FIG. 20B. Alternatively, the PPMV can be set to a mode where the remaining portion of the prescribed assist level is determined and adjusted automatically by the ventilator on an Inter-Breath or Intra-Breath basis (e.g. Pressure Regulated Volume Control Mode). In some embodiments, the system 20 also calculates or otherwise obtains the stimulation characteristics that correspond to the diaphragm contribution. In other embodiments, the clinician can enter data indicative of these stimulation characteristics.
  • In some embodiments, the condition of the diaphragm is periodically reassessed after the therapy has been administered for a period of time (e.g. 12 hours, 1 day, etc.). For example, as described briefly above with regard to the closed-loop control method for regulating the diaphragm output, the variability in volume or pressure between breaths in some instances is attributable to changing respiratory mechanics of the patient, including changes to airway resistance and/or compliance of the lungs/chest wall. In other embodiments, the diaphragm muscle, through the administration of the therapy, has strengthened, and thus, the diaphragm contribution can be increased or the intensity of stimulation can be decreased to adjust the diaphragm contribution. In these cases, it may be beneficial to periodically reassess the diaphragm and optimize pacing therapy accordingly, after therapy has been initiated.
  • One example of a routine for measuring changes in the diaphragm condition without removing the patient from the ventilator 32 is shown in FIG. 22. Similar to the diaphragm assessment described above, a successive approximation routine in some embodiments can be used to determine the optimal parameters of stimulation for the patient.
  • As best shown in FIG. 22, the routine 200 begins with the clinician providing the initial system parameters, which may include maximum allowable stimulation parameters. Stimulation parameters can be provided either as a predefined stimulation train with fixed duration such that the stimulation train is fully defined by the user using methods as previously described or as a stimulation train in which the number of pulses and the train duration are based on the detected ventilator inspiration time. Next, the routine carries out the breath detection algorithm to detect the inspiration and expiration phases using the flow/pressure data sensed by breath sensor 50. In addition, the flow and pressure data for one or more breaths without stimulation are collected and stored.
  • Depending on the ventilator mode, the system 20 can trigger off pressure or airflow signals. Once the inspiration/expiration phases have been determined, to stimulate during the inspiration phase, the stimulation train can either be started by triggering off the start of the expiration phase followed by a delay or the start of the inspiration phase, as shown in FIG. 23. Triggering off the start of the expiration phase allows stimulation to be generated prior to the start of the inspiration phase to maximize diaphragmatic force during the inspiration phase. In addition, stimulation during the expiration phase can be achieved by triggering off the start of the expiration phase or the start of the inspiration phase with a delay, as shown in FIG. 24. While using the inspiration and expiration start are preferred, the end of the inspiration/expiration periods could conceivably be used as well. Furthermore, it is also possible to provide delayed stimulation such that stimulation would begin in the middle of the inspiration phase for example.
  • Flow, volume, and/or pressure data, or derived parameters thereof, for at least one breath with stimulation is recorded. For the data with stimulation as well as without, if more than one breath of information has been recorded the data can be averaged together. The collected flow/volume/pressure data with stimulation is then subtracted from the collected flow/volume/pressure data without stimulation. The difference, calculated as an area (and shown as the blacked-out area), can be used as a relative measurement of force generated by the diaphragm, and is shown in FIG. 26. In the case of a pressure controlled ventilation, the difference in volume (area under flow curve) would be used as the measurement. In the case of a volume controlled ventilator, the area under the pressure graph would be used as the measurement.
  • FIG. 27 is one example of another assessment routine 300 carried out by the system 20. The assessment routine 300 can be used to guide the placement of endovascular electrodes during normal ventilator operation (i.e., without interference to the ventilator operation or disconnecting the ventilator), and can assess the diaphragm recruitment in response to varying (decreasing or increasing) stimulation charges. When executing the assessment routine 300, the system 20 can administer low-frequency stimulation (such as 1 Hz to 5 Hz), during one or more quiet expiratory periods, to elicit unfused diaphragm contractile responses in the form of single twitches. The charge delivered can be progressively increased to build a complete nerve recruitment curve for each endovascular location, and the operator can define across how many breath periods this stimulation is delivered. The system 20 can analyze this stimulation and response information to algorithmically estimate the best position of the electrodes to stimulate one or both phrenic nerves using minimal amounts of charge (highest degree of efficiency). During this assessment routine, the system 20 can also gather information regarding the relationship between the stimulation train profiles and the corresponding diaphragm response, including diaphragm output (in volume, pressure, or both). Some stimulation parameters that may be obtained include but are not limited to Threshold Pulse Width and Supra-maximal Pulse Width required to recruit each phrenic nerve from appropriate endovascular electrode locations.
  • As exemplified in FIG. 28, the stimulation charges in routine 300 can be programmed to periodically occur during periods of baseline flow/volume, which can occur at the end-expiratory pause of the ventilator breath cycle, which can also be referred to as the end-expiratory delay. The benefit of selective stimulation during the end-expiratory pause is that the length of the diaphragm muscle fibers is the same before each stimulus is delivered and thereby establishes standardized conditions for obtaining comparable results. This provides a standard baseline to compare the diaphragm twitch responses and can guide the placement of the endovascular electrodes.
  • This period of zero volume can be determined prior to stimulation to determine the duration of the end-expiratory pause. In that regard, FIG. 29 illustrates one example of a routine 400 for determining the duration of the end-expiratory pause. With this routine, flow data is collected and the end expiratory pause is estimated. In some embodiments, volume of the inspiration and expiration phases are calculated. The point at which the expired volume reaches a user-programmable percentage of the inspiration volume is used as the start time for the end-expiratory pause. In one embodiment, the percentage used as a default is 85% of the inspired volume. In some embodiments, volume is used as it is less influenced by noise than other measures.
  • While using volume data in some embodiments is one technique, this does not preclude using other measures of the end expiratory phase such as a slope close to zero or simply using a fixed time interval at the end of the expiration phase as the end expiratory pause. In other embodiments, the system 20 can compute relaxation characteristics of the respiratory system, such as Expiratory-Time Constant (i.e. time required to exhale a certain percentage of the air from the lungs) to determine the ideal end-expiratory pause duration and prompt the clinician to adjust the ventilator settings accordingly. At any point in the assessment, the user has the ability to manually override the system and select the duration of the end-expiratory pause as a percentage or absolute value of the measured expiratory phase duration.
  • Returning to FIG. 27, the assessment routine 300 will be described in some detail. Routine 300 begins at block 302 with the clinician providing the initial system parameters or accepting internal default values, which may include the characteristics of a low-level starting stimulation signal, the maximum stimulation level, the estimated duration of the end-expiratory pause, one or more ventilator parameters, etc. In some embodiments, the characteristics of the low-level starting stimulation signal are based on the estimated duration of the end-expiratory pause.
  • Next, at block 304, the breath detection algorithm described above can be employed to synchronize the administered stimulation with the end-expiratory pause period of the ventilator 32. For example, the breath detection algorithm can be employed to identify the period of interest during a breath cycle when stimulation can be delivered, as shown in FIG. 28. The diaphragm being a skeletal muscle, its force output changes with its length, as described by its length-tension relationship. Therefore, it is beneficial to stimulate the diaphragm near its resting length, as it provides a standard baseline to compare the diaphragm twitch responses. The resting length of the diaphragm is reached at the end of every expiration phase, as the lungs reach their Functional Residual Capacity. Therefore the inspired and expired volumes can be monitored to provide a non-invasive estimate of when the lungs reach functional residual capacity. In addition, signals from one or more of the sensors 48 and/or sensor 50, such as pressure signals in the form of esophageal or intrathoracic pressure can be used to confirm that the lungs have reached Functional Residual Capacity.
  • At block 306, based on the aforementioned monitored parameters, a determination is made as to whether the patient's lungs have returned to Functional Residual Capacity as the ventilator carries out the breath cycle. When it is determined that the Functional Residual Capacity is reached, the system 20 administers a starting stimulation signal at block 308 and then monitors and measures the diaphragm response to the administered stimulation at block 310. Signals that can be monitored and measured to quantify the diaphragm response may include, but are not limited to, EMG, Airway Pressure, Airway Flow, Intra-Thoracic Pressure, Pleural Pressure, Central Venous Pressure, Thoraco-abdominal motion, various patient impedances, etc.
  • Next, a determination is made at block 312 as to whether the next ventilator breath is about to begin. Estimated end expiratory pause duration and/or the monitored signals from sensors 48, 50, can aid in this determination. If not, the routine 300 increases the intensity of the stimulation at block 314 and returns to block 308 to administer the increased intensity pulse. If the next ventilator breath is about to begin, stimulation for the current breath is stopped at block 316, the intensity of the current stimulation level can be increased at block 318, and the routine returns to block 304 for another stimulation to be administered in synchrony with the breath cycle. The routine 300 can continue to loop in some embodiments until either the preset range of stimulation intensities has been reached or the maximum stimulation level has been reached.
  • As the Functional Residual Capacity can change with time, due to factors such as Extrinsic PEEP or Intrinsic PEEP, the system can also employ validation checks to confirm that the functional residual capacity (and therefore the diaphragm resting length) has not changed between breaths. One of the means to perform this validation is to analyze the trend data of the end-expiratory volume, before stimulating the diaphragm.
  • The next mode of operation that can be carried out by embodiments of the system 20 includes a Pacer-Initiated Ventilation Mode. FIG. 30 illustrates one example of a routine 500 executed by the system 20 to carry out one or more functions, including the Pacer-Initiated Ventilation Mode. In that regard, many mechanical ventilators have an assist/support mode, whereby ventilation is provided when the patient attempts to breathe on their own. In this embodiment, the system 20 can be programmed to trigger the ventilator 32 working in assistive modes by using stimulation shown by “D” in FIG. 31 (and resultant response from the diaphragm) to mimic spontaneous effort by the patient, as shown in FIG. 31. The ventilator 32 responds to this trigger signal/event and delivers a breath to the patient (based on parameters set by the clinician) shown by “B” in FIG. 31. In effect, the system 20 drives breath delivery from the ventilator 32 (which is opposite from the Ventilator-Initiated Pacing Mode described above) shown by “C” in FIG. 31. In some embodiments, the system 20 does not perform breath detection, and thus, the breath sensor 50 can be omitted. In some embodiments, the breath sensor 50 may be used to carry out various assessment routines and feedback schemes. The system 20 can control the rate of pacing via the programmable parameters such as breath rate (in Breaths per minute), skipped breaths and sigh breaths. Similarly, the Pacer-Initiated Ventilation Mode can also include one or more of the adaptive functionality, closed loop control, diaphragm assessment, successive approximation features described above with reference to Ventilator-Initiated Pacing Mode are also applicable to this mode.
  • In the Pacer-Initiated Ventilation mode, the system 20 can use feedback to ensure proper diaphragm contribution. Some ventilator modes suitable for this embodiment are Pressure Support Ventilation (PSV), Pressure Regulated Volume Control (PRVC), Proportional Assist Ventilation (PAV) and Adaptive Support Ventilation (ASV).
  • Embodiments of the system 20 can also be operated in Autonomous Mode, or A-Mode. A-Mode is a life-sustaining mode that can operate independently of the ventilator 32. FIG. 32 illustrates one example of a routine 600 executed by the system 20 for carrying out one or more functions, including the Autonomous Mode. In that regard, the A-Mode operates in closed-loop control fashion using feedback from various sensors, such as one or more of the sensors 48, 50. These sensors can be used to monitor physiological variables that can include, but are not limited to: central venous pressure, mixed venous oxygen saturation, heart rate and movement activity levels. A-Mode provides adjustable diaphragmatic pacing to a patient retaining none, some or all of his/her spontaneous breathing and requiring assisted breathing and can automatically adjust to the patient's physiological needs and changed activity levels, as needed.
  • Although A-mode can be a life-sustaining mode, it may or may not be used in this capacity (i.e. could be interfaced with a backup ventilator). For example, A-Mode may be applicable to patients who are permanently dependent on mechanical ventilators or otherwise in need of continuous pacing from the system 20.
  • As opposed the embodiments of the system 20 described above for carrying out the Pacer-Initiated Ventilation Mode and the Ventilator-Initiated Pacing Mode, embodiments of the system 20 carrying out the A-Mode can be totally implanted under the skin of the patient in the upper chest area. In this regard, the system 20 is powered by a power storage source, such as either primary or rechargeable implantable batteries, and may be integrated with other implantable devices that support heart or other functions to a patient.
  • As shown in the embodiment of FIG. 32, the system 20 operating in A-Mode involves a closed-loop operation to autonomously pace the diaphragm. This mode may make use of any patient response signal (feedback) that will help indicate that pacing is required; these signals include, but are not limited to: oxygen saturation, end-tidal CO2 (EtCO2), airflow, heart rate, movement-detecting accelerometer signals, etc. Pacing is administered continuously in A-mode, and an algorithm is used to detect and/or modify physiological response signals to determine whether a change in stimulation pattern, frequency, breath rate, intensity, type, and/or shape profile is required to elicit the expected response.
  • The principles, representative embodiments, and modes of operation of the present disclosure have been described in the foregoing description. However, aspects of the present disclosure which are intended to be protected are not to be construed as limited to the particular embodiments disclosed. Further, the embodiments described herein are to be regarded as illustrative rather than restrictive. It will be appreciated that variations and changes may be made by others, and equivalents employed, without departing from the spirit of the present disclosure. Accordingly, it is expressly intended that all such variations, changes, and equivalents fall within the spirit and scope of the present disclosure, as claimed.

Claims (31)

1.-55. (canceled)
56. A method of stimulating a diaphragm to provide a diaphragm assist level, comprising:
(a) obtaining an attribute of a breath cycle of a patient;
(b) based on a stimulation parameter, the attribute of the breath cycle, and a desired value of a breath parameter characteristic of the diaphragm assist level, transmitting a stimulation signal to an electrode positioned within a blood vessel of the patient such that the electrode recruits a phrenic nerve of the patient;
(c) after transmitting the stimulation signal, determining an actual value of the breath parameter from a prior breath;
(d) comparing the actual value of the breath parameter to the desired value of the breath parameter; and
(e) either (1) maintaining the stimulation parameter if the actual value of the breath parameter is within a selected range of the desired value of the breath parameter; or (2) modifying the stimulation parameter if the actual value of the breath parameter is not within the selected range of the desired value of the breath parameter; and
(f) repeating steps (a)-(e).
57. The method of claim 56, wherein the patient receives respiratory assistance from a ventilator during the breath cycle.
58. The method of claim 56, wherein the stimulation signal includes at least one pulse, and the stimulation parameter includes at least one of a rate, a duration, a pulse width, a frequency, or an amplitude.
59. The method of claim 56, wherein the breath parameter is at least one of a tidal volume, a pressure, or a time.
60. The method of claim 56, wherein the blood vessel is at least one of a left jugular vein or a left subclavian vein, the phrenic nerve is a left phrenic nerve, and the method further includes transmitting a stimulation signal to a second electrode positioned in a superior vena cava such that the second electrode recruits a right phrenic nerve of the patient.
61. The method of claim 56, wherein the blood vessel is at least one of a left jugular vein or a left subclavian vein, the phrenic nerve is a left phrenic nerve, and the method further includes transmitting a stimulation signal to a second electrode positioned within at least one of the left jugular vein or the left subclavian vein such that the second electrode recruits the left phrenic nerve, and transmitting stimulation signals to a third electrode and fourth electrode positioned in the superior vena cava such that the third and fourth electrodes recruit a right phrenic nerve of the patient.
62. The method of claim 61, wherein transmitting the stimulation signal to the first electrode occurs at a different time as transmitting the stimulation signal to the second electrode, and transmitting the stimulation signal to the third electrode occurs at a different time as transmitting the stimulation signal to the fourth electrode.
63. The method of claim 56, wherein each of (a) the step of obtaining the attribute of the breath cycle of the patient, and (b) the step of determining the actual value of the breath parameter from the prior breath includes detecting with a sensor at least one of airflow, volume, pressure, motion, or electrical signals.
64. The method of claim 56, wherein the step of comparing the actual value of the breath parameter to the desired value of the breath parameter includes calculating at least one of a change in pressure or a change in tidal volume.
65. The method of claim 56, wherein, if the actual value of the breath parameter is not within the selected range of the desired value of the breath parameter, the method further includes:
determining a cause of a difference between the actual and desired values of the breath parameter, wherein the cause is at least one of: a displacement of an electrode; a change in respiratory mechanics; or diaphragm fatigue; and
based on the cause, modifying at least one of the stimulation parameter, a position of the electrode, or a selection of an electrode to receive the stimulation signal.
66. A method of stimulating a diaphragm of a patient to provide a diaphragm assist level, comprising:
obtaining an attribute of a breath cycle of a patient receiving respiratory assistance from a ventilator; and
during a breath cycle that includes respiratory assistance from a ventilator, transmitting a stimulation signal to at least one electrode positioned within a blood vessel of the patient such that the electrode recruits a phrenic nerve of the patient,
wherein the stimulation signal is based on a stimulation parameter, the attribute of the breath cycle, and a desired value of a breath parameter characteristic of the diaphragm assist level relative to an assist level provided from the ventilator.
67. The method of claim 66, wherein the attribute of a breath cycle includes a start or a duration of at least one of an inspiration phase, an end-inspiratory pause, an expiration phase, or an end-expiratory pause.
68. The method of claim 66, wherein the stimulation signal includes at least one pulse; the stimulation parameter includes at least one of a rate, a duration, a pulse width, a frequency, or an amplitude; and the method further comprises calculating the stimulation parameter.
69. The method of claim 66, wherein the breath parameter is at least one of a tidal volume, a pressure, or a time.
70. The method of claim 66, further comprising adjusting the desired breath parameter relative to the assist level provided from the ventilator.
71. The method of claim 66, wherein, during a breath, expansion of the patient's lungs from the ventilator and transmission of the stimulation signal produces an actual value of a breath parameter within a preselected range of the desired value of the breath parameter.
72. The method of claim 66, further comprising (a) measuring an actual value of breath parameter of a prior breath, and (b) adjusting the at least one stimulation parameter based on the actual value.
73. The method of claim 66, further comprising (a) determining a functional characteristic of the diaphragm from a prior breath, and (b) based on the functional characteristic, determining whether to stop respiratory assistance from the ventilator.
74. The method of claim 66, wherein, during at least one breath cycle of a plurality of breath cycles, the assist level provided by the ventilator is zero.
75. A nerve stimulation method, comprising:
obtaining an attribute of a breath cycle of a patient receiving respiratory assistance from a ventilator; and
based on the attribute of a breath cycle, transmitting a stimulation signal to an electrode positioned within a blood vessel of the patient such that the electrode recruits a phrenic nerve of the patient;
wherein the stimulation signal is transmitted to the electrode at a preselected time of the breath cycle of the patient.
76. The method of claim 75, wherein the stimulation signal includes a plurality of pulses, and a first pulse is transmitted to the electrode when a diaphragm of the patient is at a resting length during an end-expiratory pause, and a second pulse is transmitted to the electrode during the same end-expiratory pause.
77. The method of claim 75, wherein the stimulation signal includes at least one pulse, and the at least one pulse includes a charge injection phase and a charge balance phase configured to maintain a net charge of zero.
78. The method of claim 75, wherein the stimulation signal includes a plurality of pulses, and at least two of the plurality of pulses are transmitted at a higher frequency than a frequency of the remaining pulses of the plurality of pulses.
79. The method of claim 75, wherein the stimulation signal includes a plurality of pulses, and the plurality of pulses are characterized by linear change in at least one of the frequency or duration of consecutive pulses.
80. The method of claim 75, wherein, of a plurality of consecutive patient breaths, the stimulation signal is delivered during a subset of the breaths.
81. The method of claim 75, wherein, of a plurality of consecutive patient breaths, a stimulation signal having a first charge is delivered during each breath of a first subset of the breaths, and a stimulation signal having a second charge higher than the first charge is delivered during each breath of a second subset of the breaths.
82. The method of claim 75, wherein the preselected time of the breath cycle begins during at least one of an end-expiratory pause or during an inspiration phase.
83. The method of claim 75, wherein the preselected time of the breath cycle ends during an expiratory phase.
84. The method of claim 75, wherein recruitment of the phrenic nerve triggers the ventilator to deliver a breath to the patient.
85. The method of claim 75, wherein the ventilator is configured to provide time-triggered breaths.
US14/410,022 2012-06-21 2013-06-21 Transvascular diaphragm pacing systems and methods of use Abandoned US20150265833A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US14/410,022 US20150265833A1 (en) 2012-06-21 2013-06-21 Transvascular diaphragm pacing systems and methods of use
US16/114,064 US10561844B2 (en) 2012-06-21 2018-08-27 Diaphragm pacing systems and methods of use

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261662579P 2012-06-21 2012-06-21
US14/410,022 US20150265833A1 (en) 2012-06-21 2013-06-21 Transvascular diaphragm pacing systems and methods of use
PCT/CA2013/000594 WO2013188965A1 (en) 2012-06-21 2013-06-21 Transvascular diaphragm pacing systems and methods of use

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2013/000594 A-371-Of-International WO2013188965A1 (en) 2012-06-21 2013-06-21 Transvascular diaphragm pacing systems and methods of use

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US14/839,432 Continuation US9776005B2 (en) 2012-06-21 2015-08-28 Transvascular diaphragm pacing systems and methods of use
US16/111,644 Continuation US10406367B2 (en) 2012-06-21 2018-08-24 Transvascular diaphragm pacing system and methods of use
US16/114,064 Continuation US10561844B2 (en) 2012-06-21 2018-08-27 Diaphragm pacing systems and methods of use

Publications (1)

Publication Number Publication Date
US20150265833A1 true US20150265833A1 (en) 2015-09-24

Family

ID=49767975

Family Applications (7)

Application Number Title Priority Date Filing Date
US14/410,022 Abandoned US20150265833A1 (en) 2012-06-21 2013-06-21 Transvascular diaphragm pacing systems and methods of use
US14/839,432 Active US9776005B2 (en) 2012-06-21 2015-08-28 Transvascular diaphragm pacing systems and methods of use
US16/111,644 Active US10406367B2 (en) 2012-06-21 2018-08-24 Transvascular diaphragm pacing system and methods of use
US16/114,064 Active US10561844B2 (en) 2012-06-21 2018-08-27 Diaphragm pacing systems and methods of use
US16/460,728 Active US10589097B2 (en) 2012-06-21 2019-07-02 Transvascular diaphragm pacing systems and methods of use
US16/778,952 Active 2034-02-16 US11357985B2 (en) 2012-06-21 2020-01-31 Transvascular diaphragm pacing systems and methods of use
US17/498,870 Pending US20220023625A1 (en) 2012-06-21 2021-10-12 Transvascular diaphragm pacing systems and methods of use

Family Applications After (6)

Application Number Title Priority Date Filing Date
US14/839,432 Active US9776005B2 (en) 2012-06-21 2015-08-28 Transvascular diaphragm pacing systems and methods of use
US16/111,644 Active US10406367B2 (en) 2012-06-21 2018-08-24 Transvascular diaphragm pacing system and methods of use
US16/114,064 Active US10561844B2 (en) 2012-06-21 2018-08-27 Diaphragm pacing systems and methods of use
US16/460,728 Active US10589097B2 (en) 2012-06-21 2019-07-02 Transvascular diaphragm pacing systems and methods of use
US16/778,952 Active 2034-02-16 US11357985B2 (en) 2012-06-21 2020-01-31 Transvascular diaphragm pacing systems and methods of use
US17/498,870 Pending US20220023625A1 (en) 2012-06-21 2021-10-12 Transvascular diaphragm pacing systems and methods of use

Country Status (8)

Country Link
US (7) US20150265833A1 (en)
EP (2) EP2863987B1 (en)
JP (5) JP6359528B2 (en)
CN (1) CN104684614B (en)
AU (1) AU2013280184B2 (en)
BR (1) BR112014032002A2 (en)
CA (1) CA2877049C (en)
WO (1) WO2013188965A1 (en)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170128684A1 (en) * 2015-09-10 2017-05-11 St. Michael's Hospital Method and system for adjusting a level of ventilatory assist to a patient
US9682235B1 (en) 2015-12-14 2017-06-20 Stimdia Medical, Inc. Electrical stimulation for preservation and restoration of diaphragm function
US9931504B2 (en) 2013-11-22 2018-04-03 Lungpacer Medical, Inc. Apparatus and methods for assisted breathing by transvascular nerve stimulation
US10039920B1 (en) 2017-08-02 2018-08-07 Lungpacer Medical, Inc. Systems and methods for intravascular catheter positioning and/or nerve stimulation
US10293164B2 (en) 2017-05-26 2019-05-21 Lungpacer Medical Inc. Apparatus and methods for assisted breathing by transvascular nerve stimulation
US10391314B2 (en) 2014-01-21 2019-08-27 Lungpacer Medical Inc. Systems and related methods for optimization of multi-electrode nerve pacing
US10406367B2 (en) 2012-06-21 2019-09-10 Lungpacer Medical Inc. Transvascular diaphragm pacing system and methods of use
US10512772B2 (en) 2012-03-05 2019-12-24 Lungpacer Medical Inc. Transvascular nerve stimulation apparatus and methods
US10561843B2 (en) 2007-01-29 2020-02-18 Lungpacer Medical, Inc. Transvascular nerve stimulation apparatus and methods
US10940308B2 (en) 2017-08-04 2021-03-09 Lungpacer Medical Inc. Systems and methods for trans-esophageal sympathetic ganglion recruitment
US10987511B2 (en) 2018-11-08 2021-04-27 Lungpacer Medical Inc. Stimulation systems and related user interfaces
US11207517B2 (en) 2017-07-06 2021-12-28 Stimdia Medical, Inc. Percutaneous electrical phrenic nerve stimulation system
US11357979B2 (en) 2019-05-16 2022-06-14 Lungpacer Medical Inc. Systems and methods for sensing and stimulation
US11553963B2 (en) 2021-03-09 2023-01-17 Circle Safe Phrenic nerve stimulation
US11771900B2 (en) 2019-06-12 2023-10-03 Lungpacer Medical Inc. Circuitry for medical stimulation systems
US11883658B2 (en) 2017-06-30 2024-01-30 Lungpacer Medical Inc. Devices and methods for prevention, moderation, and/or treatment of cognitive injury
US11944810B2 (en) 2021-02-02 2024-04-02 Lungpacer Medical Inc. Systems and methods for trans-esophageal sympathetic ganglion recruitment

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014228794B2 (en) 2013-03-15 2019-04-18 The Regents Of The University Of California Multi-site transcutaneous electrical stimulation of the spinal cord for facilitation of locomotion
CA2925754C (en) 2013-09-27 2023-02-21 The Regents Of The University Of California Engaging the cervical spinal cord circuitry to re-enable volitional control of hand function in tetraplegic subjects
CN103933648B (en) * 2014-03-26 2016-09-07 北京雅果科技有限公司 A kind of diaphram stimulates suction and discharge system
CN104353167B (en) * 2014-11-28 2017-03-29 山东大学齐鲁医院 A kind of PEP Ventilation mask with external diaphragm pacing function
EP3322477A4 (en) * 2015-07-13 2019-03-20 The Regents of The University of California Accessing spinal network to enable respiratory function
US11298533B2 (en) 2015-08-26 2022-04-12 The Regents Of The University Of California Concerted use of noninvasive neuromodulation device with exoskeleton to enable voluntary movement and greater muscle activation when stepping in a chronically paralyzed subject
US11097122B2 (en) 2015-11-04 2021-08-24 The Regents Of The University Of California Magnetic stimulation of the spinal cord to restore control of bladder and/or bowel
US11224379B2 (en) * 2016-02-18 2022-01-18 Koninklljke Philips N.V. Enhancement of respiratory parameter estimation and asynchrony detection algorithms via the use of central venous pressure manometry
CN106215319B (en) * 2016-08-12 2019-04-16 北京雅果科技有限公司 A kind of device of electro photoluminescence assisted respiartion
WO2018028719A1 (en) 2016-08-12 2018-02-15 北京雅果科技有限公司 Method and device for assisting respiration by electrical stimulation
CN106422060A (en) * 2016-10-21 2017-02-22 上海海神医疗电子仪器有限公司 Dual-mode dual-control diaphragm stimulation mechanical ventilation assist device
EP3421081B1 (en) 2017-06-30 2020-04-15 GTX medical B.V. A system for neuromodulation
WO2019075072A1 (en) * 2017-10-10 2019-04-18 Northwestern University Digitally adjustable phrenic nerve stimulator system
CN111936189A (en) * 2018-02-06 2020-11-13 斯蒂米特股份公司 Ventilation device and method for ventilating a patient
ES2911465T3 (en) 2018-11-13 2022-05-19 Onward Medical N V Control system for the reconstruction and/or restoration of a patient's movement
EP3695878B1 (en) 2019-02-12 2023-04-19 ONWARD Medical N.V. A system for neuromodulation
CN109998518B (en) * 2019-03-05 2020-08-07 深圳先进技术研究院 Diaphragm movement auxiliary device and diaphragm movement auxiliary system
DE102019001926A1 (en) * 2019-03-20 2020-09-24 Drägerwerk AG & Co. KGaA Device, method and computer program for influencing the breathing of a person
US11324954B2 (en) 2019-06-28 2022-05-10 Covidien Lp Achieving smooth breathing by modified bilateral phrenic nerve pacing
CN111150933B (en) * 2019-09-02 2022-08-09 杭州神络医疗科技有限公司 Catheter electrode and in vivo implanted nerve stimulation device
DE19211698T1 (en) 2019-11-27 2021-09-02 Onward Medical B.V. Neuromodulation system
CA3174471A1 (en) * 2020-04-09 2021-10-14 Ronja Muller-Bruhn Stimulation arrangement and method of activating a patient
RU2750236C1 (en) * 2020-06-25 2021-06-24 Евгений Александрович Горемыкин System for maintaining respiratory function through neurostimulation of patients connected to arventural ventilation devices
US11763947B2 (en) 2020-10-14 2023-09-19 Etiometry Inc. System and method for providing clinical decision support
EP4230319A1 (en) 2021-12-30 2023-08-23 Mikhail Aleksandrovich Meshchaninov Reactor for a waste transformation device
DE102022100939A1 (en) * 2022-01-17 2023-07-20 Drägerwerk AG & Co. KGaA System, device for stimulation and method for performing stimulation
US11890398B2 (en) 2022-02-17 2024-02-06 Mikhail Aleksandrovich Meshchaninov Air cleaning device
WO2023156838A1 (en) 2022-02-17 2023-08-24 Михаил Александрович МЕЩАНИНОВ Electrostatic friction pulse generator

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3983881A (en) * 1975-05-21 1976-10-05 Telectronics Pty. Limited Muscle stimulator
US4827935A (en) * 1986-04-24 1989-05-09 Purdue Research Foundation Demand electroventilator
US5549655A (en) * 1994-09-21 1996-08-27 Medtronic, Inc. Method and apparatus for synchronized treatment of obstructive sleep apnea
US20050165457A1 (en) * 2004-01-26 2005-07-28 Michael Benser Tiered therapy for respiratory oscillations characteristic of Cheyne-Stokes respiration
US20100036451A1 (en) * 2007-01-29 2010-02-11 Simon Fraser University Transvascular nerve stimulation apparatus and methods
US7962215B2 (en) * 2004-07-23 2011-06-14 Synapse Biomedical, Inc. Ventilatory assist system and methods to improve respiratory function
US20120158091A1 (en) * 2003-10-15 2012-06-21 Rmx, Llc Therapeutic diaphragm stimulation device and method
US8504158B2 (en) * 2011-05-09 2013-08-06 Medtronic, Inc. Phrenic nerve stimulation during cardiac refractory period

Family Cites Families (481)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1693734A (en) 1923-06-29 1928-12-04 Mcintosh Electrical Corp Switching means for effecting electrotherapeutic treatment
US2532788A (en) 1948-01-03 1950-12-05 Stanley J Sarnoff Artificial respiration by electronic stimulation
US2664880A (en) 1951-11-23 1954-01-05 Jr Nathaniel B Wales Electric stimulator for artificial respiration
US3348548A (en) 1965-04-26 1967-10-24 William M Chardack Implantable electrode with stiffening stylet
US3470876A (en) 1966-09-28 1969-10-07 John Barchilon Dirigible catheter
US3835864A (en) 1970-09-21 1974-09-17 Rasor Ass Inc Intra-cardiac stimulator
US3769984A (en) 1971-03-11 1973-11-06 Sherwood Medical Ind Inc Pacing catheter with frictional fit lead attachment
US3817241A (en) 1972-02-16 1974-06-18 Henry And Carol Grausz Disposable central venous catheter and method of use
US3938502A (en) 1972-02-22 1976-02-17 Nicolaas Bom Apparatus with a catheter for examining hollow organs or bodies with the ultrasonic waves
US3804098A (en) 1972-04-17 1974-04-16 Medronic Inc Body implantable lead
US3896373A (en) 1972-11-30 1975-07-22 Stein Paul D Method and apparatus for determining cross-sectional area of a blood conduit and volumetric flow therethrough
US3847157A (en) 1973-06-18 1974-11-12 J Caillouette Medico-surgical tube
US3851641A (en) 1973-11-29 1974-12-03 J Toole Method and apparatus for determining internal impedance of animal body part
US4054881A (en) 1976-04-26 1977-10-18 The Austin Company Remote object position locater
US4114601A (en) 1976-08-09 1978-09-19 Micro Tec Instrumentation, Inc. Medical and surgical implement detection system
USRE31873F1 (en) 1976-09-08 1988-11-15 Venous catheter device
US4072146A (en) 1976-09-08 1978-02-07 Howes Randolph M Venous catheter device
US4143872A (en) 1977-04-07 1979-03-13 Hudson Oxygen Therapy Sales Company Lung volume exerciser
US4173228A (en) 1977-05-16 1979-11-06 Applied Medical Devices Catheter locating device
US4249539A (en) 1979-02-09 1981-02-10 Technicare Corporation Ultrasound needle tip localization system
US4317078A (en) 1979-10-15 1982-02-23 Ohio State University Research Foundation Remote position and orientation detection employing magnetic flux linkage
US4380237A (en) 1979-12-03 1983-04-19 Massachusetts General Hospital Apparatus for making cardiac output conductivity measurements
US4643201A (en) 1981-02-02 1987-02-17 Medtronic, Inc. Single-pass A-V lead
US4431005A (en) 1981-05-07 1984-02-14 Mccormick Laboratories, Inc. Method of and apparatus for determining very accurately the position of a device inside biological tissue
US4445501A (en) 1981-05-07 1984-05-01 Mccormick Laboratories, Inc. Circuits for determining very accurately the position of a device inside biological tissue
US4416289A (en) 1981-05-07 1983-11-22 Mccormick Laboratories, Inc. Circuits for determining very accurately the position of a device inside biological tissue
US4407294A (en) 1982-01-07 1983-10-04 Technicare Corporation Ultrasound tissue probe localization system
US4431006A (en) 1982-01-07 1984-02-14 Technicare Corporation Passive ultrasound needle probe locator
US4681117A (en) 1983-02-15 1987-07-21 Brodman Richard F Intracardiac catheter and a method for detecting myocardial ischemia
FR2566276B1 (en) * 1984-06-21 1988-07-08 Medtronic Bv DIAPHRAGMATIC STIMULATION METHOD AND APPARATUS
US4586923A (en) 1984-06-25 1986-05-06 Cordis Corporation Curving tip catheter
US4573481A (en) 1984-06-25 1986-03-04 Huntington Institute Of Applied Research Implantable electrode array
US4587975A (en) 1984-07-02 1986-05-13 Cardiac Pacemakers, Inc. Dimension sensitive angioplasty catheter
US4697595A (en) 1984-07-24 1987-10-06 Telectronics N.V. Ultrasonically marked cardiac catheters
YU132884A (en) 1984-07-26 1987-12-31 Branko Breyer Electrode cateter with ultrasonic marking
US4674518A (en) 1985-09-06 1987-06-23 Cardiac Pacemakers, Inc. Method and apparatus for measuring ventricular volume
US4683890A (en) 1985-12-23 1987-08-04 Brunswick Manufacturing Co., Inc. Method and apparatus for controlled breathing employing internal and external electrodes
US4771788A (en) 1986-07-18 1988-09-20 Pfizer Hospital Products Group, Inc. Doppler tip wire guide
US4852580A (en) 1986-09-17 1989-08-01 Axiom Medical, Inc. Catheter for measuring bioimpedance
US4830008A (en) 1987-04-24 1989-05-16 Meer Jeffrey A Method and system for treatment of sleep apnea
US4819662A (en) 1987-10-26 1989-04-11 Cardiac Pacemakers, Inc. Cardiac electrode with drug delivery capabilities
US4860769A (en) 1987-11-12 1989-08-29 Thomas J. Fogarty Implantable defibrillation electrode
CA1330285C (en) 1987-12-22 1994-06-21 Geoffrey S. Martin Triple lumen catheter
US4840182A (en) 1988-04-04 1989-06-20 Rhode Island Hospital Conductance catheter
US4944088A (en) 1988-05-25 1990-07-31 Medtronic, Inc. Ring electrode for multiconductor pacing leads
US4951682A (en) 1988-06-22 1990-08-28 The Cleveland Clinic Foundation Continuous cardiac output by impedance measurements in the heart
US4905698A (en) 1988-09-13 1990-03-06 Pharmacia Deltec Inc. Method and apparatus for catheter location determination
US4911174A (en) 1989-02-13 1990-03-27 Cardiac Pacemakers, Inc. Method for matching the sense length of an impedance measuring catheter to a ventricular chamber
US4957110A (en) 1989-03-17 1990-09-18 C. R. Bard, Inc. Steerable guidewire having electrodes for measuring vessel cross-section and blood flow
US4934049A (en) 1989-07-07 1990-06-19 Medtronic, Inc. Method for fabrication of a medical electrode
US4989617A (en) 1989-07-14 1991-02-05 Case Western Reserve University Intramuscular electrode for neuromuscular stimulation system
US5036848A (en) 1989-10-16 1991-08-06 Brunswick Biomedical Technologies, Inc. Method and apparatus for controlling breathing employing internal and external electrodes
US5005587A (en) 1989-11-13 1991-04-09 Pacing Systems, Inc. Braid Electrode leads and catheters and methods for using the same
US5254088A (en) 1990-02-02 1993-10-19 Ep Technologies, Inc. Catheter steering mechanism
US5042143A (en) 1990-02-14 1991-08-27 Medtronic, Inc. Method for fabrication of implantable electrode
US5115818A (en) 1990-02-14 1992-05-26 Medtronic, Inc. Implantable electrode
CH681351A5 (en) 1990-04-12 1993-03-15 Hans Baer Dr
US5265604A (en) 1990-05-14 1993-11-30 Vince Dennis J Demand - diaphragmatic pacing (skeletal muscle pressure modified)
US5056519A (en) 1990-05-14 1991-10-15 Vince Dennis J Unilateral diaphragmatic pacer
US5383923A (en) 1990-10-20 1995-01-24 Webster Laboratories, Inc. Steerable catheter having puller wire with shape memory
DE9015857U1 (en) 1990-11-21 1991-02-07 B. Braun Melsungen Ag, 3508 Melsungen, De
US5224491A (en) 1991-01-07 1993-07-06 Medtronic, Inc. Implantable electrode for location within a blood vessel
US5170802A (en) 1991-01-07 1992-12-15 Medtronic, Inc. Implantable electrode for location within a blood vessel
US5345936A (en) 1991-02-15 1994-09-13 Cardiac Pathways Corporation Apparatus with basket assembly for endocardial mapping
US5465717A (en) 1991-02-15 1995-11-14 Cardiac Pathways Corporation Apparatus and Method for ventricular mapping and ablation
US5456254A (en) 1991-02-15 1995-10-10 Cardiac Pathways Corp Flexible strip assembly having insulating layer with conductive pads exposed through insulating layer and device utilizing the same
US5146918A (en) 1991-03-19 1992-09-15 Medtronic, Inc. Demand apnea control of central and obstructive sleep apnea
US5184621A (en) 1991-05-29 1993-02-09 C. R. Bard, Inc. Steerable guidewire having electrodes for measuring vessel cross-section and blood flow
JP2582010B2 (en) 1991-07-05 1997-02-19 芳嗣 山田 Monitoring device for respiratory muscle activity
US5241957A (en) 1991-11-18 1993-09-07 Medtronic, Inc. Bipolar temporary pacing lead and connector and permanent bipolar nerve wire
US5509411A (en) 1993-01-29 1996-04-23 Cardima, Inc. Intravascular sensing device
US5324322A (en) 1992-04-20 1994-06-28 Case Western Reserve University Thin film implantable electrode and method of manufacture
US5843028A (en) 1992-05-11 1998-12-01 Medical Innovations Corporation Multi-lumen endoscopic catheter
US5411025A (en) 1992-06-30 1995-05-02 Cordis Webster, Inc. Cardiovascular catheter with laterally stable basket-shaped electrode array
EP0669839B2 (en) 1992-10-01 2001-12-19 Cardiac Pacemakers, Inc. Stent-type defibrillation electrode structures
EP0605796B1 (en) 1992-12-04 2003-08-13 C.R. Bard, Inc. Catheter with independent proximal and distal control
US5368564A (en) 1992-12-23 1994-11-29 Angeion Corporation Steerable catheter
US5330522A (en) 1992-12-29 1994-07-19 Siemens Pacesetter, Inc. Ring electrode for a multilumen lead and method of constructing a multilumen lead
US5813399A (en) 1993-03-16 1998-09-29 Puritan Bennett Corporation System and method for closed loop airway pressure control during the inspiratory cycle of a breath in a patient ventilator using the exhalation valve as a microcomputer-controlled relief valve
CA2163966A1 (en) 1993-06-01 1994-12-08 Judith A. Kelleher Alkaline and acid phosphatase inhibitors in treatment of neurological disorders
US5348536A (en) 1993-08-02 1994-09-20 Quinton Instrument Company Coextruded catheter and method of forming
US5607462A (en) 1993-09-24 1997-03-04 Cardiac Pathways Corporation Catheter assembly, catheter and multi-catheter introducer for use therewith
US5486159A (en) 1993-10-01 1996-01-23 Mahurkar; Sakharam D. Multiple-lumen catheter
US5555618A (en) 1993-10-12 1996-09-17 Arrow International Investment Corp. Method of making electrode-carrying catheter
US5417208A (en) 1993-10-12 1995-05-23 Arrow International Investment Corp. Electrode-carrying catheter and method of making same
US5524632A (en) 1994-01-07 1996-06-11 Medtronic, Inc. Method for implanting electromyographic sensing electrodes
US5527358A (en) 1994-01-21 1996-06-18 Medtronic, Inc. Temporary medical electrical lead
JP3269125B2 (en) 1994-01-28 2002-03-25 東レ株式会社 Atopic dermatitis drug
US5476498A (en) 1994-08-15 1995-12-19 Incontrol, Inc. Coronary sinus channel lead and method
US5604231A (en) 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5678535A (en) 1995-04-21 1997-10-21 Dimarco; Anthony Fortunato Method and apparatus for electrical stimulation of the respiratory muscles to achieve artificial ventilation in a patient
US5584873A (en) 1995-05-08 1996-12-17 Medtronic, Inc. Medical lead with compression lumens
AU7286996A (en) 1995-10-18 1997-05-07 Ciba-Geigy Ag Thermopile powered transdermal drug delivery device
US6198970B1 (en) 1995-10-27 2001-03-06 Esd Limited Liability Company Method and apparatus for treating oropharyngeal respiratory and oral motor neuromuscular disorders with electrical stimulation
WO1997018752A1 (en) 1995-11-17 1997-05-29 New York University Apparatus and method for pressure and temperature waveform analysis
US5697377A (en) 1995-11-22 1997-12-16 Medtronic, Inc. Catheter mapping system and method
US5716392A (en) 1996-01-05 1998-02-10 Medtronic, Inc. Minimally invasive medical electrical lead
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US5772693A (en) 1996-02-09 1998-06-30 Cardiac Control Systems, Inc. Single preformed catheter configuration for a dual-chamber pacemaker system
US5665103A (en) 1996-03-07 1997-09-09 Scimed Life Systems, Inc. Stent locating device
US6166048A (en) 1999-04-20 2000-12-26 Targacept, Inc. Pharmaceutical compositions for inhibition of cytokine production and secretion
US20070208388A1 (en) 1996-04-30 2007-09-06 Jahns Scott E Method and system for nerve stimulation and cardiac sensing prior to and during a medical procedure
US6006134A (en) * 1998-04-30 1999-12-21 Medtronic, Inc. Method and device for electronically controlling the beating of a heart using venous electrical stimulation of nerve fibers
US6449507B1 (en) 1996-04-30 2002-09-10 Medtronic, Inc. Method and system for nerve stimulation prior to and during a medical procedure
USRE38705E1 (en) 1996-04-30 2005-02-22 Medtronic, Inc. Method and device for electronically controlling the beating of a heart using venous electrical stimulation of nerve fibers
US7225019B2 (en) 1996-04-30 2007-05-29 Medtronic, Inc. Method and system for nerve stimulation and cardiac sensing prior to and during a medical procedure
US5913848A (en) 1996-06-06 1999-06-22 Luther Medical Products, Inc. Hard tip over-the-needle catheter and method of manufacturing the same
US5827192A (en) 1996-08-21 1998-10-27 Cleveland Clinic Foundation Method of determining the conductivity of blood
US5971933A (en) 1996-09-17 1999-10-26 Cleveland Clinic Foundation Method and apparatus to correct for electric field non-uniformity in conductance catheter volumetry
SE9603841D0 (en) 1996-10-18 1996-10-18 Pacesetter Ab A tissue stimulating apparatus
US5776111A (en) 1996-11-07 1998-07-07 Medical Components, Inc. Multiple catheter assembly
US5785706A (en) 1996-11-18 1998-07-28 Daig Corporation Nonsurgical mapping and treatment of cardiac arrhythmia using a catheter contained within a guiding introducer containing openings
US5782828A (en) 1996-12-11 1998-07-21 Irvine Biomedical, Inc. Ablation catheter with multiple flexible curves
US5755765A (en) 1997-01-24 1998-05-26 Cardiac Pacemakers, Inc. Pacing lead having detachable positioning member
US5916163A (en) 1997-03-07 1999-06-29 Ep Technologies, Inc. Graphical user interface for use with multiple electrode catheters
US5954761A (en) 1997-03-25 1999-09-21 Intermedics Inc. Implantable endocardial lead assembly having a stent
US5779732A (en) 1997-03-31 1998-07-14 Medtronic, Inc. Method and apparatus for implanting a film with an exandable stent
US5944022A (en) 1997-04-28 1999-08-31 American Cardiac Ablation Co. Inc. Catheter positioning system
US6869431B2 (en) 1997-07-08 2005-03-22 Atrionix, Inc. Medical device with sensor cooperating with expandable member
US5824027A (en) 1997-08-14 1998-10-20 Simon Fraser University Nerve cuff having one or more isolated chambers
US6479523B1 (en) 1997-08-26 2002-11-12 Emory University Pharmacologic drug combination in vagal-induced asystole
US6249708B1 (en) 1997-08-26 2001-06-19 Angeion Corporation Fluted channel construction for a multi-conductor catheter lead
US5922014A (en) 1997-09-02 1999-07-13 Medtronic, Inc. Single pass lead and method of use
US6024702A (en) 1997-09-03 2000-02-15 Pmt Corporation Implantable electrode manufactured with flexible printed circuit
US6123699A (en) 1997-09-05 2000-09-26 Cordis Webster, Inc. Omni-directional steerable catheter
US6179832B1 (en) 1997-09-11 2001-01-30 Vnus Medical Technologies, Inc. Expandable catheter having two sets of electrodes
US6171277B1 (en) 1997-12-01 2001-01-09 Cordis Webster, Inc. Bi-directional control handle for steerable catheter
US6183463B1 (en) 1997-12-01 2001-02-06 Cordis Webster, Inc. Bidirectional steerable cathether with bidirectional control handle
US6120476A (en) 1997-12-01 2000-09-19 Cordis Webster, Inc. Irrigated tip catheter
US6415187B1 (en) 1998-02-10 2002-07-02 Advanced Bionics Corporation Implantable, expandable, multicontact electrodes and insertion needle for use therewith
US6251126B1 (en) 1998-04-23 2001-06-26 Medtronic Inc Method and apparatus for synchronized treatment of obstructive sleep apnea
US6269269B1 (en) 1998-04-23 2001-07-31 Medtronic Inc. Method and apparatus for synchronized treatment of obstructive sleep apnea
US6161047A (en) 1998-04-30 2000-12-12 Medtronic Inc. Apparatus and method for expanding a stimulation lead body in situ
US6240320B1 (en) 1998-06-05 2001-05-29 Intermedics Inc. Cardiac lead with zone insulated electrodes
US6134478A (en) 1998-06-05 2000-10-17 Intermedics Inc. Method for making cardiac leads with zone insulated electrodes
US6002965A (en) 1998-06-10 1999-12-14 Katz; Amiram Self applied device and method for prevention of deep vein thrombosis
US6463327B1 (en) 1998-06-11 2002-10-08 Cprx Llc Stimulatory device and methods to electrically stimulate the phrenic nerve
US6213960B1 (en) 1998-06-19 2001-04-10 Revivant Corporation Chest compression device with electro-stimulation
WO1999065561A1 (en) 1998-06-19 1999-12-23 Cordis Webster, Inc. Method and apparatus for transvascular treatment of tachycardia and fibrillation
SE9802335D0 (en) 1998-06-30 1998-06-30 Siemens Elema Ab Breathing Help System
US6198974B1 (en) 1998-08-14 2001-03-06 Cordis Webster, Inc. Bi-directional steerable catheter
US7972323B1 (en) 1998-10-02 2011-07-05 Boston Scientific Scimed, Inc. Steerable device for introducing diagnostic and therapeutic apparatus into the body
FR2784300B1 (en) 1998-10-13 2000-12-08 Ela Medical Sa IMPLANTABLE LEFT VENTRICLE STIMULATION PROBE IN THE CORONARY VENOUS NETWORK FOR ACTIVE IMPLANTABLE MEDICAL DEVICE, IN PARTICULAR "MULTI-SITE" STIMULATOR
SE9803508D0 (en) * 1998-10-14 1998-10-14 Siemens Elema Ab Assisted Breathing System
US6208881B1 (en) 1998-10-20 2001-03-27 Micropure Medical, Inc. Catheter with thin film electrodes and method for making same
US7076307B2 (en) 2002-05-09 2006-07-11 Boveja Birinder R Method and system for modulating the vagus nerve (10th cranial nerve) with electrical pulses using implanted and external components, to provide therapy neurological and neuropsychiatric disorders
US6212435B1 (en) 1998-11-13 2001-04-03 Respironics, Inc. Intraoral electromuscular stimulation device and method
EP1025822A1 (en) 1999-02-08 2000-08-09 Paul Hartmann Aktiengesellschaft Absorption body for a hygienic article
US6210339B1 (en) 1999-03-03 2001-04-03 Endosonics Corporation Flexible elongate member having one or more electrical contacts
US6161029A (en) 1999-03-08 2000-12-12 Medtronic, Inc. Apparatus and method for fixing electrodes in a blood vessel
DE19912635A1 (en) 1999-03-20 2000-09-21 Biotronik Mess & Therapieg Dilatable cardiac electrode arrangement for implantation, particularly in the coronary sinus of the heart
US6136021A (en) 1999-03-23 2000-10-24 Cardiac Pacemakers, Inc. Expandable electrode for coronary venous leads
US6593754B1 (en) 1999-04-01 2003-07-15 Actuant Corporation Compact subsurface object locator
US6216045B1 (en) 1999-04-26 2001-04-10 Advanced Neuromodulation Systems, Inc. Implantable lead and method of manufacture
US6126649A (en) 1999-06-10 2000-10-03 Transvascular, Inc. Steerable catheter with external guidewire as catheter tip deflector
EP1198271A4 (en) 1999-06-25 2009-01-21 Univ Emory Devices and methods for vagus nerve stimulation
ATE297775T1 (en) 1999-06-30 2005-07-15 Univ Florida VENTILATOR MONITORING SYSTEM
US6702780B1 (en) 1999-09-08 2004-03-09 Super Dimension Ltd. Steering configuration for catheter with rigid distal device
US6236892B1 (en) 1999-10-07 2001-05-22 Claudio A. Feler Spinal cord stimulation lead
US6295475B1 (en) 1999-10-27 2001-09-25 Pacesetter, Inc. Single-pass atrial ventricular lead with multiple atrial ring electrodes and a selective atrial electrode adaptor for the coronary sinus region
US7177686B1 (en) 1999-11-10 2007-02-13 Pacesetter, Inc. Using photo-plethysmography to monitor autonomic tone and performing pacing optimization based on monitored autonomic tone
US6556873B1 (en) 1999-11-29 2003-04-29 Medtronic, Inc. Medical electrical lead having variable bending stiffness
EP1106202A3 (en) 1999-11-30 2004-03-31 BIOTRONIK Mess- und Therapiegeräte GmbH & Co Ingenieurbüro Berlin Electrode for intravascular stimulation, cardioversion and /or defibrillation
US6415183B1 (en) 1999-12-09 2002-07-02 Cardiac Pacemakers, Inc. Method and apparatus for diaphragmatic pacing
US6885888B2 (en) 2000-01-20 2005-04-26 The Cleveland Clinic Foundation Electrical stimulation of the sympathetic nerve chain
US6493590B1 (en) 2000-02-09 2002-12-10 Micronet Medical, Inc. Flexible band electrodes for medical leads
WO2001068073A2 (en) 2000-03-14 2001-09-20 Children's Medical Center Corporation, The Method for improving respiratory function and inhibiting muscular degeneration
US6397108B1 (en) 2000-04-03 2002-05-28 Medtronic Inc. Safety adaptor for temporary medical leads
US6638268B2 (en) 2000-04-07 2003-10-28 Imran K. Niazi Catheter to cannulate the coronary sinus
US6442413B1 (en) 2000-05-15 2002-08-27 James H. Silver Implantable sensor
US6610713B2 (en) 2000-05-23 2003-08-26 North Shore - Long Island Jewish Research Institute Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
US6508802B1 (en) 2000-05-23 2003-01-21 Cornell Research Foundation, Inc. Remote sensing gene therapy delivery device and method of administering a therapeutic solution to a heart
US6719749B1 (en) 2000-06-01 2004-04-13 Medical Components, Inc. Multilumen catheter assembly and methods for making and inserting the same
US6695832B2 (en) 2000-06-01 2004-02-24 Twincath, Llc Multilumen catheter and methods for making the catheter
US6584362B1 (en) 2000-08-30 2003-06-24 Cardiac Pacemakers, Inc. Leads for pacing and/or sensing the heart from within the coronary veins
US7555349B2 (en) 2000-09-26 2009-06-30 Advanced Neuromodulation Systems, Inc. Lead body and method of lead body construction
US7149585B2 (en) 2001-03-30 2006-12-12 Micronet Medical, Inc. Lead body and method of lead body construction
US7499742B2 (en) 2001-09-26 2009-03-03 Cvrx, Inc. Electrode structures and methods for their use in cardiovascular reflex control
US6757970B1 (en) 2000-11-07 2004-07-06 Advanced Bionics Corporation Method of making multi-contact electrode array
SE0004141D0 (en) 2000-11-13 2000-11-13 Siemens Elema Ab Method of adaptive triggering of breathing devices and a breathing device
WO2002045795A2 (en) 2000-12-07 2002-06-13 Medtronic, Inc. Directional brain stimulation and recording leads
US7519421B2 (en) 2001-01-16 2009-04-14 Kenergy, Inc. Vagal nerve stimulation using vascular implanted devices for treatment of atrial fibrillation
US6445953B1 (en) 2001-01-16 2002-09-03 Kenergy, Inc. Wireless cardiac pacing system with vascular electrode-stents
DE10103288A1 (en) 2001-01-25 2002-08-01 Patrick Schauerte Vascular lock for intravascular nerve stimulation and fluid infusion
DE10105383C2 (en) 2001-02-06 2003-06-05 Heptec Gmbh Anti-snoring device
ZA200306564B (en) 2001-02-26 2004-10-15 Optinose As Nasal devices.
US7167751B1 (en) 2001-03-01 2007-01-23 Advanced Bionics Corporation Method of using a fully implantable miniature neurostimulator for vagus nerve stimulation
US6585718B2 (en) 2001-05-02 2003-07-01 Cardiac Pacemakers, Inc. Steerable catheter with shaft support system for resisting axial compressive loads
WO2002096482A2 (en) 2001-05-30 2002-12-05 Innersea Technology Implantable devices having a liquid crystal polymer substrate
WO2003005887A2 (en) 2001-07-11 2003-01-23 Nuvasive, Inc. System and methods for determining nerve proximity, direction, and pathology during surgery
US6569114B2 (en) 2001-08-31 2003-05-27 Biosense Webster, Inc. Steerable catheter with struts
US7974693B2 (en) 2001-08-31 2011-07-05 Bio Control Medical (B.C.M.) Ltd. Techniques for applying, configuring, and coordinating nerve fiber stimulation
EP2481338A3 (en) 2001-09-25 2012-09-05 Nuvasive, Inc. System for performing surgical procedures and assessments
US7168429B2 (en) 2001-10-12 2007-01-30 Ric Investments, Llc Auto-titration pressure support system and method of using same
US6934583B2 (en) 2001-10-22 2005-08-23 Pacesetter, Inc. Implantable lead and method for stimulating the vagus nerve
US6721603B2 (en) 2002-01-25 2004-04-13 Cyberonics, Inc. Nerve stimulation as a treatment for pain
US20060035849A1 (en) 2002-02-13 2006-02-16 Danafarber Cancer Institute, Inc Methods and composition for modulating type I muscle formation using pgc-1 alpha
US7653438B2 (en) 2002-04-08 2010-01-26 Ardian, Inc. Methods and apparatus for renal neuromodulation
US7620451B2 (en) 2005-12-29 2009-11-17 Ardian, Inc. Methods and apparatus for pulsed electric field neuromodulation via an intra-to-extravascular approach
US20030195571A1 (en) 2002-04-12 2003-10-16 Burnes John E. Method and apparatus for the treatment of central sleep apnea using biventricular pacing
CN100435882C (en) 2002-05-08 2008-11-26 加利福尼亚大学董事会 System and method for treating cardiac arrhythmias with fibroblast cells
US7292890B2 (en) 2002-06-20 2007-11-06 Advanced Bionics Corporation Vagus nerve stimulation via unidirectional propagation of action potentials
SE0202537D0 (en) 2002-08-28 2002-08-28 Siemens Elema Ab Nerve stimulation apparatus
US20040064069A1 (en) 2002-09-30 2004-04-01 Reynolds Brian R. Medical device with support member
SE0203108D0 (en) 2002-10-22 2002-10-22 Siemens Elema Ab Multi-Electrode Catheter
US20050033137A1 (en) 2002-10-25 2005-02-10 The Regents Of The University Of Michigan Ablation catheters and methods for their use
US7277757B2 (en) 2002-10-31 2007-10-02 Medtronic, Inc. Respiratory nerve stimulation
US7130700B2 (en) 2002-11-19 2006-10-31 Medtronic, Inc. Multilumen body for an implantable medical device
US20040111139A1 (en) 2002-12-10 2004-06-10 Mccreery Douglas B. Apparatus and methods for differential stimulation of nerve fibers
US7613515B2 (en) 2003-02-03 2009-11-03 Enteromedics Inc. High frequency vagal blockage therapy
AU2004216229B2 (en) 2003-02-21 2010-12-09 Electro-Cat, Llc System and method for measuring cross-sectional areas and pressure gradients in luminal organs
US7142903B2 (en) 2003-03-12 2006-11-28 Biosense Webster, Inc. Catheter with contractable mapping assembly
US7155278B2 (en) 2003-04-21 2006-12-26 Medtronic, Inc. Neurostimulation to treat effects of sleep apnea
EP3064242A1 (en) 2003-04-28 2016-09-07 Advanced Circulatory Systems Inc. Ventilator and methods for treating head trauma and low blood circulation
US7836881B2 (en) * 2003-04-28 2010-11-23 Advanced Circulatory Systems, Inc. Ventilator and methods for treating head trauma and low blood circulation
US20060287679A1 (en) 2003-05-16 2006-12-21 Stone Robert T Method and system to control respiration by means of confounding neuro-electrical signals
US20060111755A1 (en) 2003-05-16 2006-05-25 Stone Robert T Method and system to control respiration by means of neuro-electrical coded signals
US6999820B2 (en) 2003-05-29 2006-02-14 Advanced Neuromodulation Systems, Inc. Winged electrode body for spinal cord stimulation
EP1633434B1 (en) 2003-06-04 2014-11-19 Synecor Intravascular electrophysiological system
US8116883B2 (en) 2003-06-04 2012-02-14 Synecor Llc Intravascular device for neuromodulation
US7235070B2 (en) 2003-07-02 2007-06-26 St. Jude Medical, Atrial Fibrillation Division, Inc. Ablation fluid manifold for ablation catheter
TW200503738A (en) 2003-07-16 2005-02-01 Tzu Chi Buddhist General Hospital Method for extracting antineoplastic components from bupleurum scorzonerifolium
US7840270B2 (en) * 2003-07-23 2010-11-23 Synapse Biomedical, Inc. System and method for conditioning a diaphragm of a patient
US20050027338A1 (en) 2003-07-29 2005-02-03 Advanced Neuromodulation Systems, Inc. Stretchable lead body, method of manufacture, and system
US20050033136A1 (en) 2003-08-01 2005-02-10 Assaf Govari Catheter with electrode strip
US7591265B2 (en) 2003-09-18 2009-09-22 Cardiac Pacemakers, Inc. Coordinated use of respiratory and cardiac therapies for sleep disordered breathing
JP2007506480A (en) 2003-08-18 2007-03-22 ワンドカ,アンソニー・ディ Methods and apparatus for non-invasive ventilation with a nasal interface
WO2005028029A2 (en) 2003-08-18 2005-03-31 Cardiac Pacemakers, Inc. Patient monitoring, diagnosis, and/or therapy systems and methods
US7887493B2 (en) 2003-09-18 2011-02-15 Cardiac Pacemakers, Inc. Implantable device employing movement sensing for detecting sleep-related disorders
US7662101B2 (en) * 2003-09-18 2010-02-16 Cardiac Pacemakers, Inc. Therapy control based on cardiopulmonary status
US8147486B2 (en) 2003-09-22 2012-04-03 St. Jude Medical, Atrial Fibrillation Division, Inc. Medical device with flexible printed circuit
US7502650B2 (en) 2003-09-22 2009-03-10 Cvrx, Inc. Baroreceptor activation for epilepsy control
US20050070981A1 (en) 2003-09-29 2005-03-31 Sumit Verma Active fixation coronary sinus lead apparatus
NO319063B1 (en) 2003-10-06 2005-06-13 Laerdal Medical As Medical patient simulator
US20110288609A1 (en) * 2003-10-15 2011-11-24 Rmx, Llc Therapeutic diaphragm stimulation device and method
US20080288010A1 (en) 2003-10-15 2008-11-20 Rmx, Llc Subcutaneous diaphragm stimulation device and method for use
US7970475B2 (en) 2003-10-15 2011-06-28 Rmx, Llc Device and method for biasing lung volume
US20080215106A1 (en) 2003-10-15 2008-09-04 Chang Lee Thoracoscopically implantable diaphragm stimulator
US7979128B2 (en) 2003-10-15 2011-07-12 Rmx, Llc Device and method for gradually controlling breathing
US9259573B2 (en) 2003-10-15 2016-02-16 Rmx, Llc Device and method for manipulating exhalation
US20060167523A1 (en) 2003-10-15 2006-07-27 Tehrani Amir J Device and method for improving upper airway functionality
US8244358B2 (en) 2003-10-15 2012-08-14 Rmx, Llc Device and method for treating obstructive sleep apnea
US8265759B2 (en) 2003-10-15 2012-09-11 Rmx, Llc Device and method for treating disorders of the cardiovascular system or heart
US8467876B2 (en) 2003-10-15 2013-06-18 Rmx, Llc Breathing disorder detection and therapy delivery device and method
US20080161878A1 (en) 2003-10-15 2008-07-03 Tehrani Amir J Device and method to for independently stimulating hemidiaphragms
US8160711B2 (en) 2003-10-15 2012-04-17 Rmx, Llc Multimode device and method for controlling breathing
US8140164B2 (en) 2003-10-15 2012-03-20 Rmx, Llc Therapeutic diaphragm stimulation device and method
US20080288015A1 (en) 2003-10-15 2008-11-20 Rmx, Llc Diaphragm stimulation device and method for use with cardiovascular or heart patients
US20060074449A1 (en) 2003-11-03 2006-04-06 Stephen Denker Intravascular stimulation system with wireless power supply
US7077823B2 (en) 2003-11-19 2006-07-18 Biosense Webster, Inc. Bidirectional steerable catheter with slidable mated puller wires
US7802571B2 (en) 2003-11-21 2010-09-28 Tehrani Fleur T Method and apparatus for controlling a ventilator
US8224456B2 (en) 2003-11-25 2012-07-17 Advanced Neuromodulation Systems, Inc. Directional stimulation lead and orientation system
US7363085B1 (en) 2004-01-26 2008-04-22 Pacesetters, Inc. Augmenting hypoventilation
US7421296B1 (en) 2004-01-26 2008-09-02 Pacesetter, Inc. Termination of respiratory oscillations characteristic of Cheyne-Stokes respiration
WO2005077268A1 (en) 2004-02-18 2005-08-25 Maquet Critical Care Ab Method and device using myoelectrical activity for optimizing a patient’s ventilatory assist
US7569029B2 (en) 2004-04-12 2009-08-04 Clark Timothy W I Multi-lumen catheter
US7082331B1 (en) 2004-04-21 2006-07-25 Pacesetter, Inc. System and method for applying therapy during hyperpnea phase of periodic breathing using an implantable medical device
US7231260B2 (en) 2004-05-06 2007-06-12 Boston Scientific Scimed, Inc. Intravascular self-anchoring electrode body with arcuate springs, spring loops, or arms
US20070106357A1 (en) 2005-11-04 2007-05-10 Stephen Denker Intravascular Electronics Carrier Electrode for a Transvascular Tissue Stimulation System
US7747323B2 (en) 2004-06-08 2010-06-29 Cardiac Pacemakers, Inc. Adaptive baroreflex stimulation therapy for disordered breathing
US7591799B2 (en) 2004-06-14 2009-09-22 Biosense Webster, Inc. Steering mechanism for bi-directional catheter
US7225016B1 (en) 2004-06-16 2007-05-29 Pacesetter, Inc. Implantable medical device with nerve signal sensing
US7371220B1 (en) 2004-06-30 2008-05-13 Pacesetter, Inc. System and method for real-time apnea/hypopnea detection using an implantable medical system
EP1621247A1 (en) 2004-07-30 2006-02-01 MAN DWE GmbH Carry out of exothermic gas-phase reactions
US7670284B2 (en) 2004-08-31 2010-03-02 Surgical Solutions Llc Medical device with articulating shaft
US20060058852A1 (en) 2004-09-10 2006-03-16 Steve Koh Multi-variable feedback control of stimulation for inspiratory facilitation
US7340302B1 (en) 2004-09-27 2008-03-04 Pacesetter, Inc. Treating sleep apnea in patients using phrenic nerve stimulation
US9026228B2 (en) 2004-10-21 2015-05-05 Medtronic, Inc. Transverse tripole neurostimulation lead, system and method
US10537741B2 (en) 2004-12-03 2020-01-21 Boston Scientific Neuromodulation Corporation System and method for choosing electrodes in an implanted stimulator device
US20060122661A1 (en) 2004-12-03 2006-06-08 Mandell Lee J Diaphragmatic pacing with activity monitor adjustment
SG171607A1 (en) 2004-12-08 2011-06-29 Ventus Medical Inc Respiratory devices and methods of use
US20060130833A1 (en) 2004-12-16 2006-06-22 Magdy Younes Treatment of obstructive sleep apnea
US7869865B2 (en) 2005-01-07 2011-01-11 Biosense Webster, Inc. Current-based position sensing
US7891085B1 (en) 2005-01-11 2011-02-22 Boston Scientific Neuromodulation Corporation Electrode array assembly and method of making same
US8019439B2 (en) 2005-01-11 2011-09-13 Boston Scientific Neuromodulation Corporation Lead assembly and method of making same
US7269459B1 (en) 2005-02-08 2007-09-11 Pacesetter, Inc. Implantable cardiac device with selectable tiered sleep apnea therapies and method
US7255511B2 (en) 2005-02-22 2007-08-14 Dolan Kevin P Releasable dovetail corner joint
US7920915B2 (en) 2005-11-16 2011-04-05 Boston Scientific Neuromodulation Corporation Implantable stimulator
US7363086B1 (en) 2005-03-21 2008-04-22 Pacesetter, Inc. Capture verification in respiratory diaphragm stimulation
US20060217791A1 (en) 2005-03-23 2006-09-28 Arrow International, Inc. Multi-lumen catheter having external electrical leads
US8131357B2 (en) 2005-04-01 2012-03-06 Boston Scientific Neuromodulation Corporation Apparatus and methods for detecting migration of neurostimulation leads
US7499748B2 (en) 2005-04-11 2009-03-03 Cardiac Pacemakers, Inc. Transvascular neural stimulation device
WO2006110206A1 (en) * 2005-04-11 2006-10-19 Medtronic, Inc. Shifting between electrode combinations in electrical stimulation device
US7676275B1 (en) 2005-05-02 2010-03-09 Pacesetter, Inc. Endovascular lead for chronic nerve stimulation
US7561923B2 (en) 2005-05-09 2009-07-14 Cardiac Pacemakers, Inc. Method and apparatus for controlling autonomic balance using neural stimulation
US7617003B2 (en) 2005-05-16 2009-11-10 Cardiac Pacemakers, Inc. System for selective activation of a nerve trunk using a transvascular reshaping lead
US7949412B1 (en) 2005-06-02 2011-05-24 Advanced Bionics, Llc Coated electrode array having uncoated electrode contacts
US7553305B2 (en) 2005-06-09 2009-06-30 Enpath Medical, Inc. Push-pull wire anchor
US8036750B2 (en) 2005-06-13 2011-10-11 Cardiac Pacemakers, Inc. System for neural control of respiration
US20070005053A1 (en) 2005-06-30 2007-01-04 Dando Jeremy D Ablation catheter with contoured openings in insulated electrodes
US7879030B2 (en) 2005-07-27 2011-02-01 St. Jude Medical, Atrial Fibrillation Division, Inc. Multipolar, virtual-electrode catheter with at least one surface electrode and method for ablation
US7416552B2 (en) 2005-08-22 2008-08-26 St. Jude Medical, Atrial Fibrillation Division, Inc. Multipolar, multi-lumen, virtual-electrode catheter with at least one surface electrode and method for ablation
US7519426B1 (en) 2005-10-07 2009-04-14 Pacesetter, Inc. Techniques for reducing orthostatic hypotension
US7771388B2 (en) 2005-10-12 2010-08-10 Daniel Olsen Steerable catheter system
WO2007047989A2 (en) 2005-10-19 2007-04-26 Duke University Electrode systems and related methods for providing therapeutic differential tissue stimulation
US7636600B1 (en) 2005-10-21 2009-12-22 Pacesetter, Inc. Pressure monitoring for apnea prevention and/or therapy
US7616990B2 (en) 2005-10-24 2009-11-10 Cardiac Pacemakers, Inc. Implantable and rechargeable neural stimulator
AU2006311701B2 (en) 2005-11-08 2012-08-30 Custom Medical Applications, Inc. Reinforced catheter with articulated distal tip
US8696656B2 (en) 2005-11-18 2014-04-15 Medtronic Cryocath Lp System and method for monitoring bioimpedance and respiration
US20220212005A9 (en) 2005-11-18 2022-07-07 Zoll Respicardia, Inc. Transvenous Phrenic Nerve Stimulation System
US10406366B2 (en) 2006-11-17 2019-09-10 Respicardia, Inc. Transvenous phrenic nerve stimulation system
JP2009515670A (en) 2005-11-18 2009-04-16 カーディアック コンセプツ Apparatus and method for stimulating the phrenic nerve to prevent sleep apnea
JP2009521276A (en) 2005-12-22 2009-06-04 プロテウス バイオメディカル インコーポレイテッド Implantable integrated circuit
US7672728B2 (en) 2005-12-28 2010-03-02 Cardiac Pacemakers, Inc. Neural stimulator to treat sleep disordered breathing
US8281792B2 (en) 2005-12-31 2012-10-09 John W Royalty Electromagnetic diaphragm assist device and method for assisting a diaphragm function
US7813805B1 (en) 2006-01-11 2010-10-12 Pacesetter, Inc. Subcardiac threshold vagal nerve stimulation
US7763034B2 (en) 2006-01-24 2010-07-27 Medtronic, Inc. Transobturator lead implantation for pelvic floor stimulation
US7347695B2 (en) 2006-02-03 2008-03-25 Ware Linda M Chronic obstructive pulmonary disease simulator
US20070191908A1 (en) 2006-02-16 2007-08-16 Jacob Doreen K Method and apparatus for stimulating a denervated muscle
US7810497B2 (en) 2006-03-20 2010-10-12 Ric Investments, Llc Ventilatory control system
US7900626B2 (en) 2006-04-17 2011-03-08 Daly Robert W Method and system for controlling breathing
US20070288076A1 (en) 2006-06-07 2007-12-13 Cherik Bulkes Biological tissue stimulator with flexible electrode carrier
US20080039916A1 (en) 2006-08-08 2008-02-14 Olivier Colliou Distally distributed multi-electrode lead
US8121692B2 (en) 2006-08-30 2012-02-21 Cardiac Pacemakers, Inc. Method and apparatus for neural stimulation with respiratory feedback
US8050765B2 (en) 2006-08-30 2011-11-01 Cardiac Pacemakers, Inc. Method and apparatus for controlling neural stimulation during disordered breathing
US20080065002A1 (en) 2006-09-07 2008-03-13 Neurosystec Corporation Catheter for Localized Drug Delivery and/or Electrical Stimulation
WO2008045877A2 (en) 2006-10-10 2008-04-17 St. Jude Medical, Atrial Fibrillation Division, Inc. Electrode tip and ablation system
EP2116274B1 (en) * 2006-10-13 2012-07-11 Apnex Medical, Inc. Obstructive sleep apnea treatment device
US8388546B2 (en) 2006-10-23 2013-03-05 Bard Access Systems, Inc. Method of locating the tip of a central venous catheter
US7794407B2 (en) 2006-10-23 2010-09-14 Bard Access Systems, Inc. Method of locating the tip of a central venous catheter
WO2008070809A2 (en) 2006-12-06 2008-06-12 Spinal Modulation, Inc. Implantable flexible circuit leads and methods of use
EP2101873A2 (en) 2006-12-06 2009-09-23 Medtronic, Inc. User interface with toolbar for programming electrical stimulation therapy
US8280513B2 (en) 2006-12-22 2012-10-02 Rmx, Llc Device and method to treat flow limitations
US8909341B2 (en) 2007-01-22 2014-12-09 Respicardia, Inc. Device and method for the treatment of breathing disorders and cardiac disorders
US20080183186A1 (en) 2007-01-30 2008-07-31 Cardiac Pacemakers, Inc. Method and apparatus for delivering a transvascular lead
US20080183265A1 (en) 2007-01-30 2008-07-31 Cardiac Pacemakers, Inc. Transvascular lead with proximal force relief
US20080183255A1 (en) 2007-01-30 2008-07-31 Cardiac Pacemakers, Inc. Side port lead delivery system
US20080183187A1 (en) 2007-01-30 2008-07-31 Cardiac Pacemakers, Inc. Direct delivery system for transvascular lead
US8244378B2 (en) 2007-01-30 2012-08-14 Cardiac Pacemakers, Inc. Spiral configurations for intravascular lead stability
US7949409B2 (en) 2007-01-30 2011-05-24 Cardiac Pacemakers, Inc. Dual spiral lead configurations
US7917230B2 (en) 2007-01-30 2011-03-29 Cardiac Pacemakers, Inc. Neurostimulating lead having a stent-like anchor
US20080183264A1 (en) 2007-01-30 2008-07-31 Cardiac Pacemakers, Inc. Electrode configurations for transvascular nerve stimulation
US7819883B2 (en) 2007-03-13 2010-10-26 Cardiac Pacemakers, Inc. Method and apparatus for endoscopic access to the vagus nerve
GB0707906D0 (en) 2007-04-24 2007-05-30 Apparatus for detecting the position of a catheter
EP2148712B1 (en) 2007-04-27 2018-10-31 Maquet Critical Care AB Control unit and display unit for an emg controlled ventilator
US10492729B2 (en) 2007-05-23 2019-12-03 St. Jude Medical, Cardiology Division, Inc. Flexible high-density mapping catheter tips and flexible ablation catheter tips with onboard high-density mapping electrodes
WO2008157180A1 (en) 2007-06-13 2008-12-24 E-Pacing, Inc. Implantable devices and methods for stimulation of cardiac and other tissues
WO2008156982A1 (en) 2007-06-13 2008-12-24 E- Pacing, Inc. Implantable devices and methods for stimulation of cardiac or other tissues
US9987488B1 (en) 2007-06-27 2018-06-05 Respicardia, Inc. Detecting and treating disordered breathing
WO2009006337A1 (en) 2007-06-29 2009-01-08 Action Medical, Inc. Methods, devices and systems for cardiac rhythm management using an electrode arrangement
US20090024047A1 (en) 2007-07-20 2009-01-22 Cardiac Pacemakers, Inc. Devices and methods for respiration therapy
US8265736B2 (en) 2007-08-07 2012-09-11 Cardiac Pacemakers, Inc. Method and apparatus to perform electrode combination selection
US9037239B2 (en) 2007-08-07 2015-05-19 Cardiac Pacemakers, Inc. Method and apparatus to perform electrode combination selection
US7994655B2 (en) 2007-08-17 2011-08-09 Inovise Medical, Inc. Mechanical, anatomical heart-pumping assist
US8135471B2 (en) 2007-08-28 2012-03-13 Cardiac Pacemakers, Inc. Method and apparatus for inspiratory muscle stimulation using implantable device
US8527036B2 (en) 2007-09-28 2013-09-03 Maquet Critical Care Ab Catheter positioning method and computerized control unit for implementing the method
US8428711B2 (en) 2007-10-10 2013-04-23 Cardiac Pacemakers, Inc. Respiratory stimulation for treating periodic breathing
US8428726B2 (en) 2007-10-30 2013-04-23 Synapse Biomedical, Inc. Device and method of neuromodulation to effect a functionally restorative adaption of the neuromuscular system
WO2009059033A1 (en) 2007-10-30 2009-05-07 Synapse Biomedical, Inc. Method of improving sleep disordered breathing
CN101925333B (en) 2007-11-26 2014-02-12 C·R·巴德股份有限公司 Integrated system for intravascular placement of catheter
US8406883B1 (en) 2007-12-27 2013-03-26 Boston Scientific Neuromodulation Corporation Lead assembly for electrical stimulation systems and methods of making and using
WO2009096862A1 (en) * 2008-01-29 2009-08-06 Milux Holding Sa Apparatus for treating obesity
US20130123891A1 (en) 2008-02-01 2013-05-16 John Swanson High density terminal contacts for stimulation lead and stimulation system employing the same, and method of stimulation lead fabrication
US9199075B1 (en) 2008-02-07 2015-12-01 Respicardia, Inc. Transvascular medical lead
US7925352B2 (en) 2008-03-27 2011-04-12 Synecor Llc System and method for transvascularly stimulating contents of the carotid sheath
US8052607B2 (en) 2008-04-22 2011-11-08 St. Jude Medical, Atrial Fibrillation Division, Inc. Ultrasound imaging catheter with pivoting head
EP2211978A1 (en) 2008-04-30 2010-08-04 Medtronic, Inc. Techniques for placing medical leads for electrical stimulation of nerve tissue
US8571663B2 (en) 2008-05-02 2013-10-29 The Johns Hopkins University Portable negative pressure ventilation device and methods and software related thereto
US9409012B2 (en) 2008-06-19 2016-08-09 Cardiac Pacemakers, Inc. Pacemaker integrated with vascular intervention catheter
US8239037B2 (en) 2008-07-06 2012-08-07 Synecor Llc Intravascular implant anchors having remote communication and/or battery recharging capabilities
EP2334372A1 (en) 2008-07-08 2011-06-22 Cardiac Pacemakers, Inc. Systems for delivering vagal nerve stimulation
US8734437B2 (en) 2008-07-23 2014-05-27 Boston Scientific Scimed, Inc. Catheter having electrically conductive pathways
JP4545210B2 (en) 2008-09-11 2010-09-15 日本ライフライン株式会社 Defibrillation catheter
EP2364178A1 (en) * 2008-10-13 2011-09-14 E- Pacing, Inc. Devices and methods for electrical stimulation of the diaphragm and nerves
US20100114227A1 (en) 2008-10-30 2010-05-06 Pacesetter, Inc. Systems and Methds for Use by an Implantable Medical Device for Controlling Vagus Nerve Stimulation Based on Heart Rate Reduction Curves and Thresholds to Mitigate Heart Failure
US8386053B2 (en) 2008-10-31 2013-02-26 Medtronic, Inc. Subclavian ansae stimulation
EP2346567A4 (en) 2008-11-13 2012-04-25 Proteus Biomedical Inc Multiplexed multi-electrode neurostimulation devices
US20110230935A1 (en) 2008-11-13 2011-09-22 Mark Zdeblick Rechargeable Stimulation Lead, System, and Method
WO2010056707A1 (en) 2008-11-14 2010-05-20 Cardiac Pacemakers, Inc. Mass attribute detection through phrenic stimulation
US8644939B2 (en) 2008-11-18 2014-02-04 Neurostream Technologies General Partnership Method and device for the detection, identification and treatment of sleep apnea/hypopnea
KR101088806B1 (en) 2009-01-07 2011-12-01 주식회사 뉴로바이오시스 Micro-electrode Array Package using Liquid Crystal Polymer and Manufacturing Method thereof
EP2393551A4 (en) 2009-02-09 2013-04-17 Proteus Digital Health Inc Multiplexed multi-electrode neurostimulation devices with integrated circuit having integrated electrodes
US9226688B2 (en) 2009-03-10 2016-01-05 Medtronic Xomed, Inc. Flexible circuit assemblies
US9226689B2 (en) 2009-03-10 2016-01-05 Medtronic Xomed, Inc. Flexible circuit sheet
US20100268311A1 (en) 2009-04-17 2010-10-21 Ralph Cardinal Method for Implanting Electrode on Nerve
US8626292B2 (en) 2009-05-27 2014-01-07 Cardiac Pacemakers, Inc. Respiration sensor processing for phrenic nerve activation detection
US9149642B2 (en) 2009-05-27 2015-10-06 Cardiac Pacemakers, Inc. Method and apparatus for phrenic nerve activation detection with respiration cross-checking
US9532724B2 (en) 2009-06-12 2017-01-03 Bard Access Systems, Inc. Apparatus and method for catheter navigation using endovascular energy mapping
WO2010148376A1 (en) 2009-06-19 2010-12-23 Medtronic, Inc. Helical electrode arrangements for medical leads
US8340783B2 (en) 2009-06-30 2012-12-25 Medtronic, Inc. Implantable medical device lead with selectively exposed electrodes and reinforcement member
WO2011016864A1 (en) 2009-08-05 2011-02-10 Ndi Medical, Llc Systems and methods for maintaining airway patency
US8644952B2 (en) 2009-09-02 2014-02-04 Cardiac Pacemakers, Inc. Medical devices including polyisobutylene based polymers and derivatives thereof
US8374704B2 (en) 2009-09-02 2013-02-12 Cardiac Pacemakers, Inc. Polyisobutylene urethane, urea and urethane/urea copolymers and medical leads containing the same
US9072899B1 (en) 2009-09-04 2015-07-07 Todd Nickloes Diaphragm pacemaker
US8233987B2 (en) 2009-09-10 2012-07-31 Respicardia, Inc. Respiratory rectification
US9468755B2 (en) 2009-09-30 2016-10-18 Respicardia, Inc. Medical lead with preformed bias
US8617228B2 (en) 2009-10-23 2013-12-31 Medtronic Cryocath Lp Method and system for preventing nerve injury during a medical procedure
US8764728B2 (en) 2010-01-29 2014-07-01 C. R. Bard, Inc. Sacrificial catheter
BR112012019354B1 (en) 2010-02-02 2021-09-08 C.R.Bard, Inc METHOD FOR LOCATION OF AN IMPLANTABLE MEDICAL DEVICE
JP5537213B2 (en) 2010-03-26 2014-07-02 オリンパス株式会社 Electrical stimulation electrode assembly
US20110230945A1 (en) 2010-03-19 2011-09-22 Olympus Corporation Electrostimulation system, and electrostimulation electrode assembly and biological implantable electrode therefor
US8755889B2 (en) 2010-04-30 2014-06-17 Medtronic, Inc. Method and apparatus to enhance therapy during stimulation of vagus nerve
US20110270358A1 (en) 2010-04-30 2011-11-03 Medtronic, Inc. Implantable medical device programming using gesture-based control
US10631912B2 (en) 2010-04-30 2020-04-28 Medtronic Xomed, Inc. Interface module for use with nerve monitoring and electrosurgery
EP2575959B1 (en) 2010-06-03 2017-07-12 Cardiac Pacemakers, Inc. System for controlling target of neurostimulation using temporal parameters
WO2011153024A1 (en) 2010-06-03 2011-12-08 Cardiac Pacemakers, Inc. System for spatially selective vagus nerve stimulation
JP4940332B2 (en) 2010-06-15 2012-05-30 日本ライフライン株式会社 catheter
US20120130217A1 (en) 2010-11-23 2012-05-24 Kauphusman James V Medical devices having electrodes mounted thereon and methods of manufacturing therefor
WO2012003297A1 (en) 2010-06-30 2012-01-05 Med-El Elektromedizinische Geraete Gmbh Helical core ear implant electrode
JP5684384B2 (en) 2010-07-19 2015-03-11 カーディアック ペースメイカーズ, インコーポレイテッド System for stimulating the vagus nerve
AU2011283107B2 (en) 2010-07-29 2015-06-25 Boston Scientific Neuromodulation Corporation Systems and methods for making and using electrical stimulation systems having multi-lead-element lead bodies
EP2600936B1 (en) 2010-08-06 2018-09-19 Cardiac Pacemakers, Inc. User interface system for use with multipolar pacing leads
US8934956B2 (en) 2010-08-31 2015-01-13 Interventional Autonomics Corporation Intravascular electrodes and anchoring devices for transvascular stimulation
US20120078320A1 (en) 2010-09-29 2012-03-29 Medtronic, Inc. Prioritized programming of multi-electrode pacing leads
KR101304338B1 (en) 2010-10-21 2013-09-11 주식회사 엠아이텍 LCP-based electro-optrode neural interface and Method for fabricating the same
US8801693B2 (en) 2010-10-29 2014-08-12 C. R. Bard, Inc. Bioimpedance-assisted placement of a medical device
US8391956B2 (en) 2010-11-18 2013-03-05 Robert D. Zellers Medical device location systems, devices and methods
US8560086B2 (en) 2010-12-02 2013-10-15 St. Jude Medical, Atrial Fibrillation Division, Inc. Catheter electrode assemblies and methods of construction therefor
US8718763B2 (en) 2011-01-19 2014-05-06 Medtronic, Inc. Vagal stimulation
US8781583B2 (en) 2011-01-19 2014-07-15 Medtronic, Inc. Vagal stimulation
US8706223B2 (en) 2011-01-19 2014-04-22 Medtronic, Inc. Preventative vagal stimulation
US8725259B2 (en) 2011-01-19 2014-05-13 Medtronic, Inc. Vagal stimulation
US8781582B2 (en) 2011-01-19 2014-07-15 Medtronic, Inc. Vagal stimulation
WO2012103216A2 (en) 2011-01-25 2012-08-02 Apellis Pharmaceuticals, Inc. Apparatus and methods for assisting breathing
US9550041B2 (en) 2011-02-04 2017-01-24 Advanced Pain Center, Llc. Continuous single wire steerable catheter
US9744349B2 (en) 2011-02-10 2017-08-29 Respicardia, Inc. Medical lead and implantation
US8430864B2 (en) 2011-02-16 2013-04-30 Biosense Webster, Inc. Catheter with multiple deflections
US9615759B2 (en) 2011-07-12 2017-04-11 Bard Access Systems, Inc. Devices and methods for ECG guided vascular access
US20130018427A1 (en) 2011-07-15 2013-01-17 Khiem Pham Screw Implants For Bone Fusion
US20130030497A1 (en) 2011-07-27 2013-01-31 Medtronic, Inc. Nerve stimulator for reduced muscle fatigue
US8805511B2 (en) 2011-07-27 2014-08-12 Medtronic, Inc. Method and apparatus to detect subcerebral ischemia
US8478413B2 (en) 2011-07-27 2013-07-02 Medtronic, Inc. Bilateral phrenic nerve stimulation with reduced dyssynchrony
US8706235B2 (en) 2011-07-27 2014-04-22 Medtronic, Inc. Transvenous method to induce respiration
US8509902B2 (en) 2011-07-28 2013-08-13 Medtronic, Inc. Medical device to provide breathing therapy
US9861817B2 (en) 2011-07-28 2018-01-09 Medtronic, Inc. Medical device to provide breathing therapy
US10201385B2 (en) 2011-09-01 2019-02-12 Biosense Webster (Israel) Ltd. Catheter adapted for direct tissue contact
US9724018B2 (en) 2011-10-27 2017-08-08 Medtronic Cryocath Lp Method for monitoring phrenic nerve function
US8897879B2 (en) 2011-11-04 2014-11-25 Medtronic, Inc. Method and apparatus for therapies of the cardiovascular and cardiorenal system
CN104125799A (en) 2011-11-07 2014-10-29 美敦力阿迪安卢森堡有限责任公司 Endovascular nerve monitoring devices and associated systems and methods
US9956396B2 (en) 2012-02-08 2018-05-01 Medtronic Bakken Research Center B.V. Thin film for a lead for brain applications
EP3228351B1 (en) 2012-03-05 2019-06-05 Lungpacer Medical Inc. Transvascular nerve stimulation apparatus
WO2013142053A1 (en) 2012-03-21 2013-09-26 Cardiac Pacemakers, Inc. Systems and methods for stimulation of vagus nerve
US10413203B2 (en) 2012-03-27 2019-09-17 Cardiac Pacemakers, Inc. Baseline determination for phrenic nerve stimulation detection
US20130289686A1 (en) 2012-04-29 2013-10-31 Synecor Llc Intravascular electrode arrays for neuromodulation
US9179972B2 (en) 2012-05-04 2015-11-10 St. Jude Medical, Atrial Fibrillation Division, Inc. System and method for controlling delivery of ablation energy to tissue
AU2013266508A1 (en) 2012-05-25 2014-11-06 Boston Scientific Neuromodulation Corporation Methods for stimulating the dorsal root ganglion with a lead having segmented electrodes
CA2877049C (en) 2012-06-21 2022-08-16 Simon Fraser University Transvascular diaphragm pacing systems and methods of use
WO2014008171A1 (en) 2012-07-02 2014-01-09 Medisci L.L.C. Method and device for respiratory and cardiorespiratory support
US8504161B1 (en) 2012-08-07 2013-08-06 Medtronic, Inc. Modulate vagal signals to reduce inflammation
US10137262B2 (en) 2012-08-20 2018-11-27 Koninklijke Philips N.V. Synchronizing mechanical in-exsufflation and diaphragmatic pacing
EP2722071A1 (en) 2012-10-16 2014-04-23 Sapiens Steering Brain Stimulation B.V. A probe, especially a probe for neural applications
US20140121716A1 (en) 2012-10-31 2014-05-01 Medtronic, Inc. High voltage therapy diversion algorithms
WO2014071386A1 (en) 2012-11-05 2014-05-08 Regents Of The University Of Minnesota Non-invasive lung pacing
CN102949770B (en) 2012-11-09 2015-04-22 张红璇 External diaphragm pacing and breathing machine synergistic air supply method and device thereof
US9072864B2 (en) 2012-11-28 2015-07-07 Ad-Tech Medical Instrument Corporation Catheter with depth electrode for dual-purpose use
WO2014089266A2 (en) 2012-12-05 2014-06-12 Battelle Memorial Institute Neuromuscular stimulation cuff
US9884179B2 (en) 2012-12-05 2018-02-06 Bbattelle Memorial Institute Neural sleeve for neuromuscular stimulation, sensing and recording
US10335592B2 (en) 2012-12-19 2019-07-02 Viscardia, Inc. Systems, devices, and methods for improving hemodynamic performance through asymptomatic diaphragm stimulation
CN104994906B (en) 2012-12-19 2017-05-24 维斯卡迪亚公司 Hemodynamic performance enhancement through asymptomatic diaphragm stimulation
US9485873B2 (en) 2013-03-15 2016-11-01 Lawrence Livermore National Security, Llc Depositing bulk or micro-scale electrodes
EP2818104B1 (en) 2013-06-25 2016-01-06 VascoMed GmbH Catheter and method for producing same
US9427566B2 (en) 2013-08-14 2016-08-30 Syntilla Medical LLC Implantable neurostimulation lead for head pain
EP3038702B1 (en) 2013-08-27 2019-02-27 Advanced Bionics AG Thermoformed electrode arrays
US9504837B2 (en) 2013-10-25 2016-11-29 Medtronic, Inc. Automated phrenic nerve stimulation and pacing capture threshold test
US9205258B2 (en) 2013-11-04 2015-12-08 ElectroCore, LLC Nerve stimulator system
AU2014351473B2 (en) 2013-11-22 2019-11-07 Lungpacer Medical Inc. Apparatus and methods for assisted breathing by transvascular nerve stimulation
US10828090B2 (en) 2014-01-10 2020-11-10 Boston Scientific Scimed, Inc. Medical devices with flexible circuit assemblies
JP6537517B2 (en) 2014-01-21 2019-07-03 ラングペーサー メディカル インコーポレイテッドLungpacer Medical Inc. System and related method for optimization of multielectrode neural pacing
US9498631B2 (en) 2014-02-20 2016-11-22 Medtronic, Inc. Automated phrenic nerve stimulation and pacing capture threshold test
US9844644B2 (en) 2014-03-05 2017-12-19 Oscor Inc. Intravascular sheath with mapping capabilities to deliver therapeutic devices to a targeted location within a blood vessel
US20160310730A1 (en) 2014-03-28 2016-10-27 Antonio Garcia Martins Stimulation system for exercising diaphragm and method of operation thereof
US10194978B2 (en) 2014-06-13 2019-02-05 Medtronic Cryocath Lp Supporting catheter for use for phrenic nerve pacing
KR101654801B1 (en) 2014-08-08 2016-09-07 서울대학교산학협력단 Microelectrode array and package for liquid crystal polymer based neuroprostheses and manufacturing method thereof
WO2016033245A1 (en) 2014-08-26 2016-03-03 Rmx, Llc Devices and methods for reducing intrathoracic pressure
US9474894B2 (en) 2014-08-27 2016-10-25 Aleva Neurotherapeutics Deep brain stimulation lead
CN107205641A (en) 2014-08-29 2017-09-26 因赛飞公司 Method and apparatus for strengthening nervous function
US10507321B2 (en) 2014-11-25 2019-12-17 Medtronic Bakken Research Center B.V. Multilayer structure and method of manufacturing a multilayer structure
US10622107B2 (en) 2015-02-13 2020-04-14 Medtronic, Inc. Tools for medical device configuration
US20160331326A1 (en) 2015-02-13 2016-11-17 National University Of Singapore Flexible neural strip electrodes, flexible neural ribbon electrodes and compartment based embedded nerve tissue electrode interfaces for peripheral nerves
EP3064131A1 (en) 2015-03-03 2016-09-07 BIOTRONIK SE & Co. KG Combined vagus-phrenic nerve stimulation apparatus
US9872989B2 (en) 2015-04-02 2018-01-23 The Florida International University Board Of Trustees System and method for neuromorphic controlled adaptive pacing of respiratory muscles and nerves
AU2016297965B2 (en) 2015-07-30 2019-04-04 Boston Scientific Neuromodulation Corporation User interface for custom patterned electrical stimulation
CA3008265A1 (en) 2015-12-14 2017-06-22 Stimdia Medical, Inc. Electrical stimulation for preservation and restoration of diaphragm function
US10537735B2 (en) 2016-04-29 2020-01-21 Viscardia, Inc. Implantable medical devices and methods for real-time or near real-time adjustment of diaphragmatic stimulation parameters to affect pressures within the intrathoracic cavity
US10695564B2 (en) 2016-06-02 2020-06-30 Battelle Memorial Institute Flexible sheet for neuromuscular stimulation
US10492713B2 (en) 2016-06-03 2019-12-03 The Cleveland Clinic Foundation Systems and methods for monitoring a depth of neuromuscular blockade
US10207103B2 (en) 2016-07-05 2019-02-19 Pacesetter, Inc. Implantable thin film devices
US10898262B2 (en) 2016-10-25 2021-01-26 Biosense Webster (Israel) Ltd. Catheter distal end made of plastic tube and flexible printed circuit boards
US10293164B2 (en) 2017-05-26 2019-05-21 Lungpacer Medical Inc. Apparatus and methods for assisted breathing by transvascular nerve stimulation
US10195429B1 (en) 2017-08-02 2019-02-05 Lungpacer Medical Inc. Systems and methods for intravascular catheter positioning and/or nerve stimulation
CN111936189A (en) 2018-02-06 2020-11-13 斯蒂米特股份公司 Ventilation device and method for ventilating a patient

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3983881A (en) * 1975-05-21 1976-10-05 Telectronics Pty. Limited Muscle stimulator
US4827935A (en) * 1986-04-24 1989-05-09 Purdue Research Foundation Demand electroventilator
US5549655A (en) * 1994-09-21 1996-08-27 Medtronic, Inc. Method and apparatus for synchronized treatment of obstructive sleep apnea
US20120158091A1 (en) * 2003-10-15 2012-06-21 Rmx, Llc Therapeutic diaphragm stimulation device and method
US20050165457A1 (en) * 2004-01-26 2005-07-28 Michael Benser Tiered therapy for respiratory oscillations characteristic of Cheyne-Stokes respiration
US7962215B2 (en) * 2004-07-23 2011-06-14 Synapse Biomedical, Inc. Ventilatory assist system and methods to improve respiratory function
US20100036451A1 (en) * 2007-01-29 2010-02-11 Simon Fraser University Transvascular nerve stimulation apparatus and methods
US8571662B2 (en) * 2007-01-29 2013-10-29 Simon Fraser University Transvascular nerve stimulation apparatus and methods
US8504158B2 (en) * 2011-05-09 2013-08-06 Medtronic, Inc. Phrenic nerve stimulation during cardiac refractory period

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Lungpacer: Therapy, News. <http://lungpacer.com>. Accessed 12/27/16. *

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11027130B2 (en) 2007-01-29 2021-06-08 Lungpacer Medical Inc. Transvascular nerve stimulation apparatus and methods
US10864374B2 (en) 2007-01-29 2020-12-15 Lungpacer Medical Inc. Transvascular nerve stimulation apparatus and methods
US10792499B2 (en) 2007-01-29 2020-10-06 Lungpacer Medical Inc. Transvascular nerve stimulation apparatus and methods
US10765867B2 (en) 2007-01-29 2020-09-08 Lungpacer Medical Inc. Transvascular nerve stimulation apparatus and methods
US10561843B2 (en) 2007-01-29 2020-02-18 Lungpacer Medical, Inc. Transvascular nerve stimulation apparatus and methods
US10512772B2 (en) 2012-03-05 2019-12-24 Lungpacer Medical Inc. Transvascular nerve stimulation apparatus and methods
US11369787B2 (en) 2012-03-05 2022-06-28 Lungpacer Medical Inc. Transvascular nerve stimulation apparatus and methods
US11357985B2 (en) 2012-06-21 2022-06-14 Lungpacer Medical Inc. Transvascular diaphragm pacing systems and methods of use
US10406367B2 (en) 2012-06-21 2019-09-10 Lungpacer Medical Inc. Transvascular diaphragm pacing system and methods of use
US10561844B2 (en) 2012-06-21 2020-02-18 Lungpacer Medical Inc. Diaphragm pacing systems and methods of use
US10589097B2 (en) 2012-06-21 2020-03-17 Lungpacer Medical Inc. Transvascular diaphragm pacing systems and methods of use
US10035017B2 (en) 2013-11-22 2018-07-31 Lungpacer Medical, Inc. Apparatus and methods for assisted breathing by transvascular nerve stimulation
US11707619B2 (en) 2013-11-22 2023-07-25 Lungpacer Medical Inc. Apparatus and methods for assisted breathing by transvascular nerve stimulation
US9931504B2 (en) 2013-11-22 2018-04-03 Lungpacer Medical, Inc. Apparatus and methods for assisted breathing by transvascular nerve stimulation
US10391314B2 (en) 2014-01-21 2019-08-27 Lungpacer Medical Inc. Systems and related methods for optimization of multi-electrode nerve pacing
US11311730B2 (en) 2014-01-21 2022-04-26 Lungpacer Medical Inc. Systems and related methods for optimization of multi-electrode nerve pacing
US20170128684A1 (en) * 2015-09-10 2017-05-11 St. Michael's Hospital Method and system for adjusting a level of ventilatory assist to a patient
US10758693B2 (en) * 2015-09-10 2020-09-01 St. Michael's Hospital. Method and system for adjusting a level of ventilatory assist to a patient
US9682235B1 (en) 2015-12-14 2017-06-20 Stimdia Medical, Inc. Electrical stimulation for preservation and restoration of diaphragm function
US10300272B2 (en) 2015-12-14 2019-05-28 Stimdia Medical, Inc. Electrical stimulation for preservation and restoration of diaphragm function
US10293157B2 (en) 2015-12-14 2019-05-21 Stimdia Medical, Inc. Electrical stimulation for preservation and restoration of diaphragm function
US11052250B2 (en) 2015-12-14 2021-07-06 Stimdia Medical, Inc. Electrical stimulation for preservation and restoration of diaphragm function
WO2017106273A1 (en) * 2015-12-14 2017-06-22 Stimdia Medical, Inc. Electrical stimulation for preservation and restoration of diaphragm function
US10293164B2 (en) 2017-05-26 2019-05-21 Lungpacer Medical Inc. Apparatus and methods for assisted breathing by transvascular nerve stimulation
US11883658B2 (en) 2017-06-30 2024-01-30 Lungpacer Medical Inc. Devices and methods for prevention, moderation, and/or treatment of cognitive injury
US11207517B2 (en) 2017-07-06 2021-12-28 Stimdia Medical, Inc. Percutaneous electrical phrenic nerve stimulation system
US10926087B2 (en) 2017-08-02 2021-02-23 Lungpacer Medical Inc. Systems and methods for intravascular catheter positioning and/or nerve stimulation
US10195429B1 (en) 2017-08-02 2019-02-05 Lungpacer Medical Inc. Systems and methods for intravascular catheter positioning and/or nerve stimulation
US10039920B1 (en) 2017-08-02 2018-08-07 Lungpacer Medical, Inc. Systems and methods for intravascular catheter positioning and/or nerve stimulation
US10940308B2 (en) 2017-08-04 2021-03-09 Lungpacer Medical Inc. Systems and methods for trans-esophageal sympathetic ganglion recruitment
US10987511B2 (en) 2018-11-08 2021-04-27 Lungpacer Medical Inc. Stimulation systems and related user interfaces
US11717673B2 (en) 2018-11-08 2023-08-08 Lungpacer Medical Inc. Stimulation systems and related user interfaces
US11890462B2 (en) 2018-11-08 2024-02-06 Lungpacer Medical Inc. Stimulation systems and related user interfaces
US11357979B2 (en) 2019-05-16 2022-06-14 Lungpacer Medical Inc. Systems and methods for sensing and stimulation
US11771900B2 (en) 2019-06-12 2023-10-03 Lungpacer Medical Inc. Circuitry for medical stimulation systems
US11944810B2 (en) 2021-02-02 2024-04-02 Lungpacer Medical Inc. Systems and methods for trans-esophageal sympathetic ganglion recruitment
US11553963B2 (en) 2021-03-09 2023-01-17 Circle Safe Phrenic nerve stimulation

Also Published As

Publication number Publication date
JP2018140249A (en) 2018-09-13
AU2013280184A1 (en) 2015-02-05
US20150367127A1 (en) 2015-12-24
JP2015519975A (en) 2015-07-16
US20220023625A1 (en) 2022-01-27
JP2020089795A (en) 2020-06-11
JP6677764B2 (en) 2020-04-08
US20190321632A1 (en) 2019-10-24
EP2863987A4 (en) 2016-07-27
EP4233953A2 (en) 2023-08-30
CA2877049C (en) 2022-08-16
US20200164207A1 (en) 2020-05-28
EP4233953A3 (en) 2023-11-01
WO2013188965A1 (en) 2013-12-27
JP6359528B2 (en) 2018-07-18
US10589097B2 (en) 2020-03-17
US20180361148A1 (en) 2018-12-20
JP2023118874A (en) 2023-08-25
US11357985B2 (en) 2022-06-14
US20190030333A1 (en) 2019-01-31
US9776005B2 (en) 2017-10-03
AU2013280184B2 (en) 2017-08-24
US10406367B2 (en) 2019-09-10
EP2863987A1 (en) 2015-04-29
US10561844B2 (en) 2020-02-18
BR112014032002A2 (en) 2017-06-27
JP2022019870A (en) 2022-01-27
CA2877049A1 (en) 2013-12-27
JP7176773B2 (en) 2022-11-22
CN104684614A (en) 2015-06-03
CN104684614B (en) 2017-10-17
JP7313723B2 (en) 2023-07-25
EP2863987B1 (en) 2023-08-02

Similar Documents

Publication Publication Date Title
US11357985B2 (en) Transvascular diaphragm pacing systems and methods of use
JP6846824B2 (en) Diaphragm pacing system
JP5389650B2 (en) A system for neural stimulation using feedback by respiration
US8140164B2 (en) Therapeutic diaphragm stimulation device and method
US7979128B2 (en) Device and method for gradually controlling breathing
US7596413B2 (en) Coordinated therapy for disordered breathing including baroreflex modulation
US20150034081A1 (en) Therapeutic diaphragm stimulation device and method
US20120158091A1 (en) Therapeutic diaphragm stimulation device and method
JP2010502276A (en) System for neural stimulation during respiratory disorders
US11471683B2 (en) Systems and methods for treating sleep apnea using neuromodulation
US11266838B1 (en) Airway diagnostics utilizing phrenic nerve stimulation device and method

Legal Events

Date Code Title Description
AS Assignment

Owner name: SIMON FRASER UNIVERSITY, CANADA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MEYYAPPAN, RAMASAMY;HOFFER, JOAQUIN ANDRES;BARU, MARCELO;AND OTHERS;SIGNING DATES FROM 20150203 TO 20150212;REEL/FRAME:035069/0253

AS Assignment

Owner name: SIMON FRASER UNIVERSITY, CANADA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MEYYAPPAN, RAMASAMY;HOFFER, JOAQUIN ANDRES;BARU, MARCELO;AND OTHERS;SIGNING DATES FROM 20130730 TO 20131107;REEL/FRAME:035366/0534

AS Assignment

Owner name: LUNGPACER MEDICAL, INC., CANADA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SIMON FRASER UNIVERSITY;REEL/FRAME:043444/0948

Effective date: 20170627

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION